var title_f34_54_35680="Triple rhomboid hexagonal flap";
var content_f34_54_35680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Triple rhomboid hexagonal flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure depicts closure of a defect with a triple rhomboid hexagonal flap. The orientation of the hexagon and the three rhomboids is adjusted to maximize laxity of the donor flap closure. In addition the flaps can be oriented with either a clockwise or counterclockwise transposition, also depending on tissue laxity. Note that all three flaps must transpose in the same direction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35680=[""].join("\n");
var outline_f34_54_35680=null;
var title_f34_54_35681="Thumb spica cast 6";
var content_f34_54_35681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the stockinette and webril are in place, begin to apply the casting material. Fiberglass cast tape is applied in the photograph above. Apply the tape so each layer overlaps the previous one by about half the width of the material. Be sure to leave the ends of the stockinette extended until you are ready to apply the final layers of casting material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35681=[""].join("\n");
var outline_f34_54_35681=null;
var title_f34_54_35682="CT scan insufficiency fracture of the pubic ramus";
var content_f34_54_35682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan insufficiency fracture of the pubic ramus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. The transverse images using bone windows reveal a nondisplaced fracture of the superior pubic ramus (A, green arrow) and a fracture through the inferior pubic ramus (B, red arrow) These findings are consistent with insufficiency fractures of the left pubic rami.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gregory Waryasz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35682=[""].join("\n");
var outline_f34_54_35682=null;
var title_f34_54_35683="Blastomycosis granuloma";
var content_f34_54_35683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph shows necrotizing granulomatous inflammation in a patient with blastomycosis. Neutrophils frequently are prominent within the necrotic centers. The outer portions of the granulomata are composed largely of epithelioid and multinucleated histiocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35683=[""].join("\n");
var outline_f34_54_35683=null;
var title_f34_54_35684="Etonogestrel: Patient drug information";
var content_f34_54_35684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Etonogestrel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"     see \"Etonogestrel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3325519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Implanon&reg;;",
"     </li>",
"     <li>",
"      Nexplanon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug does not protect you from diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702090",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to etonogestrel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease, blood clots, breast cancer, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where rod was placed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A rod is placed under the skin in the upper arm. This is a minor surgery. The rod must be changed every 3 years.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid heavy lifting for 2 to 3 days after placement.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11732 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1591A33FAF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35684=[""].join("\n");
var outline_f34_54_35684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3325519\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026238\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026240\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026239\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026243\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026244\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026246\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026242\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026247\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=related_link\">",
"      Etonogestrel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_54_35685="Thioguanine: Drug information";
var content_f34_54_35685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thioguanine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3605?source=see_link\">",
"    see \"Thioguanine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/51/35637?source=see_link\">",
"    see \"Thioguanine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tabloid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lanvis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F226934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/51/35637?source=see_link\">",
"      see \"Thioguanine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pediatric ALL (unlabeled use; combination therapy):",
"     </b>",
"     Oral: Delayed intensification treatment phase: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 14 days (Lange, 2002; Nachman, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F226917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children: No adjustment required (Aronoff, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F226918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deterioration in transaminases, alkaline phosphatase or bilirubin, toxic hepatitis, biliary stasis, clinical jaundice, evidence of hepatic sinusoidal obstruction syndrome (veno-occlusive disease), or evidence of portal hypertension: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tabloid&reg;: 40 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10329934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally; total daily dose can be given at one time.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F226892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute myelogenous (nonlymphocytic) leukemia (AML)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10329861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pediatric acute lymphoblastic leukemia (ALL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F853383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thioguanine may be confused with thiotepa",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       6-thioguanine and 6-TG are error-prone abbreviations (associated with sixfold overdoses of thioguanine)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lanvis [Canada and multiple international markets] may be confused with Lantus brand name for insulin glargine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention, hyperuricemia (common)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, intestinal necrosis, intestinal perforation, nausea, splenomegaly, stomatitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (may be delayed), bleeding, granulocytopenia, leukopenia (common; may be delayed), marrow hypoplasia, pancytopenia, thrombocytopenia (common; may be delayed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, esophageal varices, hepatic necrosis (centrilobular), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatitis, hepatomegaly [tender], hepatoportal sclerosis, hepatotoxicity, hyperbilirubinemia, jaundice, LFTs increased, nodular regenerative hyperplasia, peliosis hepatitis, periportal fibrosis, portal hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F226897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior resistance to thioguanine (or mercaptopurine)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to thioguanine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F226880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Myelosuppression (anemia, leukopenia, and/or thrombocytopenia) is a common dose-related toxicity (may be delayed); monitor for infection (due to leukopenia) or bleeding (due to thrombocytopenia); withhold treatment with abnormally significant drop in blood counts. Patients with genetic enzyme deficiency of thiopurine methyltransferase (TPMT) or who are receiving drugs which inhibit this enzyme (mesalazine, olsalazine, sulfasalazine) may be highly sensitive to myelosuppressive effects and may require substantial dose reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Long-term continuous therapy or maintenance treatment is associated with a high risk for hepatotoxicity, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), or portal hypertension. Monitor liver function carefully for liver toxicity and discontinue in patients with evidence of hepatic SOS (eg, hyperbilirubinemia, hepatomegaly [tender], and weight gain due to ascites and fluid retention) or portal hypertension (eg, splenomegaly, thrombocytopenia, esophageal varices). Hepatotoxicity with or without transaminase elevations may occur. Pathologic findings of hepatotoxicity include hepatoportal sclerosis, nodular regenerative hyperplasia, peliosis hepatitis, and periportal fibrosis. Long-term/maintenance treatment with thioguanine is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Thioguanine is potentially carcinogenic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Hyperuricemia occurs commonly with treatment; institute adequate hydration and prophylactic allopurinol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thiopurine methyltransferase deficiency: Patients with genetic enzyme deficiency of thiopurine methyltransferase (TPMT) may be sensitive to myelosuppressive effects. May require substantial dose reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not recommended for maintenance therapy or long term continuous treatment due to toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cross resistance: Cross resistance with mercaptopurine generally occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Avoid vaccination with live vaccines during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F226909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid; may increase the risk for hepatotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10329862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse effects. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F226923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10329863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends to discontinue breast-feeding during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F226899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tabloid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (25): $376.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F226889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count; liver function tests (weekly when beginning therapy then monthly, more frequently in patients with liver disease or concurrent hepatotoxic drugs); serum uric acid; some laboratories offer testing for TPMT deficiency",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hepatotoxicity may present with signs of portal hypertension (splenomegaly, esophageal varices, thrombocytopenia) or sinusoidal obstruction syndrome (veno-occlusive disease; fluid retention, ascites, hepatomegaly with tenderness, or hyperbilirubinemia)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      6-TG (IN);",
"     </li>",
"     <li>",
"      Lanvins (BR);",
"     </li>",
"     <li>",
"      Lanvis (AE, AR, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CY, CZ, EE, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PL, QA, SA, SC, SD, SE, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Tabloid (UY);",
"     </li>",
"     <li>",
"      Thioguanin Glaxo Wellcome (AT, DE);",
"     </li>",
"     <li>",
"      Thioguanine Wellcome (IT);",
"     </li>",
"     <li>",
"      Tioguanina (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F226879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Purine analog that is incorporated into DNA and RNA resulting in the blockage of synthesis and metabolism of purine nucleotides",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F226896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~30% (range: 14% to 46%; highly variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not reach therapeutic concentrations in the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; rapidly and extensively via thiopurine methyltransferase (TPMT) to 2-amino-6-methylthioguanine (MTG; active) and inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 8 hours; predominantly metabolite(s)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 173.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broxson EH, Dole M, Wong R, et al, &ldquo;Portal Hypertension Develops in a Subset of Children With Standard Risk Acute Lymphoblastic Leukemia Treated With Oral 6-Thioguanine During Maintenance Therapy,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(3):226-31",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dressman JB and Poust RI, &ldquo;Stability of Allopurinol and Five Antineoplastics in Suspension,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1983, 40(4):616-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/6846371/pubmed\" id=\"6846371\" target=\"_blank\">",
"        6846371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elgemeie GH, \"Thioguanine, Mercaptopurine: Their Analogs and Nucleosides as Antimetabolites,\"",
"      <i>",
"       Curr Pharm Des",
"      </i>",
"      , 2003, 9(31):2627-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/14529546/pubmed\" id=\"14529546\" target=\"_blank\">",
"        14529546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Estlin EJ, &ldquo;Continuing Therapy for Childhood Acute Lymphoblastic Leukaemia: Clinical and Cellular Pharmacology of Methotrexate, 6-Mercaptopurine and 6-Thioguanine,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2001, 27(6):351-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/11908928/pubmed\" id=\"11908928\" target=\"_blank\">",
"        11908928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange BJ, Bostrom BC, Cherlow JM, et al, &ldquo;Double-Delayed Intensification Improves Event-Free Survival for Children With Intermediate-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(3):825-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/11806983/pubmed\" id=\"11806983\" target=\"_blank\">",
"        11806983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nachman JB, Sather HN, Sensel MG, et al, &ldquo;Augmented Post-Induction Therapy for Children With High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(23):1663-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/9614257/pubmed\" id=\"9614257\" target=\"_blank\">",
"        9614257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Morosco RS, and Hipple TF,",
"      <i>",
"       Pediatric Drug Formulations",
"      </i>",
"      , 4th ed, Cincinnati, OH: Harvey Whitney Books Co, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vora A, Mitchell CD, Lennard L, et al, &ldquo;Toxicity and Efficacy of 6-Thioguanine Versus 6-Mercaptopurine in Childhood Lymphoblastic Leukaemia: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 368(9544):1339-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/54/35685/abstract-text/17046466/pubmed\" id=\"17046466\" target=\"_blank\">",
"        17046466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9989 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35685=[""].join("\n");
var outline_f34_54_35685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226912\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226913\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226949\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226934\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226917\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226918\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226891\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226876\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329934\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226892\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329861\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F853383\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226947\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226897\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226880\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300132\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226885\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226909\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226887\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329862\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226923\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329863\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226899\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226889\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038839\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226879\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226896\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3605?source=related_link\">",
"      Thioguanine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/51/35637?source=related_link\">",
"      Thioguanine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_54_35686="MR placenta accreta";
var content_f34_54_35686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image suggestive of placenta accreta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 355px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFjAcoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5atbea7uYbe2ieaeZxHHGi7mdicAADqSe1dr/AMKk8eYz/wAIxfnnHAXr+dY/w3GfiJ4WH/UVtf8A0ctffttpk7SpLNEF2jChF+VcdhxWM3PmtD8r/qh6Janw6Pg94/PTwvffjsH9af8A8Ka+IJOP+EYvP++4/wD4qvutoAowS27ruIpY4i0ihjk46Z7jNL973X3f8EOaPb8f+AfCv/Cl/iF/0LN1/wB/I/8A4qk/4U18QB18N3A+s0Q/9mr7quLZiGZCXX68DFclrkKTKyyn2GeopP2vdfc/8w5o9v6+4+QT8HPHoHPh6X/v/D/8XSj4NePicDw9JnOP+PmH/wCLr6N1S3toLGae4lCIpwAw6ds471R0ZraSdGsbhpSRlmDZH45qOatfdfc/8yXUiun4/wDAPAh8F/iAenh5ycZx9pg/+LprfBrx4pIbQgCvUG9t8j/yJX1zfXUHhnQLi51Aj7VKuI0A5xXy7c3Et9qzhTJIzSFvmOe+eSfzqm63dfc/8xucV0/H/gGVH8GPH0hIj0AuR2W8gJ/9DqVPgf8AER22p4cct6C7g/8Ai6+hvhTpd7Z+Hbm6ZF3yH92CAMe5H9a7vRRD4fje4v7kG6lBJy3C8njrTTq9Wvu/4IKcX0/r7j5CHwI+JOCf+EZlwP8Ap6g/+Lpf+FEfEndj/hGZM/8AX3b/APxyvsyDxppcMCwpNvl5L7iMDPvVqPxvoc7eW1z97j+dWnLuvu/4I+aJ8Tj4F/EY4x4bbn/p8t//AI5T/wDhQ/xKxkeGZD/292//AMcr7ks77SsNPFcxEHgc5xV62khuBv8ANEh6Yzxmmufuvu/4IXifBf8Awon4j7c/8I2QPX7bb/8AxynH4DfEkHB8MuP+3y3/APjlfe88ObXYduBz9KSOFkUMBlgOrHOKdp9193/BDQ+CB8CPiQenhtj/ANvlv/8AHKgb4KeP0Yq2hxKw4KnULUEfh5lfc97OlneqTKFLgYTGRmsDxjYJHAdRQFkAzLgZOKhuoluvu/4IXXY+Nm+Cvj1SA2iwgnpnUbXn/wAiUjfBjx2pw2jwA/8AYStf/jtfQ+pa1Fcabi1Qo0eSH2dOP8/41h6XYSXllNGqhSxbJZyWJz061DnU6Nfd/wAEz9pHsfNXivwvq/hPUIbLX7VbW5mhE6Ks0coZCzKDuRiOqsOvasSvV/2h08vXvDSndkaIn3jz/wAfNx1ryitaUnKKb3NH5BRRRWggooooAKKKKACiiigAooooAK7af4Y+J7YlbqHSrdwAWSbWrKNlyARkNMCOCOvrXE17j8UolTxff3W55FdIDt243L5EfPoRWFSclNRj1T/C3+YPRXOEPwx8Thd3l6Pt27s/25Y9PX/XdKYfht4jDFSNFDDPB12x/wDj1dHPfma3iS0tyqoQ5JI3t/h/n8aMkS3E7QQK88S5bdGDkMefTt0p3n3X3f8ABI5/IzYvhh4nmYrFHo7kLvIXXLE4X1/13T3qtL8P9biYrLNoCMOobX7AH/0dWo1xJp8DLIhinyfnDFWYEdx6Vz99ctcS7ixP1PWmnU7r7v8Aglx95lj/AIQbVv8An78O/wDhQ6f/APH6P+EH1Y/8vfh3/wAKHT//AI9Wdmiq97v/AF95pyI2bT4ceIbzP2M6JcYO0+Vrti/J6DiatSP4LePJRmLR7dx/s6naH/2rXVfDDw5afZYr+8lZbi4YxwoF3bR3Y+nfntivo3QEt9ItFtZJEEZ/jZdzH6n61nzTvuvu/wCCY86vY+SW+C3jxULnRoAgGSf7StcY/wC/tUT8LPFYjeQ22mBEzub+2LPAx1z+9r2P4seN3iL6VpkqmeTiQRj5V/GvHFiCXKRFVnRTmTrjd3/wpc1R9V93/BHzIfF8KPF0yB4bPT5EIyGTV7NgR7Yl5o/4VP4v2B/sVhtIzn+1rPH/AKNq3qM5jkjWABAygGNTwOMYOO9Nhs7hLQ3hgzbr8o2/MMHg/lzzQ/a9Gvuf+Yc67EDfCTxkoUtp9kA3TOq2nP8A5Fpo+E/jAttFhYlvQaraZ/8ARtXVsp5p0QFpYlw0HG4gf5/lUlx4cv4XV5oz05brtHqcc9+KTdb+Zfc/8w54lL/hUHjb/oF23/gytf8A45S/8Kf8b9tJtz9NRtT/AO1KtWMs+mOybjEOQVP9fSp7a8+1XrrAGW3kADxlQQSP/wBVF63dfc/8w549vx/4BnH4PeON23+yId3oNQtv/jlH/Cn/ABxux/ZEOeuP7Qtv/jldbca3CZLbyGWJFzGyCLJYHoMH8q6D+zrG+tPPktH3xssiPHkh+Pu+v+RScqyV7r7n/mL2ke34/wDAPNP+FN+O9m4aIpX1F9bn/wBqU1fg945Y4GioSO3223/+OV71oM11HbGHKKACJfmXIB+79cDFeL2j2mneLbmN2xI07ZkbGADn14780c1Z9V9z/wAxqcWtn/XyOP8AFngzX/CSWjeILD7It2XEJ86OTfs27vuMcY3L19a52vXPjPfQX/hbwy9vIsgjvb+Nio4DCO0JAPfrXkdbUnJxvLcd09jpPhrx8RvCv/YVtf8A0ctfo+JTtIyd54C4xj8a/OH4acfEbwr/ANhW0/8ARy19x+B/HqeILXy5WxOCVbgBww6gj8KOZKdgvZHamUhyJPXqTT9iOVLAq+OUHXPSqMd5cBP3fKjrlcHNTRm5MbGUkZHUAcVYrkOovJaQPJ0POAK8Y8Qa9uv55GLIIyd4IJya6T4j68NPxaws245UEN65rwLV77UI38pZ5CzH5ww3D8MnP/6zWM23ojOT6Gx4k16+vz5YV/LDbRgYI6Zrvfhraado2nHWNSaOOOJNxJ6bq8u0eYpIryOokBy4cAA9unX1ra17XNSvdOMcBjFonCRiMNyMfnUvQhPUz/iL4suPFerPJHKI4EOECsMIB64zn/61M+H/AIfm1bWUgiRHQMDLNn7o/L0Bqjo+gXOoXqxSx/f5IVdob1Pp0r0+G503wjpD2ttGounBMjbs84+vp6U7j33NPx54iTQbm3t9KdDFAAJFLYDHjp/ntXm+p+NtT1GYxrPhHUkhRgrn88jr6dqZqFxFeyM7xyhn4Jds5x/9b+XSqF1fW1mxaKGOEkY3E5JPA/KnuK9xG1JgWNxJJjrIQxzimxNNHGrKbgEDMZAzx3yfUc1Tk1V9h8ryhGckErv3cf8A6qqPf3MpLT3ZMZ7JwT+HbpQKxtDWNSHlGOW4/djGN3P/ANf/AOtXV6R8S9S0sRwXBYKc87un415nNNNHl4pZERWJJC5J9yadDdiVMBm39CzdvX8KLW1GfQOj/EyfUYFtiVdvv5DdcdR/n1r03S/FEc9h5rRnO3AA/r6V8ZR30lrKjWk22Uc7lPAPtXp3gbxJrGs3MenbwiqCplHBP/6/8aabRak0ejjWhea+7S3EaFW5j3Dn6ZrY1DXLePTbiK7uI0gZCGLPxjHvXF638L0uybq1vbmC5Y5L72bP4E+vpiqumfCdrh92t6nd3kSHPktK2w/hmjXYLs42z1ezi+2S2V3J9lilbyy4ySefuk9en86f4V8UyaZdTTX1g0VlMNy3XlYGfT/PpXqp8B6PGsPmQRxwRjIBJwfrW1JoWk3enfZjDby2nACAZXP+OaSiLlZ8oftF3kWoeIvDl3bnMU2io6n1BuLjBryavZv2prO20/xtodpYqFtotGjVFHOB589eM1VFWgrm7CiiitRBRRRQAUUUUAFFFFABRRRQAV7R8SdSa0+JOsojqMeRww3A/uIxjmvF69M+MzZ+JOsEdf3HT/rhHXLU1rwXlL84mijzQa9P1KqmSecbchpTzGDwCO9X5MGWQW7AIVwSoPU+vuefaua07VDFtE5ZtnTHXHpXTxOs1mdRhdFErFBByGfp8wA/Lt2rVqxzSi09TnfFEmb5UV3YKig7zk8AViZqzqM/2i8kkwRk4warVaVkdMFZBTl6jNNFSRRvK4WNSzHsKCmeyeAPEy6Xp7N9nhMaKnCAKQe5J5/pU/jL4nSJBJDYW/lzugUZbdt9SfevKZJry10xoGcCCRgduRy3r61SRS7BpX3NngE9ajk1OWMepp2cF9qE5b95LJJkl8ZI9a24NJm0zTmkv5FSJ+m05Y5Hp/n+VXbK8bw5pqSIVS4lO5W+8dvQ/hWFqOqS38cks85nkfHXjHtgUO70FdyOt8AeGzq2ptd3CiaGMfKFAA/GvRx4at7WLzY4JI2QsdpclGyOQR0I6Vh/s/H7V9phl5HqDtKj8Otez3unG0VcYa2K4XjrSauK1zyay8MQIiSxWsaMAcAryuSeSc1ftPD0q2tzFO5eEnhScMPq3XH+ea9IjtYvLJiThs4X+6fc+lOOlpKirsUIVz94/MfyqeUfKeJ3vhdYr9LZ4Va2Zuc5PA9+n4mua8UaOdPeU2IVYjgBdg3DvjNe8eJNMjFoXKtGpGMk53Y64rzfxB/o1pLMx2QHOcjcSuO/HXP6VLbQrWPLYWmgKTo6mWQbgrfdwPX368VoW3jy40i4nMcMdyrgAxS52q3qB2rMl3w3UggbFuzbkUndnpyPes642M7eeQX3YA74rTcaS6mg3jnWPKYQrFEzEkOic81zMsNwsu58mRuSc561rQRxxA7ypf8AhXg4q3eecJcXBTeANpXGB+IqtFsWpKOyM7xErp8PNCEmd39r6j19PIsf/r1xtd741ZG8BeHtg/5ieobiOhPk2X/1q4KnTd4/f+ZW50nw1OPiN4VOcf8AE1tef+2y16T4W1u70jUY57Ob5WbLer+/tXm3w1GfiL4VHrqtr/6OWuvtxHLDG8GI0OTjGD7Cs5/xPkKfwn1l4C8Z6br+niPzI1mQAkMeT9fyNdss0QtxITGIACchutfGGi39xpVyl3EyLISDu3/eGen0x/KvoD4deLtP8QRusmFvEh+5tIjHHUetUp9CIyPPPG3iOLV/EFzFC+1fN8tDgg9TnqP85riteEcc8cbZlbYcM/06n6cener1hp41Txc9tfy+ajXLvMIzyvJ6E/Sqfilsa9cooSGKNhHFuOSccVmu5m9x2iW4nXISRgx2KjEkYz9OetemWfhS4NrBGwK8/wAZA+U9geBXIfDbTru5vZtRjgja3sBul81sKT16H6D9K1b34m/aNVF07mSYLsihHESD1PHJ6UOw15nU669h4Q04hVE11KOFbkLwP/rV49NfSXl4z4bzJDzuGCasatqsur3xmYv5qkEnaQp9f6d6iltgUdrkeau3LEMAAT6fh2z6fSjYTdzO1m9ZAYZgSW4yRkEZ9aoRJGCDHsfC4Yk/MKZegxO0eQ0bnITAO32I71nwTPHMxG0qQd2efertYaWhplHVG5xz8vPT8/w5+tMgLxTgxuEkX+NTz9KtOYwkcrldxHBOSPy96rXjow2MVU59sr7+mOaAJJLrzZAJJCj46AcY684qjKwZw5Z/u/Kobp+XepFtsoWldSn99uc/4U5wLeBi/wAkmMhQ3yn3B65oQEsFynIG4MRjJUmug8Jak9lq42yu8Z7MACOew/HtXJpIA8bDBycfMN1aujMpvYhgjP3U4IH9aHsJn1NoGorfacu8lVAA3Dv+NYvjrxrF4Qs2KOk1/cKVhTsPf1x0qXwDNJdWsCuyvAEyHXvivnn4m6tcy+Or9rlyYo5WjiAHCjPp60XvsaXui/Lr/iidbtGLSxXGXcKPujrwPx7f41Z8H+MNW8KuHtoA0W8maJiRuB68E9eldb8PVtr2wzbToJkAzF1BznnntXR+LPA8fiHSYxbrFa6gjcSqOPofrSRCu9TxD9pvUYtX8W+H9QtwwiudEikUMMHBmn7V49Xq/wC0Pp02ka74Y0+7YNPb6FEjkdz58/NeUVVH4Fc6GFFFFaiCiiigAooooAKKKKACiiigAr0741Ef8LM1jA4Ig/8AREdeY16b8aufiZrPT/lh0/64R1y1P94h6S/OJtT+F/L9Thx1rpvC2r/Z5ZItiC9nKol5IxJgQckKOmT0/TvXNUZwcjiuhilFSVia8dpLuZnbcxc5bGM81CwwcUpDfeOeeh9aCPXrjNA0Fa5XUNEt13w+R9sjDpIfvFc9vT/9VZtoP9Ij+TecjC+vtVzVbq51C8Xz3MkijYqjoo9BSIk7uzGCWIxSSyySSXbHg9sVY0PSbzWL0Q2Me6ReWJOAB6nNMsNIubu4MaISV+/jqPw6n8K928HwWljotpHYRmFyhMsgBznHVu+f85pSlymU5qOkTndI+GQe2e61a/eScKCoh5x+hz+lQ6p4CtrW3uZrOWSTyV3HzSN0hHUdABXoumyXNrfSowE0O0/NkLkdsYPPOewqxqet6dpcCw3Fs8s90PKgjU53M5/Tk96y5mzO55P8NfEsPhbxXHPcSNDBMBDK2c4B6H/69fXukyJqdmhsnhaAp94cnn19DXy78RfA9zo0kBjs2aaUbvk5CY7D0/GtT4WeP9T8GI1tqMJnsjzv3bnQdxj0q1JDTs9T3y7tYreRoyu0jJYb+tVo5Ukgb7OOF6bic/Ue1S6N4p0XxTEJ7SWPzNhO0nHPv+VVr65RNjMGRTyCPWjTdFszG/eZF6yEjJjRv4a818ZOt1eyQzohgft6genbP5V3GuXNwyb9KkTnhy4JwPYetcW+nZZ7Fklmjc7pOQWGT06cColroRLY871rSpAsVwQUt4iVhi4LlR047D61xmrwCC7M0gBBwccH+VfQ114UkmmF4rkkJhcA7SPQ4NeM+M7SK11edplAKDAh24HHGePzqo6MSOULxyvnGzHIzxn2qbUJEtrJQCPNfpg9BVRpmkcKseATT9XHmRq/GV+U1oaJaq4uu8/DrQ2JJJ1jUf8A0RY1yFdfrv8AyTjQv+wxqP8A6Isa5CnDY0ludL8Mv+SkeFP+wtaf+jkrttNgSeJUjXaVzhguCMdiOorivhj/AMlJ8J/9ha0/9HJXdWEP75IQ5WH7+5OWAPT8Kyn8fyM6nwlR0MU4imUpJyjNjKj0PH41oaVqk+i3sc9tKI51+X5QfmQ4H+ePX3qK4SKWczOBtHypjOSPXP5frUbxw+TKkZcSMuBuHAHtnt+lBieg6ZatpPiC3uxuZLmNpflGAG6nJ9/p/wDW468uWn1Ke5dDHJNI2xhhlx0J5+p7V0dprMf9g27zqJWt41jQ52hc8df89q4DXNUlhmubWL5ZZPlk45UZ6CktWCVy82p6hq9uND0dpPsTS42wgqZmPHze314q/ceHU0mX7HdS+ZqG0NIg5VfQEkd/w7V12lzDwD4QtPLhKarfLuLP/wAs8jqR1AGR+tchaBXummllZ5mLOxIxknvn1o06DbILwsrvbp5aE4YjDYHpxj6e9WNHlCXP2aPk4LbVUbCe+VPXiopM3Eksu0fM3y/Lgn8up961AJLWwtokRY3kG5iSevv6daGSZmswLyUhRbjdksDgjv0+mPzrMjtt4YzbfqoB/WtzxBHdJBG6oBP90pxkjOAeegrGuojJh0JEQ4Yd859M8009BopTH7MwG8uvQqTjv2p8LKAjeauBk7ivI9j+tU3jVrlg4baDwDwKsHYRs+6+Tt2g8fjVDJZbph+8UcntyBj/ADxVe4fznwQFGDySTmrM8u6FCGUkcc4PP5024Mi2C+Y2ZpOw/hX/ADzSTAqK75VshcdccAjNa1hdyBwlvtBJAyTjJ7AZ+nrUNlEsdt877hgnGMK3T+VX7OYIylIwsg4yeD9PQ9xQwPfvhlZumnq8jsuAepztFcL8YfCIu743n2fZKx++g++ScY/z/wDrb4W8fro8Yt2tpLiRQWeeQ8Dp0zXrXhLUm8R6cl5cIY43XzPmHQYzSXYa2seG6B4V1fS4bSSNTaI0gIlc5JHHb9Pxr33Q5vPgjhhmDPGo3vtz+VeDfFTxVf8AiHWW0zSWK6Tp8hDjdgyEZHPcgYP866D4JJqeueImupbmRdLgTAQLjLZFC8g2Z57+1x/yUbSwcgjSIuvX/XTV4hXun7YOf+Fl6ZkYP9kRcf8AbaavC6ul8P3/AJm7CiiitBBRRRQAUUUUAFFFFABRRRQAV6b8aTn4l6ycf88Mf9+I68yr0741KR8TNZBBz+56/wDXCOuWp/vEPSX5xNqfwv5fqcPQKMGjtXQMl8+RoEgZiYkYsq+hOM/yFNJ3uSB1NJtPp2zQOlArdjo/Aen/AG/xFHwvlwI0pLHAGBwfzxWhcS2elz3VrpRF5fXI+e6cD90M5Ozjg+ppng3T55NOurjZKYHby9sbEGQjkjjtjn0/lTJ7OG1sY9Ruf3plP7oBvvH1wBwB+tQ3qc0neTPTvgr4b026g/tASKdRR9vzOG2992CePT869CvNKjeK6uAZbTLf65SAPqOeleNeDNBu9UQ3OlXc9jK5G9Ldvlyfxx07V6KfDfiWDT45b3UZdSkUfu4ZMeWig/xDPJ9zUO5noasS29tKdw3XBwCIVLMwHfpjHtWjr+gWGs2VtczvNYS27B0kTG8kexBx61X02wv7VXbU/nckEFduACB2HQdab4tne30iYum1HGCzfwZHDYHviktEV0Oz8KRp4j0u6SWVLlsBYpG5GB3461wHxA+GEunWUr6ajyQMcugJwTn9O/0ql8Inu/D2vXc1tdNPbXRXzEZTt4zux6da9tj8c+GLnVG0mPV7abUgButowzsp9wOnb/Jq9GrMqKUkfJtz/aPhu7Se3U2XmEssTMFY46g4xn/PQ11dl47nmsRDfSCYxgAyRIcrz9OvSvoDWn8MNetHerGLjgDMDFVJ6HIGK5q08LeHLuVZreWN0ic5C25wB37UnEXK0cTpFxPqN2iMJWtlUNG20AknqPWuy0DQA+pXV/8AZ3ZBgNwN0mB6+grtdB0vRgRLYmKUoCuE7fhW4lrEsLRKq7G6gcZz/n9KqMOpSh3PNNTvra1tpIYY48MMvIBnBrwH4rafDJJZSwuxkmQkBgQWAx6/XvzX0B43NvoyPLcxyfZbcFkjRQd2B1xXzf4ovoNVjmu4YJjdO+0bzkoOuR2xz/Koe4nucTbLYwRzG7u3MwH7uGFc5PozHp36Zo1Iwyx7oNwfoIeT+NUL6I2VwU8tlcYOX61JF5gRpZN5kzkk1rbqVa2qJNeUr8OtDDDB/tjUeP8AthY1x9dx4si8v4feHWAx5up6g/X/AKZWY/pXD04bDvfU6b4Yf8lK8J/9he0/9HJXpV8j2/hnS9XgkWQu/kugA+Xg8ZrzX4Y8fErwn/2F7T/0cleueFo4b34XFd0aMrnDtHkA/wCOPxFY1PjJnsjHtvJnSRvMiUqCRvBJz3wRUUnkPdQo0m4k5YxAk/TnA/wrGnM2myxmZl2H5sc/Nz3HbpV2zlEn70MxYDCIG4/KnbQxsdLqtukKBbZGSPlgFYYPJPTOT0P5msb4beGJfFHjk/bV/wBGt28+4DdMDkLz2r0b4MeHW1/XbyQsy21uhIODlZT9RnirnxM0m8+HnhhYLCdP7S1m6K3F4gCyMmM8fhx/nNJXKitDgfHGorqnia9kjkDwxnyYvRdpxx685/ziqcczNbJHDChzwHj+979evQZ7/pVVIogY4Yj5jD5QEzknnnPepPtcNu0iyfuRGvzDfuZumBjpnr1o6EstWkEDHy5RKpRSWUZyuM9QPpU8sjFzKpKgjLB23ZGB1GAfWqWjwJJaG4vWuBNJkIoc/KOmSP5VoopN4PKgLRHkkFsR+vHrSJe5DJKohke6EsjEYSFOo5GDj0rk72drVdk+A7tkhsg//Xrs9XubWygZZAioThmbIJ9O3PT16/rRhS3uWju5Vw/RJOCQOxAI9Mdaa0Vxp2MO3sLg2/nSRqEyApx2/wA4qUWkm5iLaUJg7SpwPzJ966K5jEc3Dbt3QttOe/4f561GbUGSRpRFmNTk7jgn0HP6CmmFzmLkSwxgSROsfXOMk/jUU1wJHBXB2jAyc4FdFcwQ3EKxyBpOOBHn5uMcZ7HHB/xqtNp9sYyn2baoGNofPP1Ofb8uKNBpmOstuyAHzBg/cU9eDWpeSRRW6xxu3I+VVXIBrBuY2tyXKzAHoWyCKtW0pa0kBkZTnO/knt/n8adh2NvSLe3eS1tfnubmZv3iHgAZH+NfTOoX0Wg+FGaC3JZYcJEnAzjufauJ+CXgPS10yHVrlpLnUZAeZGx5Y6YFd3qi2+rTHSobfz7c/JO5faFU8HHr+lHQqK6ngXhrSL7xfrk9vbywmEPuuJY4x/e+7k+/evonQLCx8LaLcSyKEtbdN0zNwDjsPzq1oehWHh/TxZ6PCkSNwNo5J9Se9eWfGDVpNaLeH7K/jt9IsQHvZSOJX6hMnr2P4UW5UCSWrPFP2k9UfW/FOganIrIbrRklCt1VTcT7QffGK8jr0747FzqHhLzEMbf2DECh6r+/n4rzGnQ/hq5tLcKKKK1EFFFFABRRRQAUUUUAFFFFABXqHxrXHxI1Y7s58noOOII68vr1L42kn4k6rliRiHAPb9xHXNP+PH0l+cTWHwv5fqcHS0UVuULUqwSGZYlRjI2AFA5ya0vCektrevWtim752ydoycDk/wD669H8J6Jp6+N5tV1+9gtdPt2P+tyNzY+VeOOn9KTlYynU5XYwLjV4LbS7XRNOhV5ITunvowCS3OVX/wDXXU+E9L0/XLhtU8Q3lraadYItvFayusYkxjLN2HOOnX8KwdR0z7LqUMdvZySWN7cCcW8IUHYT0GeRnp6Vf/4Re71bxeif2Qtrpn8SRFT5cQOSGPQnA6jNZXW5z6HaWPjvw1pV0bTw5Z3N7cKxxHYW3mYA7qWIDfUV2dneanqs9rdXl09isoOLCfAkA55YKSFznvVOw0PT7G+iXw7p7Rae0ax3Cqo49yTySe9aEuoQ2e+yh0+SdYm3y3Oz93/us3UnA96WgbbF3VZtK0p7e6vruTKDmNBkH06dfrWPc6vpWszM0vmPYSLuZUQs3ToVPeuT8S6dL4lvo765l+1Q5MlusSHyol6ADnk8Zyc/SprPw9dPpz2xkkhmmTy7eZ84XIIzweMe/NJsL6hrWrWWhQzppc4llvl8uGJZN8oz32D7uPr1rvvBWlJoGnnUrqBIJbpRJI8iAOR2APc/jXnXwi8PxaTaz/aJYLieaaTdNG2CI1ODjIyQSMn8K9F1NE1gGMulxbptBDjjI5GPfIqttRpE1iy373GrTHz7tj5aQkthV6A89z9K04L3ypY7RbeOMOedrcHuc1nWsL+SftEqjYpIwDjj1OOtR/2is062zkKVbdvBznjpgdPxppjK3i+DU0aJdDkfT5AczXsZXcVHQc9fxrptE8TX8FhBvI1CHaQZ3wkrHjDEdP7w98jpisaSZpLhYQ0jjGSUjJGMdCQcVq28G51SCHMBUZTPAH+fWhb6Du7k3iHVNM8T6LNGrpFPtI2swyw9jXzD4ikXS5mRkvLWPeWMIQDfg8fhgmvafGOk22k2rXWm26iVTvwDgsc84AOCcZH414v8TbmzvblruK5ERu0y1qQS8Tr1BPY+3ele7E9Xqef6vqD6pdmb7OsY+6AnP/6609Es0mmitJRLukzu2ruI/CnaJcxShLWG0RoSQXbA3Fvr2Feo3V5oXg2xgbSmtZtfuFPmSBhIbc47L0HXv+vSrbsrIJP7KPPPizHDb+FPDlrbhRHb3t7Hx1z5NmTn0PNeW13/AI7eSbwhpE80jSyzaxqMjyMoG9jDZZPHHX0rgKdL4fv/ADNFsdP8Ls/8LL8JY6/2vaf+jkr1v4cor+FIrMRsfPjLDDEA9OnpXknww/5KV4SyCR/a9pwP+uyV754N04WVhbFyEKIAjBc/hnvyetZ1H71iKmyOI8b6Dqb26BIC/wBmTLuOOPxPWsTwRDJcLdBVJaJeobBzn/PSvZdWPnWsqSRDyyp3b2xk49cde1cx+z/pA1LX9atXRSu4fKR15NCbasQtrHvfwq0yPw74ahadiHuF8yRivfrXhvxd8SyeJfiFcwIpFpYLtibnuBknjj/61fU01kiaRJFFGm8RYXjHOMV8T6u10nifV4rzJdblt6kj5lzxjv6VUtLItrljZDLVT5rNv8tSuFRcgk+vGD39q1bWERQtH5R4GSQVbJ+vX/8AVWNp9s9v5wuWy0hwgxkIK2gka7GCpIUyODnb/wDX71LMWWF3PMM8KxIHlnGe559+D/nidX8ogEgkHAwN+AM+9RA7lLMTuQH7nO7pjnt1P609mK7JQ8jAMcKQTjjt+Hr/AIVJJBcfZ79UjmjjSHeWKdW69fb/AD2p8m6LHlZG9RsVk6YJHU8D8+9TTbUXbbxqF+9ubByRjv36Y/CoJQzS5YuRImCV6L1x1/pQ2MS6UZCEBXKhTtBIPPp6cimGNJElLSIj9TjJYdOx+nf2qcBoowRgYYqSCvHr1HGMe9QgERADeQeCGlyxI9f1/X609xFWfESE5CFjg7hgkY7c1XK+e6FFwB1IIBP4/n71dkU5JEZJx9wgYHVh+oziqrBxLty8jqfmzlQc/p/+uheZRXlj+0jy3hIVgcbkx6nH8/0pnhnSryeRrOyiy10/lLJKw2xju2O9SGKRpI8tll4AzjP9en411Xwn8Kyat4xtpLSWZ7eBy88hJ2rweB+VNbWGj3bwZpVnpOgLoumXjXMkKgXE5XaAcc4rcttKtrZkMQPmJyZOzdqu2/khnFkkaQxHDddxPqag1G/jgtHkhDO3bJ4J/wAK12WptaxynxK8WRaBpjWFl5l3rV8DHFb2w3OexIPYcjk14VD4fil122svEc95aLuLtZwZeQscjLtggE5r1PX7+HRYpb57i3Gt3W7bkDCr6An6/j7VneEYLRJZdb1jbJcvySzZwMdv896zu2zOTvoeIftKWUem+KPDtnCrrHDokSqHbcwHnz4ya8ir1/8AaYvI9Q8W6FeQDEU+jRyICMcGefFeQVVH4FY3YUUUVqIKKKKACiiigAooooAKKKKACvUvjUD/AMLM1lS2FBh756wR15bXrHxhXHxK1oqGUHyP4un7iOuaf8ePpL84mkXaD+X6nCJAzRlx26io1XJx0q9bYZzE74B9Fzk+9M0yFbi8ETOAGBGemePetyVN6nXfD0T6Rb3ermNgsyG1hDKQHyRuYNjjGMZpnirW3v8ATZrG43K0VwrxdNuACPz5rqPDGnxr4UMLSyTwMrTSo65WNgSAB3B4Pt+dcx4wjtpdC065jMn2mR23K6qPlHHY59PzrK95GCfNO5qeFr6aDw/earNm61AKtnaBz84J5+TuTjPvXtPw0jvrLwdaS6xZGC5uGKqs3+sbnqVxxWPY6ZpPhDwxa6hOd89vbBgxXdhyMcD1JrZ1nXpdE0q21bU7YskioFt1ALK7f1yTSb1uJW3Ga3rM+ny3mlJl5eC3JXap6HPf0+oqroUUt9Aqo7tG4yu3lcd8kcevFVtL1ePWLo3kdjcQ3F5/rC44O3gAc+g/WuxsQJ40lhURInUY547e9JbhvqFxp6pYxpCQzhgApAyXrkPGemPcMLW6vJnuJ5FYJHuIULjpjoB0962L3WBaiS7uAoEAJUKCenXgcVW8MXFz4hht9aNuVaXLR7jnauePzx70aMb7GnpmlrLNbS5KyR2xRkjBxjjk9u3atyGwawCRD9+hBZc8BWx3PrUNrBPBqpZmRgE5CnOfbnpWjc/vuI5WVoyGO1c8+lUkkNIqBzNaKZ5Y1EK4znAGOuf8ayJJraO5WHgB33qob75x0HtWrcSW9refY57iOOecM8Sbhukx97ap64yOlUtNtY7jUZL4AARZVQ38PHpQwLunuYLYF4uZXJJX0zwMVd1G6eK2QQbllbGducj6isqC6S7luIYM7opQrNgdfb60+8nCNI53Nv4GTgr+HagDL127tBDJJeTxQ2oUnd0VR/eOfevlnxVdpfa3MYLjzoC52vgqD74PSvoXX9O/tSzltLpiUkTHykjkc9P6/SvAPEukW9hr7WFjKZQmCzE5x7Z9cUQet2VFq5tWOqyDQk0fTtLh3LlpLw/MzjOTtGOPrk1nz2ybTKH2sFA+c5LZ9h/Wpbi9EDRWlv5qPtwXi+UD29+Kc8aRaeqSMygNwpH+sP17AdaZBm+NAB4H0EAj/kJ3+QBjB8myrg67nxexPgPQuc41XUOfU+TZVw1XT+H7/wAzVHT/AAv4+JfhLHX+17T/ANHJX1JYRCKRUbcQn909B2H5V8t/DD/kpfhL/sL2n/o5K+krbUUc+fDcIxkO0YHygex/rWVX4yZ7I1dW0sXEbiLLSFcgCuN+DKXWj/EuW33KGlYrIMjnHP8An616RpTGdPL2qyAZLDuTXFsq6J8ULO4ChdzhThepNJaambPpDVCzQrEmSznqO1fInxEs30/x/qwlxK8uJFz0HAHrzX1rrYl/sq+a3ZRN5DbGb+E4/wDrV8k65qtnbXU1rqF1bSsdzTXFuGMrSZ+73K496uo9UXU2MS0Ty1y7MznnzQMAjnp7f4Vo20qhhtDeY/GwnDA9+fw+nauXt50lvFuCHIHChW+T24weevrW9aaragnbcqCclvMJ6/j9MZqGtDFo1RLFJHv3bMfMC4yWHsAOeq/QmkmlG/yoD5pYdCOB+PU/596prqEYwwkg3Zx13BhjsBwCOadbSv8AbGDTRSYBICupYD8/rSQglkW3nRJ3dYlbIKp83XAwMZxirklr5sIlSV8N8w+UbiAO6n+nNVZ1ilZYZESQ7sqQT17+3p3p6zJC7QxBYiVy2GICk+w68k0adAJU2lGQXEqjbuyEwwJ74OTUM0sqwyeZIChO1CowSPftj/P1sOySQbArXD45HIPT3H0HTv8AhWRNcxwwHayRgA9VbqM84xj1poCWedQxt2MRYg7n3E9+o9uaGjzlvL80Ywdqg459TyOn61WmuVS1iN3LmIDeCDtb9B6EVj3Wr+cfLeMMh4BJwf8AJppajSOt8MaLd+KNWj0vQlWW4JBuJsHbbpnufXjp+tfVfgrwzYeFdHXTtPjwy/NI+D87dckmuO+AV7bXXgWBbDSrexG8hxBn94QSCxPXsOppfEXi9pPiMmjWV45t7GHzZ4kj+QMeAGbv9KtWjqbRtFXO/v44hbskjx5Y7ti8ZH+e9cnrs+yzdklxGqlVjH8Z/wDrVbhnt7uZb1Vj+0SHaJM4OB25rj/HmpRaVIxYs0gUsqIM45/z+tEmDZ5X8QL+JpjbPKrXLnDDyyTg9vT0/KuX1TV57i3TT7UOIEB3DzMBjnrx05qvrN1Le6hPLLEcu5567fTNXNG0S51uSIRQ5t4xuZj8hDdffjgiosZHL/GsfvfBf3cf8I7Bjb0/109ebV6r+0LGkWueGYoyCqaHEnBz0nnFeVVdD+GjpYUUUVqIKKKKACiiigAooooAKKKKACvXPjAiL8S9W6kEQHHYfuI68jr1P41EL8TdZxknMPBPT9xHXNP+PH0l+cTRK8H8v1OWePIOz75PyhRVK3Zo5kZfvA8VetrtUURvFGTjAfGD+dU5wnnv5ZJTPBNboiHVM9Jiu7ie2tIxGFvpSdiQgoN2OOvXg9jn86u678PtYn0PT7qwCXN7NJ5cttHwU6kOCeg4Gc9zUPh+GVrTw3NHMskbXAQLEvzKcD5S/c9sH0r6A8NfCaO9kOp+JdW1i4aWARJZmQQhI+PlfZy3T16HmsUm3oYRTvoeZeOvFulWmgmxtPKubuCRY2kTlY5Bzu69iPzrjfFHjiLxJa2iyrLbLaAMig7/ADpenPoADmvrWT4eeE2sWsxoGnJbMcsiQqu4+p457V574y+AWjXsHmeF55tJuY28xYwdyMfx5X6iq5Wty+QzvCNklx4ftoWAjvWtxKCeqMR06Y796zrqw1/SdHGoJqkLqZGyGxtAGVZTjuCD6YPFW9N0vx34eiOm6r4fn1iBG+S+tZFdnHbcCQePX2qHxjrfiHVtI+xaf4S1yRAhiEj2L7RngHkc/WoaJUdLM8Z8YeONQ8RSR2L+XFEpKHavPXsfyr6A0C4GleELZoJCVgtk8wFNpYqvYdzXy/NpGr6DfJNfaXeW3lMHBuLZ0HB/2gK7+D4rXs2qwQvDb/YTtXAQ7s8DPXH6VTXYpq2x6d4P8RX13cmfVdHvIhLgw7l4YZ4GfWu+1G3SG9to9hhnmXfGh5AAx1x6VzGna1extH9nigCKMsjnPJ79RXNfEfx3Y2UMQkaRLjJKeWrYLD+EnpipTEj0HUkSa6lY28bXCoY1k2cgHGQD1wcAnp0HpTbSEPaysJBuVfmUHABH9a5eDxhp194Ytbp9Qs1cw8gTLgSHAI9c9qp3Xi3QLRNMs49XiuNVk27V37Y2Y9N7/dH0yM9s072Dcl0KQr4r1a0MpbcqzgJx2wSe3px7Gr2oTJFbeZczqE6/MQMe3tXAWXhH4leJfFlzqtjbxafbzOV+1GQLA6qcAqpJLA4645r0rTPgRp0wSXxbrOpazNg+ZCsnkQE5PRV+Ydf73P6VSi2gUWeM+M/iDHdWw03w4JJLyY7fOGNqqew9T79q4KHThZGVnkMtwCVkKDdg555/rXufxh+GmjeFbPSm8Lp9ijv7r7JNHLKzjBUkNliTkY9cda8b1j7ZpOjjbbx7I5vLFyxBy3XK889OopLTRDaadkV4LO8ub2OCwikleZ9gUJ/F+VP8R6bNZTXMFwM3Frhbh2OBk9FUVtWeuQ6f4Pk/s8TjXrtsSXWDgKc5YH+92GK57WbNIYYgss8yohaZnP3n7k/iaa3JRl+KCx8BaGWI/wCQrf4HoPIsq4uu08TsW8A6GSc/8TbUOnT/AFFjXF1dPb7zU6f4X/8AJS/CXX/kL2nT/rslezsskcdtKE3rwcqdoHHce9eM/C44+JnhIntq9p/6OSvpq/02za1j+4rRjh0XBHHNY1fi+RFRaCeGdVX7SoSSMMw53d8c4469c/jU/jGxS+vLa7j8svCyybtxycEHFefxRl9etra3eTbITuIY8jP1689a6+T7TCHsfPaa3Vd25uXGeg44/wD1D61PQyT6Hp/xU8SXOj/DZ7yxbE80QTKttxkAHH518aySFizBw5ySXPBbP86+mZy/if4c3GlyNmWNf3axsScDkbs/TkV813du9tcy20gIZGKc9RjitL3Zo3cFXdCd3GwDjPUnvx+P5VErlSCu3PXK9RTlkIjIw3Ptk0yMFRgrweuehpiJCQAGJxzjGe/0oeQM5P3j7D/PpUjYTPC7yMnHJFIBvYcncRz7Gi4iaHVLyJVUOWjX+FuQO/Sp4dbuI2Y4UtnPzc59OPSs6VMMOCCRximgAHCj5j1JPGTRYLI2X1u8lhdHlBixnAGAP881ktezyMWeZsjGMGmqwEbeYMovQ7u9NkcFs7mOe2aYJEskm6bLlgvbB6Hr61G+eqqWOMc8GmOpIHoD616V8GvAb+MfEMb3O9NOtSHlkj4yRyF5oGfQ3wZ06XQPhxZLOrGRl3bOScknrn3Nef8Ai3WLHTNX1eORl+3zpvnl43DrhR+eK9vnmtdPS2t1QkfcgiUZ6dz/AJ/nXyl4x0e7vPi1q9jNHIqyfOW7sMdiO3b8PxpT6IqSsjvvhfqieKtJkXzTDfWznJVj0zkdef8AP4Vx/j26nv72aN5hMIywDHOfp9PetbwhYN4L0e+khDtNKDkPjYMcdcZH61w+q3f2mRIt4EYyx3Mdzk5OOefXn2qHq9DNvSxTstOuL9ZorNckY3LjJ54xnI96+h/BPhf+zfC6qwUzzRHHTIOPQVx/wF0i2mt9QvJo3YFuXKfKoAJzk/WtjxJ8XbOxv207Q7A3MsLiMOzDY3TP3TnvVaLccV1Pnn9oK3mtNa8MW1zt8+HRI0faCBkXFx6815XXtH7VcvnePNHl8sRmTRomKjPUzTE9a8XqqKtBI3luFFFFaiCiiigAooooAKKKKACiiigAr1L42HPxN1k4H/LHOP8ArhHXltey/FPTG1H4r6xF5iqT5AXd3PkR8fWuaf8AHi/KX5xNIyUYNvy/U8+sIxPdIjlEUnlmBx+lT6lZiGdjGjJHngN1/lXrUHw606y0Nr67cPNCAWCNiMtjgYPOTx3FcZ4h/wCJkbyUKiyQ4RlA2hce2c5/xrTn1Mfaa3R6f8BvB2i+IBpdw0Er3tnMLiRmlYKuGJHy9D619XDoM18t/sq6rFZajeWs5IEwXYScjPP+Ir6kPBxzk+lVEIdRG/X86OjdCCfalH1oz096o0EOM5AyRQBleP8A64pD0AwfbFKvPB4+tAEdxHFPC0VxGkkLDDK6hgfqO9eU+M/gT4X1+6a90kSaDf53BrRQYS3GCYjxx/slevevWckDJ4x2NAGFwc0NJgfOOrfDH4rJcvHp2v6RNaNhVbOxgB3IaJiPwY1f0/8AZ/udXMdx488U3N1cbceTp0aosZ9ndfm/74U19AAjAxjA9KGz2zmkopCSS2PMNL+BfgHTzEW0V7yaPnzbq5lbd/vIGCH/AL5rp7b4e+D7SdJ7bwtokU0bbkdbCIFT2IO3r710447E/wBKD0zjH1FOwxFAUBQAFA4CincnGcg4pCBnkf41BqF1BYWM91dSxw28SF3eQ4VQOpJNDdtQPC/2j7y3v/EHhvQpbmONY0lvpsscphSqcDnkk49cGvDPiRZW2naXotlDJKGVGklEhwTnG0lOx61peL/Fl7rF1deKpyi3V/KqQQ7AfJhQ/InOSMnJOD9K47xndzT3ca3YIuyBJMTkEsQOufSsYpt3I3mULDUSlyipChBAQKx/X610J8SzQaZdWWpWkc7yLhZJCC0fp+Ht71xO4q4ZTgjoRV/Ur1biKLaBvKjeff8AzitHFMqUNVYm8RHPw+0T31fUD/5Asa46uw14/wDFu9CHGf7X1D/0RY1x9OGwS3Oo+F3/ACU3wjjr/bFn/wCjkr6S1O7UWrjeANvDK+WHXtXzb8Lf+Sm+Ef8AsMWf/o5K9km02CwsxJfXImLDIbso/PocD+dY1fjM6myGaPqsU+pMIkdupZh65x8x9fr+HSuwaX/RJm35/wBnHXuPSue0nSmsPDc17NbpF9offlhgKoPBAqkPE0msSfZNOtAZI8J5gPGO/X8eP/1VL8jE6jwf4hj0fUPOltImtpjtPlptJPTk9/Y1zvxW0G1uZv7Z0YKI5P8AWxf3T68f54qTUjCxhit/LHl/6wq2OnsevOT2rd8MahavHNY6jHujc7A5/LoenahMadtDwvb94k4YenenKoU7WXLH1YZrtPiD4Pn8P3/nwgtYzNmNuMjIBwe3r6VxbjaCcgZPAzjFaJ6FCOc/KVIwvcYH5igEeZ2GOfmwc03B+6ACfbpUqgCPc5JOSM9h9KbAbtAiY4yeOhAqI8n1HPFSjJQsQQOgyM5pNqtwygMR1HNIBpDE5IC8Y560Fj5TcYI79eKVAxbg4HqDXUaV4UuPsB1PUd0FgoGC3WQnpgdfxouBB4L8J3/izWbfTNOAFwwEm6QHYid2Y/yHevpjRdR0XwJo8Xh/S7hTLDj7TeSLlS5BJC4xubrwOgrxnw54xksbKbSrTTrfSsHc9xCC00ufU/TiqV9Nd3nzxSsW8zcqmU8c9frUuTQlKx9O+H9W0zXGDW93KkgOCm4Av9f8K8/8R6PbwfFn7ZgEm2ULnBwT9fqa818K+IZ/D+pw3MS741mHniV8Yz1I+hPTvXr/AIgvLS/8Y6ReW7K5mj2nBo5rotS5kZHxadNP0y2sYeJJU3t8o+U/lXiFvukm8wZK7WZwSTk/j2/zzXrPx6mlTxFFCHI2wgqABxXlEwMVncSY3KgA3c8+nTvmk92RLc67TfGcfh74fXGkaXBcG+vgfMmEi7Ys5H179hisXwRo0us6vYxwLHKI/nkRtuSM9cnr/wDrqDWfD+oaRBYTR2zvDew5DKp+XoTn8x+VdT8N9FvonTUpLeUShSIYyNrAd8cd6fqLeyOC/av2f8J9o4i+4NHiUcY6TTDpXilez/tUEt440UlmY/2NFknrnz58/rXjFaUfgOmQUUUVoIKKKKACiiigAooooAKKKKACvovUVt5vjVrJufLWKJIWYyNt48iME9etfOles/F2+uLL4p6xNaytG4MPKnr+5TrXLV1rxXlL84l8vNTa9P1LnjvxNfPqqQR+fBYCTzRFvyCRwOnB6Z79a5yQ3F3czO4iiSQlnkKkLkjJ4HSsnV9YvNVujcXDEE8ALwo9gKsW0zR2O1pxjOV9c1oo2Ri4tI0PDWsyaHqsb20jJiRf3odhjBGTj8PSvuX4f+ILTxB4as7q0ufP+TDM33sgkHNfnxI53k55J65zmu18BfErXvB97HLYXBltxgPbSE7GXPT2Pv8Azq7W1L5WtUffGMetJjGScfnXO+AvF2n+NPD1vqumllWTIeJvvRsOCD+NdFjHfj61Q73E6fT1pe59T+lKe/Gf60hHrQMQ5wP6UuAOi/SjpRnryOlACfnS89R+eaCfm7nHfNJyc88cigBeffpSHO3rx3oHA5z179qDxyTgDrQAHOT9OK+avj342/4SLVpvDGlTKNI09g+pXAfAkkH/ACy464J5HPzD2NW/jL8bIPtqeHvCOphLdjtvdWtWDbFP8MLYIyByXGeuAc5I8A1/XLdbT+x9DUrpcbbjO6YmuGxyWPYZJAHoOfQZyvLRbA77IW61Ce4v/tMUcKSKSyLI42RDryxwM9cCuevizymR5fNZurc8/nV6DVl+yx2s8C/Z4yHVUJA3erAkhiferni5yY7PdtKyr50bAKPkPAHH06VSViY3jK1jnURpHCIpZj0A6mmdOtXtLi3tNIR/q03A5AGfxqiTzzTNU7uxra6c/DzQv+wtqH/oiyrkK67Xv+SeaF/2FtQ/9E2VcjSht9/5kS3Oo+F3/JTfCP8A2F7P/wBHJX0X4Q8Bw6nDDK+otdyQ4xAWzlgMENyemK+dPhbj/hZvhHPT+17P/wBHJX0xqV8+j6XaBI/s7TjczEDrjjBHvis6nx/Iyna2pveLdDk1qzgs2uIlRV2lE5EePWsT/hDBpFqIbZ1uWHBdCVUH3x3xmuds/F15ZxuQxnlYsW3YPPXBx06ntTrnxR9oJkthLZyrkKwBCj3xuP61D1M7oo6xbC1crMuBlljx8u4nk8+v+fWqto8gdWlly24ABcA46ck//WqxNrl1eJ+/CqzNt8xTu3DAPTt2/wA9abzR3Df6LuiRhypX5hweARzxk/lSIPVPC1vaeLvBt1a6z+8kgDIkuACpGcEA/hXgvi/wzdaBqTxzpJsc5jcrw34+uK9C8KyajBP5NvDOsTDB+dlXn8SPw+ld1ptvpWrxnSddkTYvG/bu+bHc9fxq0y07o+ZhbvkFRz1xjp+FPRWLN0PTAGQDXser/Bu7e6lHh/ULG7jIJ2LMu76da57W/hxq/hyyF5q9uikYACyfT3IPX9Kd9Ljd0efSxlmTCs2TnHU+v9Ks2enTXMjMqt5S/ebb0+tdTpulQ3UkKmUxK2cgrk/QHpmu20Pw1bF2mltX2HGNrHB7g4/Sk5E3vsY/hHwUkqrd+QY41wd06hix9QO3NdVr76fpMIa/L3MoXesZwXPpheg6Z4qzqutRabBFZadEj3LDZBAQeBxzgdK5nUdKutNRb+7mme8PzSSuQDGMfdUelS/INjnf7Mu5Yr7XL4tZLL8kEMYDBs8YJ6joO3eltZpYQpwynGFBk3EY7546VdujqU9qZjKZbZiFy7LwTxnjjJJ9PT1qpZNDIhLuuCQpbPzKfft3z/hSuIc9hI7n7RLGJWG4b8qeM9CCe38q7r4Yw2V1r1nHfmee8gI2vHuZAfc9sYrkBNsnLkrJIBhSTzn0wPxrpPCPiRfDuuRXFzbmK0LKsrjlQScAnGD+lNPXUFuXPjyv/FZxAkndbjAzx747dq80myuk3EBzskCghCCcqRxnOAPp6HnmvVvj/GJPEmh3KuPIniKbicd/5V5TeDyji2BYHgbyMAD/AD1603uVP4j6h8OrA3gjTp9QWD7NFACGcZKjHavOPE/xK/syeW38P2cIkC/LNOgwPfGfTP6U3x3e2l/8KtCFtqLwTQFcW1tkI5HBDY5wOo/yK8xXT7+8t7meIO1oCQ85IPYccnnH0xTcr6FOXKlY5v8AaU1GTV/E/hzUJ4kiludDhkdEOQrGafOPxryGvUPj0CNT8KAkEjQIeR0/109eX1VB3ppm0twooorYQUUUUAFFFFABRRRQAUUUUAFeqfGoR/8ACyta7H9z09fIjryuvWPjLaTD4laq6xMUYxbSO4EKc+1c0/48PSX5xNI/A/l+pwxldbZY8YG4tn1qNpGYYJJq9fK8pjWWZWkUbcbsgfjTLiOC2gEZRjd5+Zi4KgewA/XNbijJFcyAxKoXBByT60gOKWIJglj0pCQRgYplLyO6+GfxB1PwTq0c9rKz2nPmW5Y7XBxnj14619p+AfGel+NdEXUdKl9pIm4eJvRhX55qcV6R4H8dz+E57S8guXe8CqhKNlGiB/1cin0HRgCR781D01RElbY+6eCOvXikAxnJ7/jXM+BPG2k+NNOFxpk2y4VVaa0kYebDnpkDsexHBrpunXqKtO+wkIQcEYzn1o6nC46fnQOfp15FKeSMcY7UDE+pyPag4znAJxwaB254PevLPjP8WLPwLZmzsGjutfmU+VDwywjs8noM9B1P5kJyUQSueg67rmmaBYPfa3fW9lbIOXmlCg57DPU8YA6ntXyZ8XvjdqfiqSbTvD7TaZof3WKttmufUsw+6vbaOo6nnA808Sa/qvifWJL/AMQX01zdv3fogwMBV6KOB0+vJpYIdNitS93I6SD+EENvHtxxUO7+Ibko6IwXcsTk5qM1JcMjSM0Y2pnhT1xUVaFoM08sWgxzw1RUDkgZxmgGjW02zM2kalcZIEKqR8udxJAx7dc1kV3+maeI/h5rNzanzAmFklGcHLL09uR1rgKlO7ZFN3uzW13P/CvNC9P7W1D/ANEWVcjXXa6B/wAK80I8Z/tbUB7/AOosq5GnDb7xS3Oo+F3/ACU3wj/2F7Pp/wBdkr6Rv/Eia/4aaxnsAbm2kxC6DJCj1P8A9evm74Wf8lO8If8AYYs//RyV7z4Vs38QajbWOm2rqkqjzXhx5Z7nOKxqO0zKd7aGRdaYk9yP7MdTLLz5YAGcY5H5j9Kamk6vdTLDDYyzyHOBvVOcepIz+tew3Hwikhjjl0y88uSMZWP+EHHb864i98KahFcSPq+gK9zG/wC6nDFkI4wSp6HP8ql3W5lyNHK3vh/xJBdpFLpOcgb2EqER9uoP+c1nzWGuBisVmvB/1obOO3XPrXbpbXNvtS8sXg80Ay7YsHv/AJ/xqS6mhhESo0qLt2/u0PHseOOoqeZILPsc1ZNrUKGG4u5pFDZbDkjHp+Xauh8M+I7awuVN3FEiuTucup2L6kdv8fzrPube/dSba2uZ/JUD91blVI9ie3sKxLvTJ7onzUeFyDtE3yEjjqDg9h/X2OZbis7nump+KvBH2WNxexrPj5ZY2Gc+5HvmvK9e8a3N0LzTGvI9QtX4RgxcYOeMk9PWuF1PwrfqAR5j5z2OOnBqhFpmrW7kC0lljQD5kXp364+tVzRfU0d2ju/D97Dd6hBb28e2NBnYqYB6c13mq30Gm6c8pbbAibju4BNeJ6Tc3+n30d3FZyxqg2HfCSe3fqK2bbU9V1TW7RLiJ0t45AwjZCASeMnPUVPNHuSk10Nq11OUTNqRhmNxcgeXLIpVUX/ZOPTFa9v5F1pLvc3AurlPmCSszn8zVzXdA1SO3iN9q5kgmGY1MRZUXHA64H1rnhDNY824luI848xSSMe360OSW7FytdCBLvyWP9lOqFs/uWJCEd16df8AGtHxDpFreaNHr+gw+ZEP+Py2PzMhGQSB/T2rElgl8x5XZiCMhVT06nPPPetHQbu70jVGmt1do5PlnhJyHXkcD16+/FCkg5WY6Tq0wIdHeQZEgT5Tj19+n5/hU2oyNIqoxOyVMONucsO/t61qa9ptpxc6EpgtnbL2Z42HPJXHQdTWddqJY0XEijG9WJJHv17fT2/Fc8e4crOj8SajJr/wq029ZmmvtOkAO4c8NtPXB6HPauD8QypBarcCSMgIduxuRu64rsPATP8AaNS0OYObO6QujMDgE5yPbjHHHSvO/FdvLbaRcpKjoYJjA5IODjkdvrV80b7lcrdjT8PXmmaj4WuYLrUUs9VR/wBybhyFkX6gf5zWlo9nr9lElystp/Z5ced/pKiMr0J6+9ZXwi8LQ67JcfbYXfYB5a4+8CM8V3OufCeGWJ5LKBhLGciLsfr+FN26CcdbHCfGa00a5+Ing+21bURZ6I2kQ+fdwIZNkfnTk7AAc+g4PXvVO+8EeC7L4aaT40mfxEbK/wBRNl5CzweYiBpR5n3ME4iJ25HJxu71S/aDs5NP1vwxZzIEkg0GFCozgYmm9a6DXmtLn9mLw7pEGraM2q2l82oTWf8Aalv5qxHzyPk35LYkT5B82TjGcislzcsGnbX/ADOtW1MXw98MdF1yx8f6jZeInltvDX2t4YYoQxuY0SUwSGXO3DGPJCqcgHlcgjyWvdPgPPZ2Pw6+IsF/quj2c+sad9msYrnUYInlkEdwuNrOCvLrywA5zXhdb0nLmlFu9rfkS0rJhRRRW5IUUUUAFFFFAHsPwk+HnhTx7fWWkjVdUXVf7Pkvr14lRYoWEyosShlyxKsGJzge+SBgWmieAbv+zbufxFqWl2TtOt3bzQLcXAaNotip5eMB1kYhmAAMbD5sYPV/soalp+i+OtU1HWNS07TrMac0AkvLuOHLtLGwCh2BbiNs4BA4zjIzyPgbwRY6t45l03xJ4h0TTNKs2El1dHUoCs69QkDhirMw7jITnPICnjbanJOTsl/XQ0VrLQf8ZfAlh4H1jTl0XV11PS9TtBe2ztjzFjYnbnHDAjBDYGeRjitb40XUsXxI1yJHwjGEMFPB/cpR+0BBYnWbC/i8X2fibUbrzBILAIttZW67BDDGqu+0D97xuyeCeSWZnxxiZPiVq0jZCSGLaxBAOIYwR74PFRB3nTcnfSX5xLSVmrdv1OFjfYGG1ST0J7U0kknJzmg4HUgfjSZX+8v512XCwtLSPhGw5Cn0JxSb0z/rE/76FNMB4NTRhmQbVzg9QOarqyMwAkT/AL6FdNea/pi+FrfS9O063huA++5vXYPJI3oD/CvHShsiTeyPT/gDqWl3f2rTNR1b+xdYgIl07Uk2o4H8UZY8Onco2Rg+3H0PaeM7/TIlXxbpM0MO4LHqulhry0nH94hAZIun8SkD+8a+D9PkLXcItmElwWGxEO5s9sAV7FoPiXxL4OW3vFmurq1lxlNzEqxJyBn5c4z161lKXK9zN+6z6Hv/AIweArO1a4fxLaTAY+SBXlc/8BUE1xeoftJeGYZ3Sz0/UrlAcLIEChh64JBFeU/EbxJ4A8WeGpb+zSLTvE0eNwjXYJTnkMM4PfkdK8ZM8X/PWP8A76FUm3uWrSR9C+Nv2gtYvrMw6Daf2SJP45SGkI45HYcfzrxC6luL24lvryUzXEz7mZjlmPqaqWUSybXbJjJ+8CAPz6U+4njgiOXjIf7h3Y49aFa/mS7rREd7tRyMESH34FUySTzyaaZoy2TIhJ9WpDLH/wA9Ix/wIVaNIqwtJSebH/z0T/voUnmR95E/76FBVx1JSeZH/wA9E/76FJ5kf/PRP++hQB2Ohz6le+EdVtIL6MWkEe6SGZ2zt3A/IOn1rkK1/C95AmoPbT3EaQ3cbQsS3y5I+Un2zisbzI/+eif99CktzOKs2jZ10/8AFu9CH/UW1D/0RZVyFddrjK3w70Lacj+1tQ5ByP8AUWVcjRDb7/zFLc6T4bwJdfETwtbymQRy6raoxjkaN8GZQdrKQyn0III6g19teKPBlrp1oJLO41d2LBcS67qJHv8A8vAr4q+FX/JUPB//AGGLP/0elffPjjUrezWzjfb58rEKpzkge9TUgpbiu0tDhbzRdPtrd5JH1b5FyxOv6iB/6PryfXvGD2mrzW9pDcrbLgpJPreqMcfhcj+VavxV8X288y6TZuC4x5qt0RgRjnof/wBVeaxo8wxNAxJb5twGVHt7cYrL2cTJ1JdzqT4z1ARB1gmII+WT+2dUAJz1x9r+lUJfiBfrJ5bQyI5PzE6vqm0nOM/8fdUJ408mRi6x7zjejBWX5uynr07etYMgEKqgimkH3VZh1/Kl7OPUFUl3PSbLxZPPcJC8VxuK5AGt6mu71xm6+nr39KV/E13JO6RQ3WTnYH1nU2PTJ5F0K4rS2Nsibop0m4xIpJY+wAxnr0/ydpLCRoGumKrLgsqE7TkE9gcc8Gl7OJLqyXU338RzwW6SXkNyWJIAGs6mp+uDdHj3obxPPHEZHtrhiqhtq69qS7hznDfaSM/nWJNasLdZ/sqtIxHPQpxj5Rnpx0/pWPqiNIu6dkcqATsG3acjqe/X+fryvZRD2su56ppWr6Nq88KWN7qLBhueKTV9URo/YsZ8f5zWy1gl3KItKlvWmQ/vIZta1QEgHkq/n4OPSvD7bUL1UjurJzFN0KcfMp9PU13fhLxsFtpF1G5lifdgTIuSPY5z7dqfs4j9rJHevpKROguG1SMfxltY1JcdehNzUWiWVjqGoSxS3N/FCh+UrrWplsfT7RWnp+sDULNMtGI3zskLiTf7kY4p/hO3S51a4jn1GxeOE5DJmPb7EZ5p+zi2V7SRfu/Cekx26tBday0jYwG1rURx648+szWNAtbNAYf7XZtvVtb1Fsn8LgcVsapqryEwWAhljHytKRyfoTTJZC0UUPllsfxkH8eBQ6cR877mVFotiLRftJ1drgrxs13UAq/UfaCfWsnXbBdOsmntFv5pBkLnXtRwPX/l4BP4HtXZbQqhpPmz252j3xXPa2Y9RS5sYmVxENxWNim3PTOOaHTVg9pLueV3nibVImOyGdYxyWk1XVAPw/0zPp2Fbmi6pJfW8cjpdgNxhNZ1MZ+gNz/n+XIeINF/flIrqNbgNlkV+Rjgc45+prr/AA3p62W1fMlJVcrv549se1TyRI9rLuJ4x1b+wtNaeKO9Mu4BfM1nUivPP/P0D0rjJPHt82zZEoY9pNX1XP1yLutX4jyNHp32fy5Q1wcqzOWLY9j07Z/znzfyo1ZI/N3S9pC2QPpj/P8ASo0421Gqku50Oo6ppuuakkmpaDpd/cmMJ51xd6hM3AyF3vdjAyT/AJ5rNuotMhlKDwd4cbaSGIlvyPzF1iltI4HuyLy4+YD5SqAnPpjFUJVMJKbmSFicBevp8wq1G2gudlxJNFKtu8F6CSDjcJr8Djrx9qqxFJ4ZV18/wfoxXncFnvs/Qf6T9azfJCZkjbMWSCy5/UdqdBBFFAZpA8qsSOOAD1/Hr29aLeb+9j52Xbibw67MbXwPpEcSnAea5vm3H8LkcVE82gkkw+ENAZQMHMmoZz/4FdM1FLqMt9p0duESMwPmNo0xkeh5+lU1c4yzqD/eB6Hmjlt1f3sOZm7rPhnQ9QX4dG30yHSjrmozWl79ikmIKCaJAV855MEB29s9qzptK8HjVr2xTRNeLW0rx7xrcXzbWIzj7JxXT53H4OK2QRrc4PGMf6Tb1yt0zW3iPxA+1ci6mjOecZdulYU5Sk1Fv+b/ANKsdErKDa8vyJ9J0nwRevOJ9K8QwJCMs66vE6g/7R+yjb+tNn0nwSG22ul+IZyThT/a8Kg+ucWpxXPKzr5wVnQyEBgDwR7113hewUpLLcAZXPl7c5OB1AroatrcwlNopHQ/Ce1iNE8QZHZtahHr3+ye1Fxo/gqBFL6dr24n7o1mE8f+An9Kv+ItUEG6CFlLlcsRzx2z7964e8uJJX+ctuHfPWiMW+o4OUjoJbXwJFnfpfiQn+Hbq8OD+P2Wt9PEek2kMMOm6j468mMBI0TxKI1jUYAAH2bjAA4HArzoyMwIYk0jbl4BOBTdNPc0Sa6np6+I7WSWRINQ+IEqquSy+KAB+ttWxpsz3CLNNqPj+C2Y480eKg3P0+zf/q5rx+0uJ43HlOwGcnBrXh8SXcBKCWbGMbjIcj8qh0V0Jk57Jnftq9uj3EcuueOBJERtC+Kyd3P/AF68f5+lZUvjARzOn2/x9he//CXf/ctc0byK/YSBds453BuD9RVm0xFasz20cpk+Xe5JwR70ezS6E+0ktzupNYs2gsxZeI/iBNcygNMj+KNiQD/e+zkt+C9qq6r4hs7fU0s9P174gXyBd80v/CUbFjH0+zHNcckdwix3MauskeSI9pAI9cY5FS6IsCXlzc3Txb3GBub5WJ7c0lTiHtJI73QNQtNTtLi4uvEfxDtYo+YwPEokaQfTyBt/WqsmtWq2clxHrnxGYAgJnxLgN9T9n459jXLpCtzZG1jcJDJLuLIDhAMkqeP1/wAa0L5Y7IIohYRRAE/xLKPTGf1qeRXF7WXc6qSeOK2SSTxB8RFlYZ8seJ8n8/s9ZOveI4dKvo7dde+Ic7YBkx4pwYzxxj7Pz+dZtlqMt7PaR+aAASse/LYXOdvJxxk8mua1O6a41iZ7kmQBuSuPmxxxQqd3qCqS6nrvhl9G1+Panjn4iQXeceRJ4gySMdiIsdv0rmfFfiP+wr4w2+ufEK9g6ecPFmwZ7j/j2P8AOuLt55tOkW5t2dZVXCqpILZ7mr1+pGibbiS3kYp5kjZBZc8hRg8Hnn61XIkx+0d9SyPiG2cDUfiH/wCFj/8ActSx+PyxGdU+Iisev/FX54/8Bq862MzblQgE8Y7Urs0cxO7kdxWvs4m3od//AMLDfP8AyEviFx/1OJ/+Rac3xDIVSNU+IhbPI/4TDp+P2WvOM1ZtrOa5AMYyM46E0vZx7Ddlud6fiIQwxqfxEI9f+EwPH/krTh8Q13OP7W+I2MfKR4u6nHf/AEbj9a5dPDozmW6CoOrben4Eise+higuGS3nE0Y6NjFL2cWKMoy0R6QfHcH2CGb+2/iOZ3Zg0I8VcLjoQ32fnOfTiqjfEVgx26n8RCB0J8Yf/ctcZp7xG3j+1Kxt4pSWCnBbI6A/hWacFsD1oVKILVs6j4jagda8PaHqp1DxFc7rq7tPK1jVft/l7Etn3Rny02583BGDnaK8/rr9fXb8PtEU9Rq+oj/yBZVyFaU1aJEtzqfhV/yU/wAH/wDYYs//AEelfV37R/iX+ybnTI4pdskQaQgYz0/xr5R+FX/JUPB//YYs/wD0ele6ftbyTnxdp0bN+5a2+QehB5/pSlvYlq6scfofg/Urzw2fEUm0yXErPsckHZ6jHqe3oRWbGJJJ3jBDyAnlm2j2H86+nfDulb/A9vbmMRAwKFRWAA49Pxrw7xJ4a/0+4NvKHkt32yRHHyc5H1PPes5Mxfc5W7Nw04tWKymIZDlNwT6k/wCeahZpMyxsoQlQPMJJwR6Vc08Lcag9u0KtlSQI2Cbj16k/qf8A61Q3d19iuFt7Pe6DKyI53H8Ox4xzQuwiK1mkERRRLKqnHnvk7R+H0ratZLf+2IUaWaU43qH7Hr1z+lULSG3uJiH2BJCcKH4B9OmB+R696ilM+n6pGjO0Sn5SVQPhc+3T/wDX6UNC3Oo1OeNopWYxxMVAdmHC/wAu38q49bpI2e2MBkcnIllOF246YHWtUyLexkQM21Rz5sXLnkY7AfjWLdxebE6NEsYjJw7sMhvfH4dM9RSiCLENqt5IHRMFPvMOF47c98fyq1bACXzI0xhsEg5Vu5yCOfTvWDGZXsw4LieM8KzZDfQVtaU63Vk5njm+0EfKVQEH/wCtTeg2dx4QvtONkttqdrNbF3P73zGVSeoIPGPpXf6D4ai1IXDW0k95EvI8xicHsM9Tj3rwm83PfKmJS3Lc/IV9MAnr+X4V6Z8G/FKWLXEV7/pADBFlccDqP8PzosgWm5313pOr/YY7bT0h01ScPdSqrHb6IvrV6LT4rGNYElkaZhl5ZiSze4/wrcvEiubGNwDg/MuCRx/SseWMkY3TNGfu7xyD7Zp2saMivT5OnyeY+5l5DtKDz6betZdo1naxmV4BGki4Z5SxXP4Dinawk8dg1s4Yl2HzE8n8uadYSW8ts1sJoPNRQTF96Q/gD9OaVxX1OeOk210JvNVbqAscOfuqp7Doccn161HdWirMI4yUWLDLIGHT0x3/AM96PENu0TWyS3EkUrODtDYVee6jg/X/AOvTNS8wz3PlxeZIy4B52sPoe2RUWJbOC+KIudtmqAKoPUPkH6/nXnc0t0ZAShkCkfvBgn/Gu/8AH6+TJaLIyjKklihC/Uk1w6SzQWpSSyyzkgSq4JP061cb2BCOlwclLaUs/IJBJPv1qKdbwjdcxFDnqxGf508zSlUDw3DbeMtjIJ9u9RzypOgTEqhOhK96oYjq6267VIO0gkP19zinjP8AZqfMWPXBJGPXH5VCoX7J88fzdMk5z+FXjaPHp01yS/kouPMRSevA7gDr+tDAy7adi/znKEYwDUrblRSqkR9iOQ1Vol3Rrs+91L5HAqxAG+UeWpYD5ck/nTY2dqkEcdx8HZtifaG1iVGlwC5QXUJVSepALOQOxZveuX8RE22ta4UYBjfzbgVyPvtjrXWjOPgyWGM61Nz6/wClQVw3ixzJ4o1yJm4F9Mcg9cSNXJRu5r/t7/0o6ZK8Pu/IpTA/KU+Zxg7jxmu70xAfDxldN/lEhkWTn5sDr6ev0615zLJIsahjyTkEd637LV3g0eS14EcpBO7np7V1yTsc8ouyMy7vCNUaQnI3DgdBXQ3+gRXOnfbdPYONgdwP4OOc/wCFcbPjz2wcgnIrq/BOsW9gZra9DmOddq4HAPPWm1pdFTjZJo5+1gR5Sh+ebdjHY/41aubCWG4jQHl1Dhcda0fECR2eqJNbBFKBTtDbgDjqcV1Onmw1XS4WiU+YjhpiyAKOPUc/lUuXUmU3ucTbaf583lxARjryeT/Ss2/spbSQ7wdpPBxjIr0J7O3t5CYkaN41AK43Zb1/zimmKHUYpI7mMKzIVVzGRg9emcf5/NKfUI1LM82jkZGyvatCHUCpHmE4xgY7VXv7KexmMc67Tk4PqKq1pozdxUtTrU1XexNuWWPb8o3bjnvjPQ1PPZnUtPjDyLDLEmQjKFJHbkdyT19xXKWcoRxuY4PGAK2bOa4Dh1LBQC3JxuqWrGEo8rG2l/d6RNCZI9jEZDMDyOcZ9RWpZ+KLQ6ZJbzW0n2yRixn3gjPbHGQPbNaAudI1XT/J1BcSsv7oAkLCf97HfPpWN4bXTINSiXUbRbyBXw43EHGeNuDzSunuL3WtVqTxaraokgs2mWRk6Hp7/wBasabZJIkN9Mn7rqWZeD2xnoDXuvg/Vvh9emcR2cFpPDGdzSr5e0EdP5f5xXk93Gulpd2TkGGJ28tYwSNuTtIGTxz/ADqL22E9tDD1e5i02GSSCGORp0xb7gGaMEnOR0zjI/zmvS/FngqOb4e+H9WgjiW5WBDcqPl+UqMjjg4rzeW1F1C0r5GSFDlcHf26H+ldVp3xCurLwddaNJLGt6hCxtISe+GyD3x6Yp20BM4C50qWwiYTpIYhJwyL94eo9utczOwaZ2AwCSQK9Um8Q27aPqpdrRbqKP8AcgggSBuCBkZyP8K8ozznvVwbe5tR1uwpQcY5P0FPnZDt2JtwOec5NRCrNt0WFLtEf3zemzcelQsAM89P1pMfLnPOcUu4bc8lvcdKBJWFMn7tUXp1OR1NPtAHuY1fO3PaltYPtG9VdRJjKqf4vYe9NiZY9rHk8/hQJ9kbni8g+B9EPBLatqDEgdf3Fl/hXD12Gv5Pw80In/oL6j/6Isa4+lT0X3mdrHU/Cv8A5Kf4P/7DFn/6PSvoL9rSxRvFPh+VFJllhkjIByGwVxx2618+/Cr/AJKh4P8A+wxZ/wDo9K+nf2o7Ij+yNTMOUt7gIzdeGH+IFEtxPY9O8Jym68L2rbY4coA2zgV478Q7PTrbxMLmcr5E/wAkoMmQwOMNx06DrxXonwc1ASacunmQNFGo2sT+hz17Vl/GzQkNpNdTRrsUcPgDPtntWb1jcyteJ5N4o8N29jIdQ0i4Zbby8gq3frxXm16s95cq0Ts+SACXxz9cV2ml6nM4a3lWGOMH7hkwGHPJB+lWdSuLURFY57VU6blRcDsfqOn1pKWpCdjD0nTro2vmXhdFXkfLuUnOOo6GoL29WKWFpYgxAXO0bB71PcanEU2LKdvIbYpUMPai4tIrjTy4m2xLnEbt91u59+9Hmw9TSuJ/tEBnlRZY5lxGAT8hz06D0/WufvUWKJlZf3rchScAf45606zmVwwlmdolG0nJIXjA/l6VFt81Gjy7ocfMDswPUU0hrQoXRkgZWkUAPxgsCGP1/Gt/TbqL7MjkywMnDGCQjcMjAxn6/wD6qypY/tMgVmYhPkVicgj/AD/Krmm/ZYoWBO7aedz556ZxTeoPY1PEJRdFguhKjsSSGUYfHAwfbg/n3qHwXMlyJFQFW35EXJyecEc/WnX8Md7JDDeSKtiV+WcOSvHt+X51gW3m6ZcSy2STPCjlFm8oqT2yDzg/jU2urAtrH0DaeOZdI8PKdTgeeNQCFt1yce47n8f51Xb4m2dzcW8Ok6RPfzOMeRbsiOh6YYNj9K8wtr5720lE1vKfNAUMylAG9vftxWRDPeWTJLazypLC/HlHD8e55PGaFcEz3K2v9Wu5nXUtDl0nyjuXznjkDD04PHb/AOvXTpKhsc+S7sVzvj4OfevEdN8c3yXML6rdTqhGx5dxYDpyQeTXq2j+IdN/s9ZLbUUuI2HDAZJ98du9F7FJ3MK404zpHfDzYpZJNzuQ2SASME04KDJeSkIyjg5wMce5/wAKsar4i0+00f8As9NSjhk3/ud0fmvyegUc96Zb6euoRF45GZWXe0ykYPHr36VIrHCeMYnF3bkPAjKhH70Myj/9Yz09frXAENCZFhaLCkboWZiAR3X07V6J8Q4EXT5Y5PLDxndESygt6457V5zNcpNkuS8m0b2Xufr+X5U4iRas5A+3e73DA48pX25+hxxzmqeqGWZXMkESbGxgoQYz6e546mpdNvliQB1YoOGyc5/A9KrXqI88wt3dYl+YdyPqaoa3Kk2fsgCREt3b/wCtWx80Hh6WR7qJ2KhGtycsVPH4f/WqnCovIZI/NzIR97PB9P5+lVngaC2kjZ8A8896e4yFbeIJvh2sjDBBJyn4VPbKE5bBQcGRASB+VU7KUJlTkAfxA9BVyMBOFBTIyNn3WpsbO02bB8G1xj/idz9T/wBPUFcJ4rTZ4z1tEGALyf2wN5rvI38xvgu3If8AtqbPH/T3BXHfEy2W28a6qUAXzLiRyFJwDuPrXLQXvL/t7/0o6+lvT8jDvFSMRqVcSDk5FbGmvapZSfabVbiQcqzEkKP7vB4+pqnZhp4WuWhWdUADgnBHbIpsEktos8SszxOfnjBwSK63rocz2sUrhVefzEjCRsfug8D863dIFssZa8HmxMmxVH3lb1/z61mpBFdTuFLRxAfImckmtuXTPK0m3kBbKEjayfKOfXrSk+gSd7Ip3+n3MFkkh3Ojj6lB/h0qv4e1ufTJ18skxMw84HoVB9K6S0vjPeBJ7pWdozEWmDcDHQDHHp0rjdYszYalLbsrIFPFEXfRhD3rxZ22oXMkyrc2WEt52zHI5y2e4z0HP860vD0aQLeT6jJMsjDeBt6kDOMEYPXr2rhNK1EwARPMFjRGA+XOCe+M9a7jStS8vSLSR5RJGPllQDIyOhIIwOM1Mk1sZyVtCp4r0+21Gziu4ICJV+Xy0YgEdQ3PPQ9uK8/htjLceSPkfPBNejavqLXavODFFMckbBlBn2x1579sVxGn6iLS/neSFZDJwXAwy/QdKcL2LptpOxVNkY45i7rvibB2MD/+urum3VvaOj3a/aok5MWcfnVJ8i42xSFV3fKrDHHvXXaD4Z0jVIGl1nXLbT53OEwdy5/2jVN23Kk/5jJufEj388US2lpbQKRt8qMAjHvWhptrbDXYIrO4W8k4YiNT8p/H0qPTbfTtI8W2MbXNnc6es4WaZ03KUzyR17c16la6/wDDbw7NP/Zlpvl2kb0VmZsnPDN0H4/SobS2JlZ7I4dLpdV12e61N4E+QwyMhA80jAyykg9u3p+FQa/a6zoMSmZRf6UcPHJ1IHOB0yP5V0eoeIPhxf8A+kNp9zFcq2SioSrD14I5rD1DxBa6eDNoGvmc8D7Nc2z5K55DEgqanXsTZ32OTn1GXUrresxiklcIByQo9f8A9Ver+HvhFHq2nRH7Q8t1uOZ1JOPTg4x+v4Vy15eeDPEFm5urX/hHNSj+5c2ytLFKQc/cGMZ/w5rr/hV8TU8NudN8QXbPbTuBb6gsRKr2yx4OOn05zVehT8jh/iF4fm8GNcaTOjS296qzWk7YYrg/Oucevb3968+jHzgsMqvJr60+N2mR+IvAUlxDLFez2hSeCVdmGBIyVPbg9K+XbmEIg+zsknnDkdxz9KqL6GkZW0IdYvU1G9E8cEduCipsQYAwAM/pVEYU5YZH6VYe0mMLutvKBFxIdpIH+H/1qrFmOATnHTParWhpGzVkObCfdIbvmmZFHUE56U2gpI6ZIdNmGkzaZLJZ37KI5UlGY/MHBcOex67ccetYtzZXEN1NDIh8yPOffHcetJHck2ogkbCo2+M4+6T1qxfz2rXsbWnniJUAcy/MS2Pmx7ZpGaTTJ9c/5J1oX/YX1H/0RY1yFdr4oMR8A6H9nz5Z1bUDjGMHyLGuKohsJ6s6n4Vf8lQ8H/8AYYs//R6V9s/Hfw++ueBdQjgR5bhEEsaJxypyPzx+tfE/wp/5Kj4P/wCwzZ/+j0r9GdShe4tniAUqy/MSabV7iex8xfB/xRGI7VGmkLnAbDYVWHYj8q+hNTgj8ReFp43VS7oVyvJ+tfIni62u/A/iq/ghTawl+0QMowrIScgew6fhXvHwr8cx6xpsEp2RpImyVM7sPjkf/rqEZL3dD551Jl0/UbnS7+3zcCQqlxtDZAP90g/pzVNomtbjyZZGKqOMHa2D68A4rrvi9ZxnxLdIJBMeXG5uUyTwO34+wrgrC/NkDFNGj7iCGz82PTIqVqibGgk6218kbNuU4K705GeeOtXri4hktpt4wJ2AMWTg+/A/r3qpL5F2FKQRWvmDOUBbd15yaktIFj8t45I7gpkBlAjIz7ZOe1AmYq3NvBdOqRearjaUzng+hFaU+Y4llBQL0wGyU9iDVudWjl/fi3gyc7l+bePw/Ef41LYGzkQoirtlO0hF5U4HzZyehov2BvqZAdCivLKJGH3Yl+Ujp1OatxyLJIEljJfGPk5BHbPv/hVq+tJbWURyt9oQ8+f03cDgc/5xVNVjkikeSB9sYCbc5bJ68r3oA17KWGWAETWKbSVKuoGD2wCeay9W8z7SscSmRQDyBtVcnnOOv1pby1tzFuWFEkC4wx+YYPXvz/KsOKGRiVEblRlt/wB4+w7U7CSNnS9ZEYFtLJ8i91+X/P8A9aq15qQe7L25RztALOqgAgYqmqYTzt+3ttKEn070k1ugh/ekbmAK+v45pWRWhKJ/MiyxhZzyFjBP86veHdUvNFuXktpxET98DJ3n0I7ViKJCuTHhRyo3c1J5hjCSu+Q3DAnPOTxTt0HY+nPg7rmn65pn+l2+7UeUnEYX5eeOfpimXc0ekR6iLXyfLgJZR5gzjv8ATvXiHhjxDN4a1i11m2EotmJW5hyGBHt+h5r2bUrq21XSJ5rCcvb3g+7Gu4KPcf04qXcL6HnHiTWY9RgTyShWUE7mYHrnjd+XavOr2OJZ5N6kZOSeeDn6VoRSi0nubSU/v4pC2JMoR64H9PpUscli9z5mrW0twj8gp99TzzgnkdfyoSsJaGOv2csqLGJcZwAf8mtnRbTzWuI5CtsTGSCx4PbHFbllDaRSBY0b+z5Bt3wxn5CeOe4P41sXmhypDcR2V3IwaMuAYyFYY7tnGe340cwmzk9JhiTT9SlYeZbQDIEZwWPuc8f/AFqsQeLdM1JIrPVdEEKfdE8MhkZBjqAB1rJ0XTdSvRdAIyIisMbgAxz0APX/AOtU/h/wheXN0TeGKAhS6o8yBvqQCTinp3Hprcxr23ja7f7BMk9rnCnIQ/ipqvOjQkRSIUYHPPf6dq6LU9KZ5CGuAbhTtKwx5xxnkcdvas+e3ms7chyQjAEnhlfHqvbr/nihMaZ00ByfgySfmOtzEnr/AMvUFVPi3HHe3FxeQHmK6lV9zDj5uw71cgxj4LlVK/8AE7n+n/H3B0rY8UWENxe6vb3CwJMZZG2qudyEnBA3cEnvXNT0kv8At7/0o6KkrJP0/I8g0ZwXkt2aNRIMBn7H69qv6lZRRFHtZ5Hkx+8Qj7p/3uhrIeN7HUSjA7on/iGK3JrdrY+Y8f8Ao9wcRvnCev8AkV2Pczno7rqY8q5XeMpKnYHk+9XNMvEfbHKu6RT8oPI96ku4jIPLO3yx91lVQ2fcd6y5gY5RwVnU447+9C1DSSsbeoW4gvIiCWhbGGHQe26s7WWaSYJIBuXhSO4p1pfh0a3uABuO4ueoP5cVox2Nve2zh5NoiGQ45/8Ar+lLbcXwvU5pDtfDHBBrYsNVmtJswS7EkwJFHTH0/CktdCub2+e1hGZhuKkjG8AZqjLaTWcrJPG6SjqrDBU+9Voy24yOo1HWbrydpnYrIvytG/6EA1x8zFpWY9c80+OZ48DrtORu6CmSsXcuRjdQo2HCPKywlxiM7WKkDgVNc3Nq8EfkxFJiv7zB4LZ9Kz0++MirD25MhWH94Qu47fSmDjFMbHHwrsQVJ6A811nhWwut3yaabi2Y4ZmX8cD9K6/4c/Cw6tpUOsak0kaL85t2TAkTtg5GPWvZLHT9P05re1tm3WbKSFZN23PXntUSkZTk5aI5jwp4b+w6WwW3WAO28tGoBPHf0+lS3vhjTbmCSV0hkJwu2Rd20DHb6V113YSadKS8m62kIK9gPQ+vX61JYf2bctJA0bLdxHDArgE4BrPqTyni/iLwhZPbzvZabJY3C8LNbElJBjunb8M1xaSDQ9Qha/t4ryyV9skTjCn2I/hNfS7Rw2shszPnzPnUH7q89j+Vct4y8EQa1HPczrEyBQX2Kd+MdyD9D+lHqFmedXPim98PaXdJ4enln8K3hKy2z9bNz/d7gcgjtXB6pJdwyWsskjurcxS/wt7g1pT2q6Fqd7o9y/mQuoaOZT/rYTyOO/r9Qao29rJLcJpDuHtZWY2kjcAPtyB7E8DHqRVJLcoy9cnDXIli3K0i4cf569Kx62NVhbyFUkGWJirrjkEcVkVotjenawrY/hJ/GnP+8XcFAI67RUY61Zka3+XyUb0YOc5/KmU9CrzSjk/WtKxtLW7jKee0V2W+RWUFNvqWz/SnXujXlldQwPHHO80fmIIHDgr+HIPGcGjyFzoseI0KfDvQAWDEatqA47fuLHiuMrsvEUZi+HehKcZ/tjUe/T9xY1xtKG33kM6n4VHHxQ8Hn/qMWfv/AMt0r9JCM5BH4V+bnwq5+KHg/wD7DNn/AOj0r9IxjaQB7Cq6geAftL+FfP0+HWrcCOW1BDEZw6kjNeAeCPE2oeG75Jomd9MjmDTxgLxnjdzzX3pq9hBqdhNa3SK8cqlSDz+NfGnjPwbJ4c+Ir2l3ARY3UmIzjcpB/HtUNJGctNzZ+KcomvNO1iEI5uF2BcAhvfOPevPb6yVY5JkVgwOSDg/rWh410PVfDFpFaGWWfSWcPBKvRT/dPp1/zzViztY5ooDK00qzjBUHPOOM859KhaIzempS01C8Ckg+UwIbJ4z9OlSWdpvCwrJEHYlQrDGOoySM9/WpYLSVL82oQxxxEsgIOF68/r+tVWWaa+kmkuAFwMuXDAemPyo3ETm2BjEUsgm8ttu7oB/j2/KmQCOJ3il3DyuyH15yfp/WpJFLjbGqyRIpIfOSffGKwED3GoLJA24KRvAO0n6DrQgSvub0t5LlbxyZrYrgEvtKdOPc/h60joqMskkbRlsY2sTuHqR+Bpkn2mEqscMksedxZ027Tz69v/rVHJJG1vsuCoJYEMrAt/nj/CkIsanbGSNntp03qvMZA3HP4YA5/SsyGVbiEmdwrIOFzj/6xrOv4kkuC0knzdmJ6imoohIjhnV2JzgD/GqS0KsadxEJLfFwyKc55OOfYCqEG85QBGCHI3ntTpEuWlCP8pfjGRuz9OtSJakxtE8oGOSCeTQMhe4XMjbD9Mkg/nVC8uTIuHAyDngAfy61pTrCQI8bAufmzkN7VTukwiyJH8o6g96aGi/YlJLWFJGzu6gjGea7f4Y61MuorpM4Jic+v3RjsB1rgDKI9MV8kOW4VTxj1qzJPPLb291blVe3xjnJyMHJNJrQR2PxX0JdMnt7tXcRyHHzAZ9ufpXE+dKZyikksBtyMn/61e0+D9dtvFmhiG9SKV4l8uTODzjrg84rh9a8IW39sPaySfYdzExyA79+fbjaOfepTXUV7HLaPrVzptwSrEgnGCevvivSLTxWkth5MVpK0rxkYj2MFbHow6815/r/AIYv9EuPKnUTQt80Vwgz5n071rfD64lEt5aqI1kePh5XwF+n5+opyV9UJ23RS8wi3ky7LMZfmTbgjvxg1nTa1qEigW85tynHmIArN7EgZrfvUXS9PkvWm33DOUaNeink84/D865qwA2rvA8xjvIVhnGD+tCGu5d003ctlcag7NIsLKsjbgMA9OnPXvVrxZfH7JaxOghmKq4VH3BlI4J/z+lT+EkFzBLbxqGmaYEqYwWA9fT86wvEcss/iC5+0OxdW2n5vugcY4/lRa7Bas7Bdufgt82VOtTHP/b3Bmuo1i1a41+4jlAVpJZQp2Z3Ddg9Pw4/+vXLR7S/wX2klP7amwTxkfa4e1dbqMijU7yATbrgTSSJIx27eTgVywtdf9vf+lG1b4V8vyPJviHoyWGpm4t7hLiGTA3A8ggYwffin6CLvxJp0elpt8y2GYjt5OT0J/xrvtf8Prq2gqJZykyK2EY8lj/PoPzryrQr2bw94gikmRlMT7ZUzgkdDXXFpoiL5426o7SfQf7OhQqGa4K4fcOSemOpA5P6dO9c/q+mt5rpOpSRVDDOeAelepPYW+vmO4tJ5FspgrE5/jHAHTj+tYHiDTAdRNsY2VwMSztGF8z0AzzjtURkzNOzPJbsMrKG5IHDetS2eoTWzKAd0Y6oehrQ1bTpoN6zRGMj15H51hmttzqhaSszpJ/EhdIzHaQpcRsSsh+bg9sH0rHv7y41G5aWULvbqEXAP4VDBOYmyQGBOSD3rUXVri2IEKiOTHB7gdcUJJbE25HojJcsCA69OOlIrbSdveuvhS/u9ND3OnTT20gZmkClhx3yOmK56eKB1/dZXBxu65oUgU09GU9qsvyZx39qt6JFNLqVssAO8yKuc+pqSG2SKMOXUnvj096msba+E63Glw3BETD94kZOD7+1NsTlo0fSFrHrGn2KRGZY0MQJixx/n61c06K7i023LEuzH5HxjJz7d6j8CavNrvhKOOYAXsOVYMNpODzgH09a19H8NTyQ/ZYXlkBJZVJ+UEnPr+Nc6RjY0dPn+3xtb30JkEf8ZwcH0qlrelraSC7iEjq33lUYLL9a19Pt57O5Hm3EKSouHU4x16nmsfWpkS6Igkch1wuWOxT64qnsWh8MHnWkkJ2oyMHiJH3Rx+dWdcWFLa1kaYoOI5j0EhI4OK52OLWJI3aOPzLYE43LnH0/SprL7VG7Wl5I8aEAkupY4z0UfjSv5Cuec/Fvw6J47e6tWIkshw7DJMbHp+BPH1rgtRe6is7m2vQ8Oo6eI57Z0cDgMPmHqf8AD2rtPi/runXmsQWWnRt59ttEpdTHkA5wQeCOferHxM0L+zJ9E1uK2jGQfNjC5DxkDk9uMn86cXbcNmcTbXkGrCPUbiy84uohvTnA8w/dYHoM/wA6xdS8LyiFLnT2E0buEMJ4eMkkAH8q3tfsF8NXkF7aOsul6iAZoE6KvGOh6jn8a0NEsYtSub/S9UuYoLX7P5sE8v3IycFdzehzwemeKadtUHM4u8TzTULG6028ktL+3lt7mM4eKVSrD8DVccGuo1CfUGSDT/EJmkiAxbzz/M8aDjCsf4fbOKx7vS5rSYxyjOQHiYcrIvqCK0TudCqLqDCFbMGIbnLDcrevtXWeNpLDT7YacYTdamVRo7xZCohXPK7f4j1HtXKXca/ZYShAbuD1BqkxknYsxZ29TScbsiKT1Zqa7n/hXGhE/wDQZ1Hn/thYVx9dhrv/ACTjQv8AsMaj/wCiLCuPqobDludV8Kv+SoeD/wDsMWf/AKPSv0kIOB1r82vhVn/haHg/HX+2LP8A9HpX6SLxk9z7YzT6gLjAGc/SuF+KHhFNfsBdQKft0GDGVUE8HNd0PTpimOiPHtP3SPz/ABoaurCavoec6f4bsPEXhmTS9UhjEyrzwR9CcGvD/GPhmfwnerp97GiQu7CKZjgkdBgg+n+eK+l/7OXRZ47m1LMm7EgZjyPfrzWZ8R9F0/xHo6LMI8n/AFcwXLIahxuZuOh8n3DlyAFKQ7zyr9R2OcH0/wA5qlc6ktspW8tnmdSDHLvCjGPYc/lXXeJfDmoaBqSQXRxG4zHOYwEYAjPbrz69TXN3NrbzxHzQWkzkS+WefaoVkZepz+oaib66jSFmRiOcEfzxT4YLm1LSRBWYEDfwQM+xwaivYp7CcGFAF3ZHy5Kn6kfyqzpc05uBJIz+eW+6Byf85quhZ0Vj4mubaxa1vrSKe3YBVIHzg9M5HpWe8LDeymGR3GdpJV8dsHGOvFUJ2xcSSKd0gYHbK2aS31a/Fwrh1aNMkqF28d6m3Ymxl3ik38iMgj25+/hj+lWbcRCNHZNpA7nBPXv2rT1awS8t0vopYlkcfMpYbnP+QayjGYVUy5VuD32n6VQ90OdwlwWRhljnIPI9gahxE2SWlxyc980LPChDGZACeAE5H6VMl0jgpGxMgwQ7cZNIZTCkgFQGjH8RPWllDmAoAAWb5gOPzp20FDnJlU5IzxToUnlfzQu6QnguRgfiaYFS5kCxCEgMygEd6s2kQhkiy4dpOkaZ/XNRyWssNyY5AzzYyVj+YD2yPrU4lVYCibQXOCWGSv8An29qBmvpGov4c1iO7tQfKODMq4HB6ivVNRtbfxAba70+6g82UDYfLYlfbcDj8D614/bys9u0bt5iNxu3YYfhXoXwwutGMN9oHiTUIbGydfNgu5hhUbrjPGORnmodyWrm1q2j/a9J/s2Y3LXlr8y7oseZ264x0P8A+rtz/hJIVvJbVomDsDxlcl+pJx+VVNA8Z6hp+uXNlNqEeqabBJ5UV9E2zcMnBCnrn9PXvUvjOGTTb+DXNKjlj83552VPlB9SPxOam2thNW0OJ1K4ludQuraUtxKQNuBjB757e/41ektBD5SRujKCGLrzjviqmueda69HfZTyL0B1mA3YPGcjtz2qwzySOEdVBKfN2LcematbDZpeFIHTVLqGO5+zpJGWGUJ3dv1rmtQg+w6hMs3luHc/MNxz+YzV7UVP2fdMwAyASpO5D6Ajg1hyvOJAZQ+5eRvPJppa3GkeizAi5+C65yv9sy7T6j7XD69q7TXNMea8mmnVFxK21yQFcluBz3z9K4gytPP8F5JM7m1mXLYxn/S4R/Su31hdup+ZfCaSBLovDFEwAU54OeoHT865YdL+f/pRrW+FfL8isIfPlbdAELyBUkfkoQR83vnH6CvN/if4ca0vZtRhdGiJAYfxc9z2r0OSSFI5hL5i/bHELKobEYycAf3hz1A/+tJe2C65bvZ3rRwxxbiueZJhjAP05BJAraLtqjCMuV3OP+B3iOCwu59Lvj+7vHQJnpnkYx+I/KvQPGNqLac3CbpLUnPmHPLY7DB44rwubTBb3clrbOkl1HMfLVcj5QepJ/nX0X4E8TWniLRbZbkbvJxFNGeQpB6tj6Z/Grkr6oqVmzwvUXj1R5IbVS90xIfA6nPJ/SuJurdreTaTkZxuxwa+oPE3gyws2v38KJH59wufNjbG8d1BJwD1/KvEbjQorrTwQzW7qrMFmjbfJg4O04x1OMU4yS0KhLkZykVuZbdWIG0HAPQ0FXuHEeMlBncBnC1pJompjbCsUhjbmNscEn/Ire1jw3BpGhRS319BDetkNCuWZuOmR0Oe1VzIblqe1/AHxJ4fvtKXRrkouoINgzxlR/F7n1rjfjX8O9H8P3suqWOr2lsLlyyWb5y5z8238/SvNfC1nqela3a3UJa3uYxvjxycEED161L4/uPEj6nbnxc0k0+zfB5hG3YcdMfQflSe+gRir2RStLQ3V24ihMIRT5gOSoGOpr1nw1r8N34ae00yGP8AtEWJiuNsWcbM7XP6V5NZ3N9qM1xcRWZkVI8SCCP7q9OcVp6Hq95oV/8AatLmMUAykjBBulib7w5z0x2pSV9CWmmej/C+3u476G91CR3NqJN8eMYd8EHjqCK9mN/NbWEMFup80kYK8sWP9O9cV4Mn0y/01L21lP2YIFUntjjHXiuq0oLI8l3I5APES5wXA9j9DUrsKNzI1i4hsb7y9UmVbe4GHbOcEcj/AD7Vsac2kTadGk7m7lDfuyQQMdRVfUdI0/et1fSh4icwq4yrHpzUOlz3E2reS32dCn+riySMd+f6UtmUX7KQCe5jg/jcKBuwQOfwNUNXtUOoQB94uIASCTjBB6EemKsavI2nv5u1o0IYHaDuQ/4e9cd4s8SR2Fn9jSD7drl2P3MSNl+nBODnA9qfkDOQ8T6d/wAJV8W7VbK13CMpLdHYAABgBW9c4A/GvaPGGn6Re+D49L1dk3KpVSOvTnHvxWd8M/Cz6V4cTVdTU/bLkmWY7SrFj9T0HQU/UL1UaSV42lAzGwI+6T39TT2VmJX3Z863Yh0zUTomsSSz6QHKW9yVwyI2CeOuAcH8Kn0LULjTZpdIeVxe2nz2F3Go3OnOODkMCD0OccjtU/irQDrGq3ZtbqMTKxkVXIVcdlzkknP88VycUEhMkLCWLVbbDQYcZBHJA9QQaFaSDRo1EuYdet73Tryf7LexO0tmnl/KWPJjHcZPQdvSm38L3HhmyVgwktyYz+J6Y6jnNUb9U1yxn1eVo7e8QrGVTgM4B5PoTirHhzU5NW1nzNWmklukUBSABuA45wOoHfrVW7A1ZXXQ5q+cSBWThk4YCorcbHV2BCN3rX8RafDpPiCeJg81m43xuDtLIw4Pfv8AyrMmiktyYLvepXlO6keo9RVrY2W2hf8AEoA+H2h8Ef8AE41Hg9v3FjXF12XiJi3w70Iscn+19R5Hf9xY1xtKGwM6r4Uf8lS8Hf8AYZs//R6V+ka845561+bnwp/5Kj4O/wCwzZ/+j0r9JFwQO/8AKq6gLwOB27U0EYyc8HNL0HAxjtijGMdaYFfUXijtJWuZFjixyxOME9P1ryvxPqj6HcLgyNA5y4KnCgnG7nnFesYwCHzIRzjA/wA9q89+Lfh+a/sH1KzkmeSGPY0CFRlfUZ71E72JktNCmRp2uaMFnK3llKpJ2jJGQOnp61534g+Hktnun0BxeW6jLW7N+9QcHpjnv/8AXrF8I+J7nwzdxW0iNLZzAJ8x4Q9+2K9dt9YLFJIFyZcY4HP41nuZaS3PnfVmhs7h0wG253wklWU9x7duayJLUwKskMjqzg4U85H+TX0Hr/hzTvFBmW8sJopMf8fMJAZT9COf1rzDxf4MuvD2nGee9iaykISFzneW/wBofw9+mfwovYXLbY89ntuAzuQCflUjB/HrVyG2tzbSSX1z56YwqR8Y59KTyiVjFxuaPOSQQefw/wA8Uhs9xUwqV65BIPP1piILS1WJdxhAj3HADE7B6mrPno0ZWVTleQduQ4zn1x+Q4zxS+XIyN++dcDOAOuOvT6UziaBYy0nYkkEM38/5UgIrmztZQ0kMYif+IMcD3x+fSqVxp8QmjVHIHcAZ5rSa7d22l12LhFIH6kmkMKSupDR8BR8vQH8fr9KLtDRUSM4eRSFwSArnlvpiopsKhGCvzZYtnB+n6VfvoHWQPKu04yCGBB/rVVIgxDMpz1VfX65pgTQW0k0ALylT6A7SB6//AFqhlWJ9xwjIMgNtPP6UTSM0i4QgsNjZHP0xTItkROAzoDk4XkD/ADmjUERjfuWSFlGfuseaiuLc3ECBmw464Hy/ianuVUyADgbeAB8y/X/61RxwsY97lwoPzELkEf160DKGs3VgdPgtoLSWO9U5lkaQFT9ABXb/AAV8YDSr290u/sor201BFQySdYMBhkDuDkD8BXPppUevXBjjlSFI14k2YJ44yP8A69d18I9E0OwF3dXOqwS6jkLHFgptHPc9Sfb2p3ViuZctupi6zZjTr+40m7edtNlk8yC4KKVwecYxkY/x45rPvopNJvBbO0SlfmSWMnO30yMYPHeu7+IVuvk71MbnO/IUnbxnP/665O4lsL6wt7i6jDNtMJ+b5m96zRmcvqzIJSR9/GFy2Qf/AK9Z8DSHlGCkdeeT9KbL5dqZom3OVY7S+CCPwqGK6CMuE3sTwBzmtEuxokelI3mT/BXOeNYlX/ybhrptXuxLqd3BbzXEkaTOJLRY8ldp4IbPHfI9MVytskkbfBRZOHOsStgjnm8ixXV6xMTrM0qxJp1xFM6YhUlLnJ4LHnnrmuSG6v8A3v8A0o0rfD935DNPvftFiYzC24OAEZgAfdW656d/8aN8llf299dQtKi5MbN92Q4+6xPPTvjHFQxwRi8ltbiEGQL5jRgkBTkcnPcflVGW7uLOC4gvN81rgCGRTvMYHY/T1rVeRyljxxbW9zE9xbWypdzDcJVUZQqOOnLfyrhrDVbjTUkl0e+a11WbMV7C6/67J4IyPlP5da7vStchvS1vFLFPPCoCZ+85JPDDGfyHc1w3jrQLjR71r6TUN2oO+ZUC7SGIzxg8jFXHszSOrsz034X6+tuCLK6huYUILWY+UwnuRnryck11XizwzY+MLWK5hu4rO8iVhH5Dc8kZUg9QSOtfO/h3UHmu4hbzraapnEcuMJLk/db6+td/pupzSXUU1tb3Fhf2kgWa03BnkyckpnGV9scZ+lNqwneOhN4h8G+LNG0eK3uoAbJSGjuYDh2JIO3HG38Ki+w+HmkhuNWsZtXCr5TXCzMqo3XoD82Oa9Y0rxemv2cWl61F+7cERO4AVeOST1B9j7+1dbeaBpR8MKmlWCX+Sf3KAKz7urY9c80rN6oaSexx/wANvAugyaqNYhZLyzlUKnUrGR+PWrvxT8G6BrVsIr2N22FvJuFkw8bdwPVe3P8AhXlOtXPjT4dwS6apMNvqiPbpv+bA7Mo/hYA9fb246rwZBJpugWVjdXUl2sILmYk5O47uASfXGPai6sNPlOj8K+GdP8O2Elro0cRkwDvAz5uB1JPWuU+LWmaY2hwzau8WmStu8uOBAWmOOenTgD9K7lr21gl+0wOyxxqS0UnG0EdSM1zviSxttYtWW+2ybhiKVedm8YOOmP60MEeCeFLPxHKXn0GGfyYSJBg4VtpznB4bp05r0nT/AB7L5sV94ystTtY0+RXiXEZ44x0P9K3fCujXOhaf/Zly3m+WWiWaEEh0OSuRjjH41ZF3Z31+lnOkU9op2eYwDASjqu09+vHfmhu7E2ZY+IvhHUrpBeavqtqq/d3RMwX2IGfzFdTP458JRWKyaXr1nabM8Ku5jx785x7VneLdD0jVLfF1ZwTu4xuVShHpgDGMV47P4BuP7RsoLaYGC7bgsvzR+zdumKFylXR3Y8b6/r9zJH4et3kt1GJrxwAc56gHPGMcc12ng/wQ1pdPqd9d+ZqkxLvcXOGLsfQj7oHTAqvpmm2nhfQYLCxYsI/neYgZkNb0GoNJaJMzFiF+ZNuQBQTu9St9o8W2utwXs1/aavoasYrnTobZYyMdGyTnr79unOaq6/q1vNHLO2k3T3EaNJGsTMMrjocHkiltbovqNxeBZI4G2pjBAz/e569asaohVJL6G8+VV+ZS3yyL/d/l/wDqpNu2hR5J4iZJpob+wguIDyZkWAhihHIU4IDDnnpWJoHha91qbUZ7UztHZw7087AaVc8Lj19/au1XV4/tT2luFDv8mDgqMjIPPUfSpdDuBDqrRQoWtLmIKflYgOAQeRwM88URdjO55H4qtoYpJJbFrgM4H2qJ1wPY8fh1rmoJpIJklicpIh3Ky8EGvbPFnhs3d5NfRFCDZssyuCNyK3BwB1xg/hXneveDrnRrjT5LmaH+z79N9vcodyH/AGSex6f5zjSElazN4TVrM67R/wCyvF/hibQ72BoPEChp9OuVYeXJ/EY2OeO/8+ted6VHb3JNhcqtvO7YiuHJHlv2Vhg8E8e2a3xFPptmJB5kN5YuCY3j5696yvEsSxa1LJFsEV2FuY2ToobnH4HIoW5MHpYi8TZ/4QDRVddrrrOoqw9xBYg1xdekfEe5tb7wdod3YxeTHPql+7Rk5Kv9nsQ35kZ/GvN6qn8P3/mWdT8K/wDkp/hD/sMWf/o9K+4PhZ46g17w7ZNcHy5XQcHqK+H/AIV/8lP8If8AYYs//R6V6d8NtRvbO4RLdjGh6+axwfp+FTJ2kTN8tmfa4O4Zxx25oJGMk4xXmPhPxl9mhaHUWUkHGFPf6mr/AIo+KPh3RbMtd3ToWGMohbaT9M1ammNSR0eveI7PSkRXlQyOcDY44PSsSw8Wx6vDcxREYQhGbHA/DvXj1v4e8Q/EHWvtUC3EOiuFkhncj94hAIIzz9PrXo3hfwBJ4Q3PDcPcRy4Em5snPqf/AK1RzSZN2zJ8eeC7TW7JrqEiK92/OIU2pIAD+RH+etct4F8TRR3Y0jVhAbgHbBNGuc9eGxgV66yNho4BvQdv7v0zXD+Mfhw2qyNf6PIq3jAGSEnZ5mPRh0NJrsS11OwQbLcRgRlmG5mXow61j+JLRL/RL63e2aZXQ52qCw/MYrz3wj47Hhy/k0fxNcxwTxERAyTAlOOj88V6fbatY3jwz2epWsi53bIZ0IbP169qTsxo+Y7iOFDm1hkSPcQ24YZT7jjp6VRU+WrRTPGPMICuBgrj8eetep/FnQtTi1ibWrw2Evh66XaGtIfnifGAWxx1HX36d680u1WEpE4AcEnzWXLfiw+gxQZtWdivbuRN5bbpUjxgSOCv1x+NUzKd7ooHOSqgkgdOn5jr6CppHkFykYaJVVfvAq2e3fvUTSIHVpSEcYAJOBx7DOO9PcBptbtlEsiYjUj5yykgdeTnjpTmuYQ6bvmYc44+U/h9KfK5jULbLy3Ejg5z7A01IMOsySGRM4dgDhP0pdNRiOiSFpGeVYD91DHkM3Trnio4/lkjQxgryMv8uP8A61TSQRrMztMWKZcL5eQR+fHaoZoo5oy7MRGcY2nJz/OhMCKdrZXYuWRt2AAo2/Xk/wCNSYaJQYiD+J5+vOKdcWsMgUxwOJFwGz/PH4/qKY9wbYu0sYjlIwwzkD/69MA3qkSHPluT80i/KCCcY96pXchLYZ1ESnow4PuO9QXV4Nzrbqu1sZkkUFifXvj8KzH3uf3jMT+dNIpRNiXUYQYo4VkjQD5trjr7DH86twwC8tppoHSRUG90AAYfUVzSoXP3efXoakgleB90TbXU5zT5RuJ3Xh7WCbG6sboPNbSofLGNxRjxu56dSeazrdSZ5raQ+YwGV6nJ+uePyo0rWUmdbos8Goq2N8bEKR6lR/SrE1vdTTi9igh8qL+OFiyv9cf54qNtzPZmZO/mpiaNWydrAkZX2GO3FVLS1ijlfPyD+E4ziuut49PvoVldHhl4VgqcfUsefTp/hjJubWK2eQQ+dIrN8smwqCv9P5UJjTOnlXbffBduPm1mU8MSP+PyLvXW3+y+v9TSKKOK4QuGiYEox3nkkeorkGUJf/BZUWNVGryYCMSM/bIvXvVyPXLS51e8W3WRZ4JpMhFLLtDnJyOx+v8A9bmhq0vX/wBKN6qfLf0/IsWr/Zb64e7JijhXETrH/q4/9pc8+vGetLZq9+xW4uBawXIMqvbITJMp+pwucDkj/CrpRdWg82YOkZ5MRO9pRxwPRfUd6qWkkszyw3ccroJQquz4eNR0AcchR09/xzWyOUytV0S0eWFbWNoBGDsCrggdyzZ5P1q54cml/s2XToVle3UkkImDIpJJBJ5PX65ragtIy8csjuzsCSqZCnHIycn25qF9PFtcLJYs4djvII++eeD6D3Aov0Hdnn3i3wTMkkt9pMavC7Em3Q5K/T1+nvWV4P16HTb2FL9XEAJy8aguCeOSew9PrXslrKlxC8UMRjYZ89HBDIOhJzz0OM+9ef8AjvwnJdn+0dKtEQqpM0cR4bvlR+eauMvss1jPm92R6L9sjEGdNnj8i8j8vb5ZxOQMjJ6Lj6elasV7PamGKJzGwYIpDY28Z69q8D8J+Jp9EmEc4keEHhST8h78V7Xp2rpfWyMsqz27LukkQAnB7Nz2559/rUuNiGnB6mp4s1+TV/C2qaXdT+ak8JVXnbCpKvKnIHXIB+oFZ3hTV7hPBNjqOrP58VvAC7gnLbSRz9Mc+vNFqssVxOjb57dhtVnXmMc7uOh64rX8K6VaRWMmm2lxJLZljIhbhlD5JBA7Zzz/AIUldjvc2dQeOS1tr4SB4ZiEYrhhhhxj3Fc1o3h68tLu4tru685FZ1t2yc7CehPIJ6V0P9i3NjZLbHyXQD92vUDnjjv2qCQIhi2q+1jtck8Kw6inYe5R0HdcWLR3TPE3zQMhJxhTwc46ng8VFqGlrqPlqT5UkUoct3RgPl5PXrUg8kXFyRwlwdyJvONw9D6/SrGl3/nJJPG4laVcoVxliPqPr0oF5EFhFNcW5iuX23UTZby2znnOcY4zxVZB5ev28EzZZZdpweUO3IqZ7qR9Tmxbqk9wgy+c5K8Zx+IqnKLj7fABtMqNmQt8u/jHQjk4pAauop9suhCVP394J7c96fMWhR3jABGBkDHTg5qtFer5zTRFWBJymckc46YrSskWRohdKFMh5ikJ3EeuF6UDGortZLJcAx2z5ZkI4BrHvElg842ID2qgNIgfcWH+zXYSrMisLSO2eKNgiImWyMe+Kx7hRKsqq6pMGOUHXr7U7A0eUeINV0258WaXDfYgPlOsvyYyT93cfz703RtbtbLUWMRMkIdsbASMZ6kYznvT/iZ4ZaXxDpjTRbUe6WGTY+5mRyDnHbvXodvoOkaZp4kMUVnbWw+RnwFVQP7zctnJ5oS0JaDUrS1isJJp5mjhKtKx3Y8sEHI4/Lp+deVabq1xPaLoGr6Yt7ZXzf6I4lCjZnJ2t0yMAjJrpL+61nxZNe23hzT5dW0Vo0jluZcQQ7s5IR269Me1TN4Y1Dw/4buLe+8GzalZTOWZoNRE01qeMGNUAYj6fjTt1KseZ6/4cvtDXzrZ11HRSR5d1GQQp6FWAOVI6en8hzl1KcLFHIRbnLpu7HHIrsF09tQ0i+u9H82304FQInkMgLY+beexz6jvXP3VlC8MUSsELx+cJJV8tf8AaQeuOx71cX3KUlcq+JEK/DzQSejatqLD/vxYj+lcZXceLYfs/gPRYt4dF1jUdrL0I8ix5FcPVQ2+/wDM0Z1Pwr/5Kf4Q/wCwxZ/+j0rrdJXUUktb9HLbAM542g88/wCFcj8LQD8TvCIYZB1izyP+2yV12nyuuHlZ3Owfuiueo7AgL+P5VMvi+RnPY9e0vVBq0f2lYASMIrAErnAzk/jUGqaDZawsUd3vEckokdSSwO3qAfem+C5LiTRLdJ1AwSqAvyB6/nnpWi2y3kVBgbSWUZIYnvjP41n1Mj1z4WeN7DxjocrWls2nz2Mv2Wezk4MTL2HqMf5611molTZzBmG0Dn2PvXyf4P8AEtj4Wl1WeIXMmq3kon+xWas7NGGILdQOue9df4F8aeNvGWrXkdgdK0iyOVaa9je4lXg42RqygnIGdxA574rVTdjZSuj19/KlYeZGGULnevGDXG3/AMSvD+j3f2FNQXVrl1Yx2ekqbmclOSu2PO0+zEdD+EreCI9RtBD4t1jVtfBRQ6S3H2aAkf8ATCDYpyf7+/6+utBoVnpkBh0bT7awtydxW2t1hTPqQoA/SlqGh5V4u0G28XWs+oTeGNF8IWHmC4m1nVpkS4cScktFF/GWPR3BJPTPFeQDwJejyNSuI7oeHZ3DQXhhWCS6iz99I2J2hgMqW6gg4PSvqTU9C0zXrqzbW7CK6azcyQI5JjDEY3NHna5wTgsDjnGM10cqRX1kLa7Vbi2OQYplyGB9+3Wmg5nbQ43wifDOveDF8PaMsENiibFhTOYsknJB5LZ5JOSTyea8t8Y+C9V8OXMcPnJLbt/qp1GGYZzgjNdh4t+G1zpN5LrHg4XJki+byYmy6DB4HXcDxwfT82aJ4us9dsn0vxzAluqN+7vSuwA4/i/uHPHOOal66MzZ4vcWL28z+fJHlsjDsckeh59qoSGNVImnhgdSR5aZJPr37cd+9dt8TfhrrOlzz6npryatpTjcs0ZLsq++O1eSzEo+MZPfJppAonVebamBZILyBhH2YEHt2PbrVK61W3jh8tbiaXdywiBA/Mn9K5854JAJ/wBmmkE9AefajlKUTZPiHaAPJklVeAzvzj04qKXXVkEm22UK5yoLH5fxrL8oZ+Yt+FNMADEqRiqsh2iXHvnlQAKu4fxdzVWV3ZS0pzznFPUBTnjP6U1huGeetCVgGrhh16+uRikXH93HOMlutOZQT6AdjSyZyqcEDng0AQvkHduyucCnLzxx+fApXbLYI+UU3BC5B69/SmMVSyyB0J+XoRxXo3w81xJL+GxuILd4bjKvCY8hm9eO/ArzdVZeM5Hauh8CQzS+KrFLcqJWkwCeg9/elJXJmtD2fxh4J0+OwS4021azliO5lWQOjr34PT8K4u8v9O1DU7VbqRol2CORYEAJx6kH6c17nHpMkeliKeT7VdbPmeToTj09K8L8b6Wmm6nIRbiA53bU+VB6d6x6kNG14rsbLT/FvwettOcvbLrDbWJ3Hm6hJ5+pNeN3t3NDql2VkJzOzNk5ycnmvV9WvhqGufBacQpCTqhHlqMAYu4hnH4V5Fq4/wCJpd8Y/fP/AOhGoorVL1/9KO5K8NfL8jvtI8floLKO5YQ3SHY85UMCM8MR1/AeldRpupWN6BFPPCbi5k/dMrY80YySRkY+nf8An4gqnsKkV5VKkO4K9CCeK3dNdDndBdD6Fs0aC2Se0aS5sZfmRDHtkH5nKj2q5H5cgIuHjniyTE5PK8dD6H3qt8JL23v/AAXZR61qDI0l1IrXMhLMiqOOhyw6Dnpmu8mi8GWuySa8vr+QjaGt0VI+vcN0+v5VlazMlA8/u7JZd89tK3noAXKty/8AsE9xyeRTtLk/0owadA3muoJjRi7MDySM5Ofw4/l18XiPw5ZXjjTPDEQccGa6dp1IB7DOOvbPamX3j/xBarL/AGXBbwWyfejtbYRkD1Gfzo0Fyrucrrnwhv8AxQGm0/SZ7S7GNkkieWrDH8W7GfqM12XhSwh8F6Tp2m+NbX4b2FtHCsMk6XGy6mdRgMVKfO5wCx3ZJye+BxR8X63e3cYvby/1CJgwK+YY3UjrhOA35VseGvFOn6awS10eR9XDl4b26iJNuCCPkRhgNy3I65wc1V7mkZpaHq9zovgy101dQu7IWNsFwrSCWFj7CNsNn/gPvXm2r39gLqSTw1G6KAWgaVwTkDlT32ntjNePfEeHxfHrg1u+1a81Qj5o7tWwYl9Ni8IPYALVDw94/ube4UX6RHcRunRACPcgdfwxQ03qhySa909m0DxU+qJpFzf+Za/ejmilypRuihs9cnp65/LPt/EFtJrd94YRszu7SNIBsO08kfXHTHtSpAb6C3uopk1G3lIYZkBWQdeM/wBf0qLxHqPhjRtRh1TVomj1FFIhzAxb6ccfjmkjJXeh1t9pGnvZWtnDGhNugRPMXJIGMAk/TrVK/DWtqY87Y532ZyR5ZPf8fX/GsL/hO9FvovtdvBfRvj5Ue2k2uR1AIBFcvdfES2/sy5vhDNPqkmTGuxjHbDoAxOAenYdaGm+hXodoskYjglRWSSFdqNknP1J9e/8AWsbUPF+nWWuWcN/PsYk+aUO7YT0z2981wNn418Vas6W2jW6PdH7y2tt5jNnuQcgfWrtz8IfiDJdC6bQnEzkMoNzCcnr/AHsfhVKm+o+Tueq3Gp6dYaSHeWKAfxO7Avgcgn0z1zUFnqkd4DcaZIrb1I4O7J7enrXAx/D34lyySSX2ivcALjyp5ojv7cYbtTLjwV8RRbNbQeH57TbwVgnjUcjGMbunajkYmjsvDPjiaS6NvqRS1uVclYoxnywB/Ec4zW1dSWk9rJdzZtZwfNLr8u4HknnjHrmuG8FfDfx5aXEkqeG7ZWkjCCa/uUIVh/Fhcnr/APrrvNN+EepateLJ471p7iLd/wAg6xUxx/Qt1I6eh460ODHY8w1PXda8a+JLa28JW81+bNeXKCNGJ6M3QADnGTzzXq2kfDSBpba/8aXs2rXGQFtpH22sTeyfxfjwfSvStA8LWPh+wSy0izgtLY8tGg2knsxPc1ZnsmdXRpk/d9CGA4qlFIfKZ6xqyqCqqo+VSnAI9MDp+FUJbeSJDtbezcgjjGP171ry28ki7DLExzw27GKgSFxJhXhK4xliT+OKBnmvjHwW2o3EmteGLyTRtWaMrM6cQ3RAwBInQtzgNjvznAx4LrFiJtFkdmm8u1uBDcsU2Gzc8BXi5wCRjcDyfevrmexhLmR5HuCO0abVFcT8StBn1DSrybSvL+2SRbZrdlVkvI1OfLdSMbhztbqDjBHNLbYXmfMvjOaGb4ceFfKVhImoagkuRwWEVngj227fxzXA16T8SNIXSPBHhoRyrJDd6hf3UYHJjVorMBCe5G3BrzaqpfDp3f5mjOp+FeP+Fn+D89P7Ys//AEeldvm5u9NjtZUFxGgDy/usEcdGA9/XuPU1xHwr4+J/hDPT+2LP/wBHpXpVrZC78mKOcqSqlkZPLJPcY57kdT6+lKfxGVTZHN/C/TbXUddvoLuztruMWrHbPGGUfMvPqD7jmt34dX97D4q1Ow095rnQYjKq/vPMjgAJ8sqTkc9MD7wOeduRQ+D+m6fqHiHUY9UtoblY7cskUsSyDdvXkZHXt+Na/hu5lsPiZc6DpE9xd+HUeUNbu5eOABSW2k/dAkO3P8XAOSRQ9WypdSnH4ulPh+90NribeJmJTaVH3sHjrn2zXq/wF/sK6gnh0+8a9kRE+2R7JAqs5bHDqAc7W6Z6V4DfsLXx9qAlAVDfyDMnA2mTIJ6cYwa9f/ZGX/T/ABQ5ZUVVs+SMjrPTSFyJam3+zHqMsnhDW7vU7wmOGdWeadyQiCMEkknAAAJJrvbz4h+Gf+Eaj8RNfXA0dpTAl01jcbC4yDgbd2MgjdjGQRnPFeL/AAQ+w3fwu8Y6dfXVzZxTrta6WImKFTEfmZsgYG35gSOOpGa1tHsb7V/g1pvhC3sBG80hY6vNcotr5JnadZUTPmksCoCtGp+YklcUkraFytfU9N13XdKg0NdW1G7l0+yMm0NcW0kMrOSflETKJC3BONuSAT05qDRfEVpc61d6XHco+pWYXzYJUZXRWUFSQQMjBHTpkA4Nea/G0J4cPw6aKa4ubXS5P3s7L5nmmLyNrOAQCxCuQMjOW5HNb/hbS7afxsviaXWBcXt7E6JFbIqRSwqFBbqSVB2fNnG7aM8gUupDPXra5dTyCjYPCuST9DWT4o8KaX4kVZbpRaXyDC3UXyvn0cdx165qCTVoEuFjMiMpwGYMQV/IelaX9oWwyYZkkbthhTuG55VIfFHw7vCzgXOjyNl0DboXGOvPKHOeOlcj42+H0PiMPrXgSFXZxvu9PYqrRt32diOvf6V9FRTwXts9vOitbniQy4weO3/1q4qfwpc+GL+TVPCUhmi+8+ntn5sf3Wz6H8aVraoVmj5IuLZ7eV45o3hnU7WjkXayn3B6Uxmwctj6V9YeI/DOh/EuzMt0r2OqwjBlihw8Z9HXuM+/0rxDxl8KPEXh5mmjt/7QsskCa0VnOPVlxkfrVXC/c85IyvJG3OelNEuCy9j6ipjAu9kO4MDg8Y2n0oks3jHzcg09B3RHkMeD+AokdmxkYIGAcYqNhsbJ5/HpT1Y7eCCfaiwxAW3bTy3fFNGdwIp2MjJY5+lRu5BwowOufWmFhWcE9FBFDYLjPX0HemLGXAIOOat29rLM3yjkcc0bDdkQAEt8ox9a9Y+DGl21jrC6zqyOwjQm3ihBkkyf4ig56fzNc94X8HT6jIJJ43CA/IfLI3Nk+3tXvmhafBocUcem24F864kcoECA9SSOaiUuhk5c2xPceL9NgRjdXDREn/VlcSLk4+71rxvV77+3/FkkMUryWrHzFOzO0Ad+46nivU/EMltPbFb60tL1lPAkjA5z2JBrM0Hw9aie8uraxA+Ty3MaYCg9R7/hWd9QfY4jVbaWy1/4Mw3EfluNWZ8ezXkRH6GvItVx/ad1ggjzX5HQ8mvdPiDLHL8Q/hH5QAVNVWPG3A4uYR0+ua8J1H/kIXHAH7xun1qKC1+//wBKO6Pw/d+R9Kfshsmsaf4j03Vbezu7KwFs1uk1tGxj81py/wA23JyVXgk4xxirPwWvj4+8R+JtA8WaFpOraVaB3jupLCFHtmL7Fj+RF5K7iG4YbDzyMU/2Lf8AW+M+cfJY/wA7mtH4FeMta8W+KvEPhPxA0N3ogtZpB5cKwGLEqJsDRBeGDt1+bjr1rob95JeZnbRv0K8XgtU1C80Xwla/brWwlY7TOgYKWbGCxG7GME/TJ5zTtL8Ha3e3M5sLJBJbTGOTZJENjjqrru+oyMg4zXefDnw9p/hj4gavpuiyyPY29t5axO+8w8xMEDdeA+OecAZ9a3Ph9C8fiLxc7Fikl9wSMAEPJwP0P41CjfcwdNN3Mb4V+XqOhamLuyt1EQBRGVX2FlbOGxyCa8+j8H6nqNpLNaMy29ufnaVxHGuegDsQD2/r1rvfgzcJPo2vOoBjBXDAcHCt9OnTFJ4fvre9+GUumXJS1MTCMS3L7Y5Tv8wAP/eAB/IHPPC6a9h8t0kef674E1i20tb26s9sUK7o5vtMRKgnr8rEkZI5GaXQvDPiO6treW4tGLzRM1u0ksavMAMkqhYMR0PA711fjjV9NvtF8O6LasuoRW7xm5vYeViQDaQre4Pt0Fb/AMTdVi8La/o2vSaZc3awRvDFJHcLHEjOdu1hsJyQ/HI6e1FkxezR5bZXKYkCedG4YqSuQd4zkEH7uDxg9PauT8WeBdP1h5Ly1uVsr9zlwVJR265YDlSfUVf8UahO3jzWpp7F9FkuZFl+ytiQByilixAAySSxxg5ODzWha37TKomRrhskAdwAOD9PTvSu1qjP4XozyJP+Ej8CX6SPHJFC7cbsvb3H4jhunY5HtXf6R430bxPpcmkeIVeNJnUmKWTOD2Mbn0PZj9M10yt5ipaNHFd2sgxcW8yhlc4xgoeAwPf9K848TfDeSNGudAMk2clrOQfOvPARs/P9CAenU1SalvoacylufTnwg1LyNOGg3hhka2GLe5XAE6Hpx1DDofccV6O1vGcZVM5/uivi74XfECbRtWttL8RCcRRSeUkrZWSBs42uDyR29Rj8vq3RPF+m6jtjWeN8cM2QNv1FaRlbRlR00Zurawwu0kESRMBg4UAN+VSEbuOAT0VuVJ9qkSRXVTHIrDjlcdKcSASOc/jV7lJFWSHClPmbHO0nnPsarJlnO5ZDJ78H8K0DnBHUE9+aZdRB4vmDEjkMPvClYLFOOQheX3MDjLNjPp9DUdzNJwCWH+zu5qSaM+URsyAAPMT+oqp8ucAjaPmyDwfx7UhMjDsqEuWC9SQQcj3qIyxFwSjO+COmMf41K6BgiHBznryPpUMqyExiMKuDgtngUhFc4EbsNj5OScYFU7pWB/dt8x5XPFWhFIo2srA8+wIOaimUAp8pJ6HI7+1IRWJaNGB3hevA/pUMmE+8D07dKmvEjMscgRQ4Xb0G5f8AOB+QrI1zUY9N026kkIG1CeenvUtpaiPm349Wi2elaOsaNHFJqupSopbIAZbU8egzk4968br1z40XUV74X8NXVvMJUmvtRbcGJ5xbcc+nSvI6MP8AB83+bNGdT8K/+Sn+D/8AsMWf/o9K9TtIZPEEbSSRyGVgFxGhQt+XIFeMeFtW/sHxPpGsCHzzp95Dd+Vu2+Z5bhtucHGcYzg16tpHxm0fS52mt/CNy0rdWl1fdn3/ANT1omnzXSuRKPMtz0jTPh9o9lZxpLpFtl0KudzbjnqCc5x7VbPhzT9FiddJjFkj4LmGMZbHQE4ycZPX1rgJ/wBoS1mbLeE5x7Lqox194KrSfHexkJLeFbo5GMHVVwPp/o9S+d9H+H+YvZ+ZteLfB1jqEL6orRTX4BlklY7QyKOOOhxgDJ7V6X8Bf+Ean8K+bo1rFZXkyhLgLI2+QqTgsQc8ZOPTccY5rwjUvi9pN/pd9Yt4b1SCO8GJHg1iNXx3GTbHg9D7Gszwh8SNI8J3v2jSdJ8QAfxRSa1CUb6gWgprnXQcYW3Z9X6h4R0zRvCOv2vhzQ7Yy3tnLE1jG7Qx3RKsNhIIxkEjIIIzwR1ryez+D3g2Wzimj1Dxt54ABzproVfjnZ9nyBn/AGsf7Xesxf2oBtUSeEpZMf3tVHP5Q04/tQQldv8AwhhXPUrqYB/9E1Tu+n5FJWVkz07wx4OW8+Gul6X48torzU/LY3PmOX2NubZhh/y0VGClwc5B5PU5Vr4c0vwHeNDpGn/Z7a6YNJM5YnjoCzEtjGeM4HPHNcJH+03Ckok/4ROckcANqgYf+iakf9pmwuZT9q8JTmJuGH9oK2Bn08ods0nfohcjZ7hBN5kMTbIm3HKtEow1TzSIsYMsUa9mBQHI+hrwG3/aK0i3j2Q+Fr0DP/P8nT2/d8U//ho3STgN4av8ehvUP/slLmfZj9m/I98jurdIvkKK+ewG0fhVyC9ScFVkQAjr0x78V87yftC6A5Cnw3qAQ4LkXEeSe/G36VBN8dfC8kiyJoWswyDPzx3EeevoRjsKnnfZ/cP2b8vvPftS07dMb21do7xP4hgCTn7p9a57XvFs+nWT3UKTpNHlZogw/Mdu9eWQftB+H4kx/Zeu5z182Ln9Bj8KyPFnxg8H+JRF9p0rxDbvHjDW80SlunXOQenp+VJzfRMXs30t95meLPE2o69qM8tz5r2vJWMKEGM98AZ+p9KwUsZrizM8gAhztChD8uOOvYD3rVk8eeBmYeXaeKIR3Eb23tzyvPT9fpUc3jbwJMu1rXxSuM4YSW+cflS9o/5X9xHspeX3owNQ0mS2L7UaWFcZkQEqCR396x2tmyWi4xySD/Su3/4TPwJ5QTyvFwwc432x3fXioG8T/DqSRHks/FfynorW4DfXpVKq+z+4pU5r/h0cYLe4cDHPvirNjo9zcTeWsLvJ6KOfyrrT4n+Gz7i9n4s3HphrfAHpUv8AwmfgIQiOKPxbAvU+WLXP59aftfJ/cwcJ+X3ozoPCs0LRNcgRCQYVSct07gdMd/SvSvBfgVrhPMlmh8mP74RgCx/2ic/5/CuT0v4g+AdPk82Kz8TGY9WZYM9D6MM9e9dJD8b/AAfGhAsPEPHQBIAP/Qqn2jfR/cyfYye/5o9TsLe10uBIbeJTMBgPj7g9RVgwIB87sTjiRj9/8K8ug+PHg6FyRp3iBs9zHD/8XT5Pj74SkZSdP18AD7ojh/8Ai6Obyf3Feza/4c7XU9HfVbd4f3sMbHEZzg/iPSumstLt9M0dbaOVxsQKw67vevLbf9obwdESf7I13d/C2yIkH1+/UrftHeFWjIbTdeLEHJMcJ/8AalPmS6P7mHsnf/glD4mQiD4k/CVAwcf2svzDv/pMNeA35/06fnP7xuc5716L41+Kei65438EarZWWopY6DdpcT+cE82QCZHIUBsdE7kcnt1rlp08FzzySHxLrS723YOhocZ9/tXNKmnGza7/AJnQmrNen5Fzwf8AEbxP4PtJLbw3qENhHLjzGSxt2eTBJG52jLNjc2Mk4zgYq7Y/Fnxjp8d2mm6pb2IvGL3Bs9NtLdpWPVi0cQO7/azn3rCWHwWVyfE2tA/3f7CTP/pVUn2bwTz/AMVXrHT/AKAK/wDyTW3Mnvf7mGn9WOi+Ffj3UPDXiKS5a/n3XLlpHc+Z5jsfmL7slsnknrnnrzXuMHxD1/z1nhvImS5wQsEKFQcnkjnnnnuce1fNkdv4K3D/AIqrWE4JydBX/wCSa6PQvFHhfSgiN4k1a5iXPyPoagDr0/0k9c1lLur/AImU4y3i/wAj32HXpIrZotK1GHw7d3DkzNb2UU6TN/tbhn9eOntXQ+ELi40/wSItObTfE0huZJfLULbhCzFugDdycEDjp2r5/t/iD4Kt0ULqWrkBWVgNMQZ9MfvuP/1fWnf8LD8GC5SQalqpjjJ2xnTAR0x/z27/AIVKk072f3MlRl2/FHufim+tLvwhO2qaPZaRrJdDawxSCR2YHJJAAOMZHzDHf0ri9b+I3ia28Kzvpeopvj2xbvs6ySwnA5Bbg9uoP+HDH4j+BwPlv9YAbJIXTkyDn/rr75/Cop/iD4DaUyLdas0hAGX05WVV7gDzhzx1pXk9Wn+IOM+n5oZDqNwkdsdUkN5LOrM06uJtx67nPUN1z9K03judKkh1GQi90krt2C2dJoX6ZyR8y59a5aDxd4T0/VmutL1/WoUf7ytpKv27N9oH06GtSf4l+HJVlR9f19wzZTdpqkKOmCPtHPqOmKd32/Az9lJ/0v8AM3bbVbCVmbzL20kL5Ex5DewB6DP86tJeWt3dqsTMoYkkrlgceh6Z5571yVn498HQGNm1XWnk/i/4labc8jODP1wfU9B3qxJ8RPBZiZZb3VpTuyMaWi8en+upfJ/cHspf00aeueF9M8QTyTSWzrICRJcWjAOp7EqR859RnNZun3OseEryFdTuFNkz+Xb6sgynGcRy9x+PQ9MjJA3xK8JLDFHbaprsaKPmU6ZGwY9eP3/B4FQN8QvB8yOtzf6pLHKpWaI6Sm2Xp94Gcg9OvWmm9mh8kv6aPa/BXxBJeaG5gZZEG4tAdwI68jo2R0K//r9T0bXbLVo0eznikyMttbp+HaviGz8QeEtN1E3Gk+IdetoA2Y7eXSEk8rPXDC5HH4enU81o6t458MX2lmzTWdZhaTmSYaOhJ9hi5GB7ZNWpSjt+pok1ufcIZThgw2/UYpHcAlQy7j2zX53uPBrtvfxDrDMeudBjJ/8ASutjRPE2laBcxvo3jfxPZ+Wcr5OjoEzz1T7Xg/iO9Xzvt+Zdl3PvGdd3GdsvYg8H61mXQ2sBgq7dxyHr5s0T9oG2sgq6rrWo6mu3Bb+w44nb6n7UR37AV08P7SvhFYgssGsucAnFnGMe3+to9pfo/uE4+Z7LHmOYGdNuwdvT29KV5IHcvJclAOik85+v4V4sP2kvBShgbPX2JGM/Zov/AI7ULftGeDPNDC01wgDp9ki9P+utHP8A1Zk8rPahIZA43gsTyu7p6VT1EB5EAJaXrxwRXkEn7Rfgoqdtlrnmc/P9li/l5tc/rHx18PXIb+zLjW7KVvvSvpsUpP4faFqXLyf3Bys9Y8Q+JNM0C2a51G4SNVAOC/JzxwO5zivnvxn45ufGN0YYC1ppyNucqfmI/wA9q5jVtb8PavdedqPifxHONxO19GjIXPXH+l8VH/aHgxdqpquviNTkA6PDn8/tVJa6y/ITVtiz8Rlt1+Hfg02kexXu9QL5GCzYthu/ID8q80rufHviPSdV8PaDpmkS385sJrqWSW7tUgz5vlbQqrI/Tyz1I7Vw1XRTUde7/MbCiiitRBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the placental \"bulge\", loss of the continuity of the uterine wall, and the dary, intraplacental bands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Resnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35686=[""].join("\n");
var outline_f34_54_35686=null;
var title_f34_54_35687="Cauliflower ear after auricular hematoma";
var content_f34_54_35687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cauliflower ear after auricular hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35687=[""].join("\n");
var outline_f34_54_35687=null;
var title_f34_54_35688="Approach to the patient with annular skin lesions";
var content_f34_54_35688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with annular skin lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Rashmi Unwala, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35688/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/54/35688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29248615\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of cutaneous and systemic disorders present with annular (ring-like) skin lesions (",
"    <a class=\"graphic graphic_table graphicRef57617 \" href=\"mobipreview.htm?40/56/41870\">",
"     table 1",
"    </a>",
"    ). The careful assessment of lesion characteristics and accompanying clinical features is valuable for narrowing the differential diagnosis.",
"   </p>",
"   <p>",
"    Diagnostic clues for the identification of disorders that present with annular lesions will be reviewed here. Greater detail on many of the disorders discussed below is available elsewhere in UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925644\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annular skin lesions are figurate lesions characterized by a ring-like morphology. Although plaques represent the most common presentation of annular lesions, lesions may also be macular, nodular, or composed of grouped papules, vesicles, or pustules.",
"   </p>",
"   <p>",
"    Additional terms that are frequently used to describe the characteristics of annular lesions include:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Arcuate &ndash;",
"      </strong>",
"      Consists of arc-shaped lesions that represent incompletely formed annular lesions (",
"      <a class=\"graphic graphic_picture graphicRef81741 \" href=\"mobipreview.htm?39/62/40931\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Polycyclic &ndash;",
"      </strong>",
"      Exhibits multiple coalescing arcuate or annular lesions (",
"      <a class=\"graphic graphic_picture graphicRef73233 graphicRef76839 \" href=\"mobipreview.htm?15/50/16168\">",
"       picture 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Target &ndash;",
"      </strong>",
"      Demonstrates a dusky red center surrounded by a zone of pallor which in turn is surrounded by a peripheral erythematous ring (a characteristic feature of erythema multiforme) (",
"      <a class=\"graphic graphic_picture graphicRef68640 graphicRef79955 \" href=\"mobipreview.htm?21/35/22073\">",
"       picture 3A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Atypical target &ndash;",
"      </strong>",
"      Lacks full criteria for target lesions; only two zones of color change are present (",
"      <a class=\"graphic graphic_picture graphicRef51037 \" href=\"mobipreview.htm?40/27/41393\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925670\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of the underlying diagnosis in patients with annular lesions begins with the assessment of several factors. The clinician should consider the following points during the skin examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are additional physical characteristics of the lesions?",
"     </li>",
"     <li>",
"      Are the lesions stationary, expanding, or migratory?",
"     </li>",
"     <li>",
"      Where are the lesions located?",
"     </li>",
"     <li>",
"      Are there associated systemic or cutaneous signs or symptoms?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the diagnosis is not apparent after these questions have been answered, additional studies may be considered (see",
"    <a class=\"local\" href=\"#H29248692\">",
"     'Diagnostic tests'",
"    </a>",
"    below). A table of disorders that may present with annular features and their clinical and pathological features is provided (",
"    <a class=\"graphic graphic_table graphicRef57617 \" href=\"mobipreview.htm?40/56/41870\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some disorders, such as tinea corporis and erythema annulare centrifugum, annular lesions represent the most common clinical presentation. In contrast, other disorders may demonstrate annular lesions only as an occasional or incidental feature. For example, annular lesions are not a classic feature of psoriasis, nummular dermatitis, seborrheic dermatitis, secondary syphilis, sarcoidosis, mycosis fungoides, or malignant skin tumors, but occasionally occur in the context of these diseases. A distinct annular variant of lichen planus has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The concomitant detection of features that are more typical of a particular skin disease can be of value in the diagnosis of annular lesions in conditions in which this morphology is not common. As an example, the identification of classic psoriatic plaques on the scalp or signs of psoriatic nail disease may lead to the inclusion of psoriasis into the differential diagnosis for a scaly and erythematous annular lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925399\">",
"    <span class=\"h2\">",
"     Lesion characteristics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248622\">",
"    <span class=\"h3\">",
"     Color",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesion color can be useful for narrowing the differential diagnosis. The vast majority of annular lesions represent inflammatory processes, and thus, manifest with blanchable cutaneous erythema. Of note, in patients with dark skin pigmentation, this erythema may be difficult to appreciate. &nbsp;",
"   </p>",
"   <p>",
"    Acute inflammatory lesions often present with bright erythema (",
"    <a class=\"graphic graphic_picture graphicRef55949 graphicRef80998 graphicRef78466 \" href=\"mobipreview.htm?30/33/31257\">",
"     picture 5A-C",
"    </a>",
"    ). In contrast, erythema tends to be muted in lesions of granuloma annulare, a disorder characterized by annular plaques that persist for months to years (",
"    <a class=\"graphic graphic_picture graphicRef62354 graphicRef76216 graphicRef61039 \" href=\"mobipreview.htm?28/48/29449\">",
"     picture 6A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lesion color may also be influenced by disorder-specific characteristics. Lesions of acute or chronic urticaria characteristically have a pink color that results from the combination of dermal edema and vascular dilation (",
"    <a class=\"graphic graphic_picture graphicRef60454 graphicRef63996 \" href=\"mobipreview.htm?7/46/7912\">",
"     picture 7A-B",
"    </a>",
"    ). Moreover, a dusky red to violaceous color, which is often seen in the setting of epidermal necrosis, is a common feature in lesions of erythema multiforme (",
"    <a class=\"graphic graphic_picture graphicRef79955 \" href=\"mobipreview.htm?18/53/19283\">",
"     picture 3B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22922?source=see_link&amp;anchor=H35143181#H35143181\">",
"     \"Granuloma annulare\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=see_link&amp;anchor=H6#H6\">",
"     \"New onset urticaria\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The color of lesions may shift with lesion age. As acute inflammatory lesions resolve, erythema may become less prominent. Postinflammatory hyperpigmentation, when present, may be the only remnant of resolved lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248629\">",
"    <span class=\"h3\">",
"     Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence, absence, and quality of scale are key diagnostic features for several annular dermatoses. When a rim of fine scale is present, the clinician should take note of whether it is &ldquo;leading&rdquo; (present at the advancing edge), or &ldquo;trailing&rdquo; (present more centrally):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Leading scale &ndash;",
"      </strong>",
"      The prototypical annular inflammatory skin lesion with leading scale is the dermatophyte infection tinea corporis (",
"      <a class=\"graphic graphic_picture graphicRef75928 graphicRef55949 \" href=\"mobipreview.htm?30/18/31016\">",
"       picture 5A, 5D",
"      </a>",
"      ). Single or multiple lesions may be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Trailing scale &ndash;",
"      </strong>",
"      Trailing scale is most commonly seen in pityriasis rosea and superficial erythema annulare centrifugum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Pityriasis rosea &ndash;",
"      </strong>",
"      Patients with pityriasis rosea typically present with numerous oval erythematous thin plaques on the trunk and proximal extremities. The long axis of the oval is arranged along lines of skin tension. On the back, this classically results in a &ldquo;Christmas tree-like&rdquo; distribution. The scale is typically described as a collarette (",
"      <a class=\"graphic graphic_picture graphicRef57568 \" href=\"mobipreview.htm?22/20/22852\">",
"       picture 8",
"      </a>",
"      ). A larger, oval erythematous plaque (herald patch) occurs as the initial sign of disease in 50 percent or more of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/18999?source=see_link\">",
"       \"Pityriasis rosea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Superficial erythema annulare centrifugum &ndash;",
"      </strong>",
"      Erythema annulare centrifugum is an inflammatory reactive disorder that occurs in both superficial and deep forms. Patients present with single or multiple annular or arcuate erythematous plaques on the face, neck, trunk, or extremities. Trailing scale is a characteristic feature of the superficial form (",
"      <a class=\"graphic graphic_picture graphicRef59741 graphicRef80998 \" href=\"mobipreview.htm?10/31/10742\">",
"       picture 5B, 5E",
"      </a>",
"      ). In contrast, scale is typically absent in the deep variant of the disease. The cause of the disorder is often unknown; infections and medications are among the possible triggers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a very thin rim of ribbon-like scale known as a cornoid lamella is a pathognomonic feature of lesions of",
"    <strong>",
"     porokeratosis",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef81011 graphicRef62258 \" href=\"mobipreview.htm?3/45/3802\">",
"     picture 9A-B",
"    </a>",
"    ). These lesions also have a distinct histopathological appearance (",
"    <a class=\"graphic graphic_picture graphicRef61211 \" href=\"mobipreview.htm?1/61/2007\">",
"     picture 10",
"    </a>",
"    ). The absence of scale is a relevant feature for",
"    <strong>",
"     granuloma annulare",
"    </strong>",
"    , distinguishing these lesions from the more prevalent diagnosis of tinea corporis. Granuloma annulare presents as single or multiple papules or plaques that exhibit a dull erythematous color and tend to be slightly firm to palpation (",
"    <a class=\"graphic graphic_picture graphicRef62354 graphicRef76216 graphicRef61039 \" href=\"mobipreview.htm?28/48/29449\">",
"     picture 6A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4810?source=see_link\">",
"     \"Porokeratosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22922?source=see_link\">",
"     \"Granuloma annulare\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925653\">",
"    <span class=\"h3\">",
"     Vesicles or pustules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear IgA dermatosis is an autoimmune subepidermal blistering disorder that may be triggered by medications (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/4\">",
"     4",
"    </a>",
"    ]. It classically presents with annular clusters of tense vesicles and bullae in a &ldquo;string of jewels&rdquo; pattern (",
"    <a class=\"graphic graphic_picture graphicRef56434 \" href=\"mobipreview.htm?15/62/16359\">",
"     picture 11",
"    </a>",
"    ). In the early stages of the condition, the vesicles may be tiny, few in number, and located on an annular erythematous, edematous base. Linear IgA dermatosis may be idiopathic or drug-induced. When it occurs in children, the term chronic bullous dermatosis of childhood is also used to describe this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H18#H18\">",
"     \"Drug eruptions\", section on 'Linear IgA bullous dermatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flaccid pustules coalescing into annular, polycyclic, or serpiginous configurations are typical of subcorneal pustular dermatosis (also known as Sneddon-Wilkinson disease) (",
"    <a class=\"graphic graphic_picture graphicRef71995 graphicRef52552 graphicRef68679 graphicRef78333 \" href=\"mobipreview.htm?38/53/39770\">",
"     picture 12A-D",
"    </a>",
"    ). Intertriginous areas, skin flexures, and the abdomen are preferred sites of involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H26#H26\">",
"     \"Neutrophilic dermatoses\", section on 'Subcorneal pustular dermatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925500\">",
"    <span class=\"h3\">",
"     Purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura result from the extravasation of erythrocytes from cutaneous vessels. Examples of disorders that characteristically present with purpuric annular lesions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Purpura annularis telangiectodes of Majocchi &ndash;",
"      </strong>",
"      Purpura annularis telangiectodes of Majocchi is a subtype of pigmented purpuric dermatosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients present with symmetric, asymptomatic eruptions of pinpoint nonblanchable red to red-brown macules that coalesce to form annular patches on the legs (",
"      <a class=\"graphic graphic_picture graphicRef76569 \" href=\"mobipreview.htm?0/10/161\">",
"       picture 13",
"      </a>",
"      ). Mycosis fungoides (a form of cutaneous T-cell lymphoma) can present with lesions with similar features, and should be considered in the differential diagnosis in patients with extensive involvement.",
"     </li>",
"     <li>",
"      <strong>",
"       Acute hemorrhagic edema of infancy &ndash;",
"      </strong>",
"      Acute hemorrhagic edema of infancy is a benign small vessel vasculitis that is characterized by edematous urticarial plaques that progress to purpuric plaques that often have a targetoid appearance (",
"      <a class=\"graphic graphic_picture graphicRef50848 \" href=\"mobipreview.htm?0/14/226\">",
"       picture 14",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/6\">",
"       6",
"      </a>",
"      ]. Lesions are primarily distributed on the head, genitals, and distal extremities. Fever may be present, but patients typically do not appear toxic. Children under the age of two comprise the population that is usually affected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Henoch-Sch&ouml;nlein purpura &ndash;",
"      </strong>",
"      Henoch-Sch&ouml;nlein purpura is an IgA-mediated small vessel vasculitis that occurs in children and adults. Cutaneous features include symmetric palpable purpura that are predominantly distributed in dependent regions (",
"      <a class=\"graphic graphic_picture graphicRef79783 \" href=\"mobipreview.htm?18/39/19057\">",
"       picture 15",
"      </a>",
"      ). Some lesions may have an annular appearance. Systemic involvement can occur, including renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Traumatic purpura",
"      </strong>",
"      &ndash; Trauma may lead to annular purpuric or ecchymotic lesions on the skin. Skin injury sustained during participation in paintball, a sport that involves shooting non-lethal capsules at other players, is a classic example. Teenagers are common participants in this activity. The impact of the paintball capsule on the skin typically results in an annular purpuric lesion that persists for one to two weeks (",
"      <a class=\"graphic graphic_picture graphicRef77611 \" href=\"mobipreview.htm?4/48/4864\">",
"       picture 16",
"      </a>",
"      ). In general, the diagnosis of traumatic purpura is facilitated by the patient history.",
"     </li>",
"     <li>",
"      <strong>",
"       Urticarial vasculitis",
"      </strong>",
"      &ndash; Urticarial vasculitis is another disorder in which purpura may occur in the setting of annular lesions (see",
"      <a class=\"local\" href=\"#H1925839\">",
"       'Symptoms'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Dependent purpura in annular inflammatory disorders -",
"      </strong>",
"      Purpura on the lower legs or other dependent areas are common secondary occurrences in nonpurpuric inflammatory disorders. The purpura develop as a result of vascular leakage. This is particularly common in serum sickness-like eruptions in children (",
"      <a class=\"graphic graphic_picture graphicRef54053 \" href=\"mobipreview.htm?7/49/7953\">",
"       picture 5G",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H29248636\">",
"       'Expanding lesions'",
"      </a>",
"      below). The most prominent purpura are usually located in areas with the highest hydrostatic forces (eg, lower legs), as blood extravasation is most likely to occur in those sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925839\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most annular eruptions are either asymptomatic or mildly to moderately pruritic, and knowledge of associated symptoms may be useful for supporting the diagnosis of specific diseases. A less commonly observed feature that occurs fairly frequently in",
"    <strong>",
"     urticarial vasculitis",
"    </strong>",
"    is the presence of burning or painful sensations in addition to pruritus. Lesions of urticarial vasculitis often look identical to classic urticaria (edematous pink wheals), but frequently persist beyond 24 hours and may be associated with residual bruising or hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef70642 graphicRef66203 \" href=\"mobipreview.htm?38/58/39846\">",
"     picture 17A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/7\">",
"     7",
"    </a>",
"    ]. Such features should prompt consideration for urticarial vasculitis in patients who present with urticarial lesions. Urticarial vasculitis may occur in association with autoimmune diseases, medications, injections, and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=see_link\">",
"     \"Urticarial vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925636\">",
"    <span class=\"h2\">",
"     Lesion progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several disorders are characterized by transient or migratory features, and asking patients about lesion expansion, lesion migration, and lesion time course can be useful for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248636\">",
"    <span class=\"h3\">",
"     Expanding lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outward spread of individual annular lesions is commonly noted in tinea corporis, granuloma annulare, erythema chronicum migrans, and erythema annulare centrifugum. Lesions progressively advance into areas of previously uninvolved tissue, resulting in a progressive increase in size.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tinea corporis &ndash;",
"      </strong>",
"      Lesions of tinea corporis expand slowly over the course of weeks as the fungal infection spreads outward, often leaving central clearing (",
"      <a class=\"graphic graphic_picture graphicRef55949 graphicRef75928 \" href=\"mobipreview.htm?30/25/31128\">",
"       picture 5A, 5D",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema migrans &ndash;",
"      </strong>",
"      The hallmark feature of early localized Lyme disease is erythema migrans. A set of concentric erythematous rings appears 7 to 14 days after tick detachment and progressively enlarges to form a lesion that is usually at least 5 cm in diameter (",
"      <a class=\"graphic graphic_picture graphicRef65203 graphicRef60256 \" href=\"mobipreview.htm?25/34/26149\">",
"       picture 18A-B",
"      </a>",
"      ). Lesions may demonstrate a &ldquo;bulls-eye&rdquo; appearance, and last approximately four weeks if untreated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/8\">",
"       8",
"      </a>",
"      ]. In patients with early disseminated Lyme disease, multiple annular lesions may be present (",
"      <a class=\"graphic graphic_picture graphicRef64784 \" href=\"mobipreview.htm?6/18/6436\">",
"       picture 19",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"       \"Clinical manifestations of Lyme disease in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The clinical appearance of erythema migrans is indistinguishable from that of the skin findings of southern tick-associated rash illness (STARI); however, the different endemic areas of the vectors assist with diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26533?source=see_link\">",
"       \"Southern tick-associated rash illness (STARI)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Granuloma annulare &ndash;",
"      </strong>",
"      In contrast to the fairly rapid outward spread of erythema migrans, lesions of granuloma annulare expand slowly over the course of weeks to months. Solitary or multiple annular plaques with a firm border are seen (",
"      <a class=\"graphic graphic_picture graphicRef62354 graphicRef76216 graphicRef61039 \" href=\"mobipreview.htm?28/48/29449\">",
"       picture 6A-C",
"      </a>",
"      ). Lesions are commonly found on distal extremities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22922?source=see_link\">",
"       \"Granuloma annulare\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema annulare centrifugum &ndash;",
"      </strong>",
"      The annular erythematous scaly or non-scaly plaques of erythema annulare centrifugum tend to expand over the course of days to weeks (",
"      <a class=\"graphic graphic_picture graphicRef59741 graphicRef80998 \" href=\"mobipreview.htm?10/31/10742\">",
"       picture 5B, 5E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29248629\">",
"       'Scale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum sickness-like reactions",
"      </strong>",
"      &ndash; Serum sickness-like reactions occur due to a variety of medications (most commonly antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/9\">",
"       9",
"      </a>",
"      ]) and are most frequently seen in children. Symptoms begin one to three weeks after initiation of the offending agent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with serum sickness-like reactions usually present with urticarial lesions that start in the flexures that then become generalized (",
"      <a class=\"graphic graphic_picture graphicRef78466 graphicRef78100 graphicRef54053 \" href=\"mobipreview.htm?26/51/27449\">",
"       picture 5C, 5F-G",
"      </a>",
"      ). These eruptions are frequently initially mistaken for acute urticaria, but in contrast to acute urticaria, individual lesions remain for greater than 24 hours. The skin lesions typically gradually expand, leaving central clearing or central faint purpura which are usually most evident on the abdomen or lower legs. Affected patients commonly also develop fever, arthralgias, and erythematous and edematous hands and feet. Annular drug eruptions with cutaneous features identical to those of serum sickness-like reactions, but without systemic symptoms, may also occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248643\">",
"    <span class=\"h3\">",
"     Migratory lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient lesions are characteristic of urticaria and erythema marginatum.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urticaria &ndash;",
"      </strong>",
"      Although an outbreak of urticaria may last days to weeks or more, a hallmark feature of urticaria is that the individual erythematous, edematous plaques last less than 24 hours (",
"      <a class=\"graphic graphic_picture graphicRef60454 graphicRef63996 graphicRef77506 \" href=\"mobipreview.htm?33/58/34729\">",
"       picture 7A-C",
"      </a>",
"      ). Marking a few lesions with a pen can be useful for confirming the transient nature in patients with numerous lesions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=see_link\">",
"       \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema marginatum &ndash;",
"      </strong>",
"      The migratory, polycyclic, and nonpruritic erythematous plaques of erythema marginatum typically migrate within minutes to hours",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef73233 graphicRef50841 \" href=\"mobipreview.htm?23/61/24535\">",
"       picture 2A, 2C",
"      </a>",
"      ). These annular lesions tend to have a thin border and often display arciform, polycyclic, and other incompletely formed annular lesions. Erythema marginatum occurs in association with rheumatic fever due to group A streptococcal infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925439\">",
"    <span class=\"h2\">",
"     Lesion location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of annular skin lesions can offer clues for diagnosis. Disorders that frequently present with photodistributed, acral, or genital lesions are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248650\">",
"    <span class=\"h3\">",
"     Photodistributed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoexacerbated dermatoses tend to occur on sites that are not typically covered by clothing or other adornments such as the balding scalp, forehead, dorsal nose, zygomatic cheeks, posterolateral neck, upper chest, extensor upper extremities, and shins. On the face, the shadow areas of the orbital rim, chin, and nasolabial folds are often spared.",
"   </p>",
"   <p>",
"    Lupus is the most common cause of annular lesions in a photodistributed arrangement. Subacute cutaneous lupus erythematosus, tumid lupus erythematosus, and neonatal lupus erythematosus may present with such features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Subacute cutaneous lupus erythematosus &ndash;",
"      </strong>",
"      Subacute cutaneous lupus erythematosus often presents with annular erythematous scaly plaques (",
"      <a class=\"graphic graphic_picture graphicRef55903 \" href=\"mobipreview.htm?12/11/12467\">",
"       picture 20",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/10\">",
"       10",
"      </a>",
"      ]. Scaling at the borders of lesions is common. The neck, upper trunk, and arms are typical sites of involvement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lupus erythematosus tumidus &ndash;",
"      </strong>",
"      Lupus erythematosus tumidus features smooth, raised, fixed erythematous plaques (",
"      <a class=\"graphic graphic_picture graphicRef69725 \" href=\"mobipreview.htm?25/28/26062\">",
"       picture 21",
"      </a>",
"      ). Lesions may be annular with central clearing or solid plaques. Scale is uncommon.",
"     </li>",
"     <li>",
"      <strong>",
"       Neonatal lupus erythematosus &ndash;",
"      </strong>",
"      Neonatal lupus erythematosus is a self-limited condition that results from transplacental transmission of maternal",
"      <span class=\"nowrap\">",
"       SSA/Ro,",
"      </span>",
"      <span class=\"nowrap\">",
"       SSB/La,",
"      </span>",
"      or U1RNP antibodies. These infants present with annular, scaly red plaques on the face, arms, or trunk that are triggered by ultraviolet light (",
"      <a class=\"graphic graphic_picture graphicRef51166 \" href=\"mobipreview.htm?17/34/17956\">",
"       picture 22",
"      </a>",
"      ). Cardiac manifestations may also occur. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Photodistributed annular lesions are also a common manifestation of",
"    <strong>",
"     actinic lichen planus",
"    </strong>",
"    (lichen planus actinicus), an idiopathic condition that most commonly occurs in dark-skinned young adults in subtropical climates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Individuals of Middle-Eastern descent appear to be most susceptible. Patients present with annular hyperpigmented plaques (",
"    <a class=\"graphic graphic_picture graphicRef82501 graphicRef54475 \" href=\"mobipreview.htm?36/16/37130\">",
"     picture 23A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248657\">",
"    <span class=\"h3\">",
"     Acral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The palms and soles are often spared in generalized eruptions such as urticaria. In contrast, the target or atypical target lesions of",
"    <strong>",
"     erythema multiforme",
"    </strong>",
"    have a predilection for these and other acral sites. Target lesions of erythema multiforme classically demonstrate a dusky red center, surrounded by a zone of pallor, which is in turn surrounded by a peripheral erythematous ring (",
"    <a class=\"graphic graphic_picture graphicRef68640 graphicRef79955 graphicRef62370 \" href=\"mobipreview.htm?29/57/30618\">",
"     picture 3A-C",
"    </a>",
"    ). Patients often have a history of oral or genital herpes simplex virus infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dorsal hands and feet are common sites for the non-scaly, erythematous plaques of",
"    <strong>",
"     granuloma annulare",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef62354 graphicRef76216 graphicRef61039 \" href=\"mobipreview.htm?28/48/29449\">",
"     picture 6A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22922?source=see_link\">",
"     \"Granuloma annulare\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248664\">",
"    <span class=\"h3\">",
"     Genital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Erythema multiforme",
"    </strong>",
"    may involve the genitals with either typical target lesions or atypical target lesions that do not include all three color zones (",
"    <a class=\"graphic graphic_picture graphicRef75314 \" href=\"mobipreview.htm?13/51/14131\">",
"     picture 24",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H1925644\">",
"     'Definition'",
"    </a>",
"    above). Approximately 20 percent of patients with recurrent erythema multiforme have genital involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Circinate balanitis",
"    </strong>",
"    associated with reactive arthritis is characterized by serpiginous lesions on the glans penis that may take on an arcuate or annular appearance (",
"    <a class=\"graphic graphic_picture graphicRef57388 graphicRef73795 \" href=\"mobipreview.htm?6/28/6600\">",
"     picture 25A-B",
"    </a>",
"    ). Conjunctivitis, urethritis, and palmoplantar hyperkeratosis (keratoderma blenorrhagicum) are additional features of reactive arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Annular lichen planus",
"    </strong>",
"    may involve the male genitalia or other body sites (",
"    <a class=\"graphic graphic_picture graphicRef53806 graphicRef68197 \" href=\"mobipreview.htm?21/56/22409\">",
"     picture 26A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248685\">",
"    <span class=\"h1\">",
"     FEBRILE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several diagnoses should be considered in febrile patients with annular skin lesions.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute febrile neutrophilic dermatosis (Sweet syndrome) &ndash;",
"      </strong>",
"      Patients with acute febrile neutrophilic dermatosis present with an abrupt onset of red, well-demarcated, tender, and often annular plaques accompanied by fever and leukocytosis (",
"      <a class=\"graphic graphic_picture graphicRef74393 graphicRef61290 \" href=\"mobipreview.htm?3/12/3272\">",
"       picture 27A-B",
"      </a>",
"      ). The cutaneous lesions often demonstrate an edematous, almost vesicular (pseudovesicular) appearance, and are typically located on the upper body. Associated factors include inflammatory bowel disease, malignancy, infections, and medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H2#H2\">",
"       \"Neutrophilic dermatoses\", section on 'Sweet syndrome'",
"      </a>",
"      .)",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Serum sickness-like reaction &ndash;",
"      </strong>",
"      Patients with serum sickness-like reactions frequently present with fever (see",
"      <a class=\"local\" href=\"#H29248636\">",
"       'Expanding lesions'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of the following disorders also should be considered in febrile children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute hemorrhagic edema of infancy &ndash;",
"      </strong>",
"      This disorder presents as annular purpuric edematous plaques in young children (",
"      <a class=\"graphic graphic_picture graphicRef50848 \" href=\"mobipreview.htm?0/14/226\">",
"       picture 14",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1925500\">",
"       'Purpura'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Kawasaki&rsquo;s disease &ndash;",
"      </strong>",
"      Kawasaki&rsquo;s disease is a self-limited vasculitis of childhood that presents with fever, conjunctivitis, mucositis, acral edema, lymphadenopathy, and an exanthematous skin eruption. Occasionally, the cutaneous eruption of Kawasaki&rsquo;s disease manifests as an annular or targetoid eruption (",
"      <a class=\"graphic graphic_picture graphicRef65707 \" href=\"mobipreview.htm?16/57/17298\">",
"       picture 28",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35688/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248692\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If after a careful history (including a thorough chronological drug history) and physical examination the diagnosis of an annular skin eruption remains unclear, select diagnostic studies may be helpful (",
"    <a class=\"graphic graphic_table graphicRef57617 \" href=\"mobipreview.htm?40/56/41870\">",
"     table 1",
"    </a>",
"    ). As noted above, circling lesions with a pen or marker can be useful for identifying the migratory nature of certain disorders (see",
"    <a class=\"local\" href=\"#H29248643\">",
"     'Migratory lesions'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Examples of scenarios in which additional studies can be of value are below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scaly annular eruption &ndash;",
"      </strong>",
"      Potassium hydroxide preparation (KOH) is instrumental in diagnosing or ruling out tinea corporis (",
"      <a class=\"graphic graphic_picture graphicRef60102 \" href=\"mobipreview.htm?4/2/4132\">",
"       picture 29",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link\">",
"       \"Dermatologic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Photodistributed annular eruption &ndash;",
"      </strong>",
"      Antinuclear antibody (ANA) with testing and skin biopsy can be useful for confirming a diagnosis of cutaneous lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H2#H2\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Cutaneous expressions of lupus erythematosus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Target or atypical target lesions &ndash;",
"      </strong>",
"      Herpes simplex virus (HSV) is a common trigger of erythema multiforme. If lesions suspicious for active HSV infection are present in a patient with erythema multiforme, the performance of Tzanck smears, direct fluorescent antibody preparations, viral cultures, or PCR studies on specimens taken from the site of suspected HSV infection may be used to confirm the presence of the virus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Evaluation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Migratory, serpiginous eruption&ndash;",
"      </strong>",
"      In patients with symptoms or signs suggestive for rheumatic fever, throat cultures, rapid streptococcal antigen tests, and antistreptolysin O antibody titers are confirmatory tests for streptococcal pharyngitis, the most common inciting factor for acute rheumatic fever. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other laboratory tests may be performed based upon suspicion of the underlying disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344888\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is always an option when the diagnosis is uncertain. It is most useful when the disorders being considered have different histopathological findings (",
"    <a class=\"graphic graphic_table graphicRef57617 \" href=\"mobipreview.htm?40/56/41870\">",
"     table 1",
"    </a>",
"    ). A 4 mm punch biopsy is generally preferred over a shave biopsy, as it allows for evaluation of the full thickness of the epidermis and dermis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344895\">",
"    <span class=\"h1\">",
"     EMPIRICAL DIAGNOSIS OF TINEA CORPORIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If performing a KOH is not feasible prior to treatment in a patient who presents with lesions suspicious for tinea corporis, empirical therapy with a topical antifungal agent with activity against dermatophytes (eg, azole antifungals,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    ) is reasonable, due to the relatively high prevalence of tinea corporis and the low risk for adverse effects of topical agents. Combination products containing antifungal agents and potent corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    , Lotrisone&reg;) should be avoided, as the corticosteroid component may exacerbate tinea and cause cutaneous atrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344912\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;If lesions clinically presumed to be tinea corporis fail to respond to appropriate therapy, the possibility of other disorders must be considered. Referral to a dermatologist for further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin biopsy may be considered if the clinician remains unsure of the diagnosis.",
"   </p>",
"   <p>",
"    Urgent dermatologic consultation should be performed if the underlying diagnosis is uncertain in systemically ill patients with inflammatory annular lesions. The acute illness or an underlying systemic disorder may be associated with significant morbidity (eg, Henoch-Sch&ouml;nlein purpura, acute rheumatic fever, systemic lupus erythematosus, etc.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29248699\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annular skin lesions are characterized by a ring-like morphology. Annular lesions are common in skin disease, and occur in the setting of a variety of disorders (",
"      <a class=\"graphic graphic_table graphicRef57617 \" href=\"mobipreview.htm?40/56/41870\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1925644\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of associated clinical features is often useful for the diagnosis of annular lesions. Physical characteristics such as lesion color and the presence or absence of scale, vesicles, or pustules can be quickly assessed. Other factors to consider include the course of lesion progression, lesion location, and associated cutaneous or systemic symptoms. (See",
"      <a class=\"local\" href=\"#H1925670\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis remains uncertain after the patient history and physical examination, diagnostic studies such as potassium hydroxide (KOH) preparations to evaluate for tinea corporis, skin biopsies, and select laboratory studies based upon clinical suspicion of the underlying diagnosis can be useful. (See",
"      <a class=\"local\" href=\"#H29248692\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever feasible the diagnosis of tinea corporis should be confirmed with a KOH preparation prior to treatment. If it is not possible to perform a KOH preparation, empirical treatment with a topical antifungal agent may be prescribed. Combined antifungal and potent corticosteroid agents should",
"      <strong>",
"       not",
"      </strong>",
"      be used. (See",
"      <a class=\"local\" href=\"#H344895\">",
"       'Empirical diagnosis of tinea corporis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious systemic disorders may present with inflammatory annular lesions. Urgent dermatological consultation should be obtained if the diagnosis remains uncertain in patients who are systemically ill. (See",
"      <a class=\"local\" href=\"#H344912\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/1\">",
"      Sakakibara K, Nakada T, Sueki H, et al. Annular lichen planus. J Cutan Med Surg 2004; 8:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/2\">",
"      Ponce-Olivera RM, Tirado-S&aacute;nchez A, Montes-de-Oca-S&aacute;nchez G, et al. Annular atrophic lichen planus. Int J Dermatol 2007; 46:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/3\">",
"      Weyers W, Diaz-Cascajo C, Weyers I. Erythema annulare centrifugum: results of a clinicopathologic study of 73 patients. Am J Dermatopathol 2003; 25:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/4\">",
"      Ho JC, Ng PL, Tan SH, Giam YC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol 2007; 24:E40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/5\">",
"      Hoesly FJ, Huerter CJ, Shehan JM. Purpura annularis telangiectodes of Majocchi: case report and review of the literature. Int J Dermatol 2009; 48:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/6\">",
"      AlSufyani MA. Acute hemorrhagic edema of infancy: unusual scarring and review of the English language literature. Int J Dermatol 2009; 48:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/7\">",
"      Peroni A, Colato C, Zanoni G, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol 2010; 62:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/8\">",
"      Wormser GP. Clinical practice. Early Lyme disease. N Engl J Med 2006; 354:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/9\">",
"      Katta R, Anusuri V. Serum sickness-like reaction to cefuroxime: a case report and review of the literature. J Drugs Dermatol 2007; 6:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/10\">",
"      Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010; 19:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/11\">",
"      Meads SB, Kunishige J, Ramos-Caro FA, Hassanein AM. Lichen planus actinicus. Cutis 2003; 72:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/12\">",
"      Kim GH, Mikkilineni R. Lichen planus actinicus. Dermatol Online J 2007; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/13\">",
"      Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 2010; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/14\">",
"      Serr&atilde;o VV, Organ V, Pereira L, et al. Annular lichen planus in association with Crohn disease. Dermatol Online J 2008; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/15\">",
"      Halpern J, Salim A. Pediatric sweet syndrome: case report and literature review. Pediatr Dermatol 2009; 26:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35688/abstract/16\">",
"      Ming A, Wargon O. Annular lesions in Kawasaki disease: a cause of confusion. Australas J Dermatol 2008; 49:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13690 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35688=[""].join("\n");
var outline_f34_54_35688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29248699\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29248615\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1925644\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1925670\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925399\">",
"      Lesion characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248622\">",
"      - Color",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248629\">",
"      - Scale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1925653\">",
"      - Vesicles or pustules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1925500\">",
"      - Purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925839\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925636\">",
"      Lesion progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248636\">",
"      - Expanding lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248643\">",
"      - Migratory lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925439\">",
"      Lesion location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248650\">",
"      - Photodistributed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248657\">",
"      - Acral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29248664\">",
"      - Genital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29248685\">",
"      FEBRILE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29248692\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344888\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344895\">",
"      EMPIRICAL DIAGNOSIS OF TINEA CORPORIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344912\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29248699\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13690|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/62/40931\" title=\"picture 1\">",
"      Arcuate lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/43/38579\" title=\"picture 2A\">",
"      Erythema marginatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/36/29250\" title=\"picture 2B\">",
"      Tinea corporis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/3/29744\" title=\"picture 2C\">",
"      Erythema marginatum on trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/16/9478\" title=\"picture 3A\">",
"      Erythema multiforme target",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/53/19283\" title=\"picture 3B\">",
"      Erythema multiforme target2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/14/13540\" title=\"picture 3C\">",
"      Erythema multiforme acral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/27/41393\" title=\"picture 4\">",
"      Erythema multiforme atypica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/24/20865\" title=\"picture 5A\">",
"      Tinea corporis - multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18417\" title=\"picture 5B\">",
"      Erythema annulare centrifugum - light skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/9/18579\" title=\"picture 5C\">",
"      Serum sickness-like reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/41/32405\" title=\"picture 5D\">",
"      Tinea corporis on trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/23/28016\" title=\"picture 5E\">",
"      Erythema annulare centrifugum - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/63/13297\" title=\"picture 5F\">",
"      Serum sickness-like reaction 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/49/7953\" title=\"picture 5G\">",
"      Serum sickness-like reaction 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/32/19968\" title=\"picture 6A\">",
"      Granuloma annulare foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/51/32563\" title=\"picture 6B\">",
"      Granuloma annulare hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/17/41233\" title=\"picture 6C\">",
"      Localized granuloma annulare on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/27/2483\" title=\"picture 7A\">",
"      Urticaria annular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/59/2995\" title=\"picture 7B\">",
"      Urticaria annular lesions 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/12/22720\" title=\"picture 7C\">",
"      Urticaria 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/20/22852\" title=\"picture 8\">",
"      Pityriasis rosea trailing scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/1/39957\" title=\"picture 9A\">",
"      Porokeratosis of Mibelli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/51/10038\" title=\"picture 9B\">",
"      Disseminated superficial actinic porokeratosis close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/61/2007\" title=\"picture 10\">",
"      Porokeratosis histopathology 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/62/16359\" title=\"picture 11\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/58/12201\" title=\"picture 12A\">",
"      Subcorneal pustular dermatosis close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/9/38036\" title=\"picture 12B\">",
"      Subcorneal pustular dermatosis on back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/56/26496\" title=\"picture 12C\">",
"      Subcorneal pustular dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/53/15198\" title=\"picture 12D\">",
"      Subcorneal pustular dermatosis - axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/10/161\" title=\"picture 13\">",
"      Purpura annularis telangietodes of Majocchi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/14/226\" title=\"picture 14\">",
"      Acute hemorrhagic edema of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/39/19057\" title=\"picture 15\">",
"      Henoch-Schonlein purpura - IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/48/4864\" title=\"picture 16\">",
"      Paintball purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/35/13874\" title=\"picture 17A\">",
"      Urticarial vasculitis - annular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/25/36240\" title=\"picture 17B\">",
"      UV lesions I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/39/1651\" title=\"picture 18A\">",
"      Erythema migrans - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/19/33086\" title=\"picture 18B\">",
"      STARI rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/18/6436\" title=\"picture 19\">",
"      Erythema migrans - early disseminated Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/11/12467\" title=\"picture 20\">",
"      Subacute cutaneous lupus - annular plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/28/26062\" title=\"picture 21\">",
"      Lupus erythematosus tumidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/34/17956\" title=\"picture 22\">",
"      Neonatal lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/2/31783\" title=\"picture 23A\">",
"      Actinic lichen planus hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/18/8489\" title=\"picture 23B\">",
"      Actinic lichen planus face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/51/14131\" title=\"picture 24\">",
"      Erythema multiforme genital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/61/19410\" title=\"picture 25A\">",
"      Circinate balanitis in reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/3/25651\" title=\"picture 25B\">",
"      Circinate balanitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/9/21653\" title=\"picture 26A\">",
"      Annular lichen planus on penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/10/19620\" title=\"picture 26B\">",
"      Annular lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25794\" title=\"picture 27A\">",
"      Sweet syndrome plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/11/10419\" title=\"picture 27B\">",
"      Sweet syndrome skin appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/57/17298\" title=\"picture 28\">",
"      Kawasakis disease - targetoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/2/4132\" title=\"picture 29\">",
"      Dermatophyte KOH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/56/41870\" title=\"table 1\">",
"      Disorders with annular skin lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22922?source=related_link\">",
"      Granuloma annulare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/18999?source=related_link\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4810?source=related_link\">",
"      Porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26533?source=related_link\">",
"      Southern tick-associated rash illness (STARI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_54_35689="Endoscopic variceal ligation";
var content_f34_54_35689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic variceal ligation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     John S Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35689/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/54/35689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic variceal ligation (EVL) was developed in an effort to find an effective means of treating esophageal varices endoscopically with fewer complications than endoscopic sclerotherapy (ES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The concept was based upon many years of experience treating hemorrhoids with rubber band ligation in patients with and without portal hypertension. EVL works by capturing all or part of a varix resulting in occlusion from thrombosis. The tissue then necroses and sloughs off in a few days to weeks, leaving a superficial mucosal ulceration, which rapidly heals. EVL avoids the use of sclerosant and thus eliminates the deep damage to the esophageal wall that occurs after ES. Collateral vessels near the cardia decrease after EVL and EVL may promote the development of deep gastric collaterals. These factors may also contribute to the effectiveness of EVL for preventing further variceal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Another interesting finding is that during acute variceal bleeding, the hepatic venous pressure gradient (which correlates with the risk of variceal bleeding) increases after ES, but not after EVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first patient was treated with EVL in 1986. Since then, advances in the technique have led to its routine use in the care of patients with esophageal varices. One of the biggest advances was the development of the multiple band ligator (Saeed Six-Shooter and Speedbander), which has simplified and improved the safety of EVL.",
"   </p>",
"   <p>",
"    The technical considerations involved in EVL and the data supporting its technical efficacy will be reviewed here. The role of EVL in the care of patients with varices is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic variceal ligating devices are placed on the tip of standard endoscopes. The device has a soft sheath potion that fits over the tip of the endoscope and a hard plastic portion. Bands are stretched over the hard portion at the distal end of the device and later deployed onto the varices. Currently available devices are designed for standard and therapeutic sized endoscopes.",
"   </p>",
"   <p>",
"    The procedure begins after a thorough upper endoscopy to identify the esophageal varices that are to be treated. Actively bleeding varices or those with stigmata indicating recent bleeding (such as a fibrin plug or a \"red wale\" sign) should be primary targets even if they are not located at the gastroesophageal junction (",
"    <a class=\"graphic graphic_picture graphicRef53168 graphicRef50222 \" href=\"mobipreview.htm?32/33/33300\">",
"     picture 1A-B",
"    </a>",
"    ). There are no absolute restrictions on coagulation parameters that preclude performing EVL, although in patients with active bleeding, attempts should be made to improve the coagulation status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is helpful to measure the distance of the gastroesophageal junction and the varices from the incisors before beginning band ligation, since visibility may be reduced once the banding device is placed over the tip of the endoscope and the predetermined measurements help provide landmarks. Following upper endoscopy, the endoscope has to be removed from the patient to load the banding device onto the endoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Placement of an overtube",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original (and still available) banding device (Stiegmann-Goff ligator) requires the use of an overtube because the endoscope needs to be removed, reloaded, and repassed after each band is deployed, which is much easier with the overtube in the patient's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/9\">",
"     9",
"    </a>",
"    ]. The overtube can either be backloaded onto the endoscope before esophageal intubation and then advanced using the shaft of the endoscope as a guide, or passed separately after the initial examination over a Maloney dilator.",
"   </p>",
"   <p>",
"    The advantage of backloading the overtube is that it eliminates one intubation. A potential disadvantage is that the overtube may pinch the upper esophageal mucosa during insertion since it is larger in diameter than the endoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/10\">",
"     10",
"    </a>",
"    ]. This can result in the tearing or perforation of the proximal esophagus. This complication can be avoided by loading the overtube on a 44 F Maloney dilator, which completely fills the lumen of the overtube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/11\">",
"     11",
"    </a>",
"    ]. The use of the Maloney dilator makes passage of the overtube easier in some patients; thus, it should be used in any patient in whom an overtube that has been backloaded does not pass easily.",
"   </p>",
"   <p>",
"    The multiple band ligating systems have made use of the overtube less necessary since 4 to 10 bands can be deployed without having to remove the endoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/12\">",
"     12",
"    </a>",
"    ]. This is helpful in patients who are receiving follow-up treatment for known varices. However, for acutely bleeding patients, the overtube still offers advantages that need to be considered, even when one uses the multiple ligating device. In particular, an overtube helps protect against aspiration. This is most important in massively bleeding patients who are sedated and thus at increased risk. Aspiration pneumonia is a serious complication of variceal bleeding that contributes to mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Applying the bands",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the endoscope and the ligating device are reinserted into the esophagus, the site for placement needs to be identified. It is best to treat the most distal varices and then ascend proximally in the esophagus, since deployed bands partially occlude the esophageal lumen. Bands are usually applied in a circumferential pattern spiraling gradually up the esophagus until all major columns of varices have one to three bands (",
"    <a class=\"graphic graphic_picture graphicRef54194 \" href=\"mobipreview.htm?3/13/3282\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When applying suction to draw the mucosa into the chamber at the tip of the endoscope created by the banding device, it is important to try to get a \"red-out\" (caused by close approximation of the mucosa overlying the varix within the ligating chamber to the lens on the tip of the endoscope), indicating that an adequate amount of tissue has been captured by the device. Maximum wall suction is sufficient to achieve adequate aspiration of the esophageal mucosa; some portable suction devices are insufficient. Trying to place a band on a small amount of tissue will usually result in the band sliding off; it may also cause some mucosal damage with subsequent bleeding that can compromise visualization of the mucosa.",
"   </p>",
"   <p>",
"    Complete red-out may not always be possible with the new large multiple ligators, which have a longer chamber at the tip of the endoscope. As bands are applied to the mucosa, less tissue is available to aspirate. This should indicate that another, perhaps more proximal, site needs to be selected for the next application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Number of bands to apply",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is usually the goal to eradicate varices in the lower 5 cm of the esophagus. However, there is theoretically no limit to the number of bands that can be applied or the most proximal location in the esophagus where it is safe to apply them. Six to ten bands are commonly used during the initial session. Fewer are usually required during subsequent sessions. However, a randomized, prospective study found that placement of more than six bands per session did not improve patient outcomes but prolonged procedure time and increased the number of misfired bands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nasogastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;We avoid placing a nasogastric tube after EVL to avoid dislodging the bands. However, studies addressing this are lacking. While a nasogastric tube does not necessarily need to be passed after treatment for monitoring, if there is a need to keep the stomach decompressed or provide medications or nutrition enterally, a tube can be passed at any time following band placement, though it should be placed as gently as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MULTIPLE LIGATING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited controlled data on the multiple ligating devices, but there is a host of anecdotal experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]. Band deployment and visibility during endoscopy are similar to the original single ligating device. However, the increased length of the device on the tip of the endoscope increases the nonflexible tip length, which can make passage into the esophagus more difficult in some patients. This problem can be overcome by using an overtube.",
"   </p>",
"   <p>",
"    Three companies are producing ligating devices for treating esophageal varices: Comed (Stiegmann-Goff Endoscopic Ligator and the Clearvue Endoscopic Ligator), Boston-Scientific (SpeedBand SuperView Super 7), and Wilson-Cook (4, 6, and 10 Shooter Saeed Multi-Band Ligators). No clinical studies have been performed to assess the relative efficacy of these devices compared with one another. The multiple ligators come with different numbers of bands currently ranging from 4 to 10. The choice of which to use depends on the situation; more bands are required for acutely bleeding patients than for those undergoing elective re-banding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACUTELY BLEEDING VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ligating devices in the acutely bleeding patient may be limited in patients with severe bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/18\">",
"     18",
"    </a>",
"    ]. Diminished visibility created by blood accumulating in the tip of the device, and the tunnel vision produced by the ligating device on the tip of the endoscope can make EVL challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/19\">",
"     19",
"    </a>",
"    ]. The accumulation of blood can often be overcome by injecting water through a blunt needle passed along the trip wire as it exits from the valve on the endoscope handle. The tunnel vision problem has been ameliorated by the newer ligating devices, which are made of clear plastic.",
"   </p>",
"   <p>",
"    An advantage to EVL in active bleeding is that it is not imperative that a band be applied over a varix, since capturing tissue without a varix in it will not cause any harm. This is in contrast to the situation with ES, where it is mandatory to place the sclerosant intravariceal to achieve maximal effectiveness and to avoid complications. Paravariceal injection produces considerable tissue damage and thus should be done only with small amounts of dilute sclerosant.",
"   </p>",
"   <p>",
"    In most actively bleeding patients, it is possible to semi-blindly place bands at the gastroesophageal junction, which reduces bleeding. More directed placement can be accomplished once the field clears. This avoids repeated blind attempts at injecting a suspected bleeding site with sclerosant, which is a cause of significant complications from ES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of investigators have reported their experience with the control of active bleeding using EVL and ES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/20-28\">",
"     20-28",
"    </a>",
"    ]. Considering these data together, EVL controls bleeding in approximately 80 to 100 percent of patients and has equal or slightly better efficacy than ES in achieving hemostasis (86 versus 77 percent in one trial) (",
"    <a class=\"graphic graphic_table graphicRef50127 \" href=\"mobipreview.htm?38/21/39259\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We exclusively use EVL for acutely bleeding patients with virtually 100 percent control of bleeding. Child's C patients or patients with elevated MELD scores appear to be less responsive than either A or B patients to EVL therapy (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, some data suggest that patients presenting with their first variceal bleed while already taking a nonselective beta blocker are at increased risk for rebleeding and death compared with those not on a nonselective beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FOLLOW-UP BAND LIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with sclerotherapy, endoscopic variceal ligation requires multiple sessions to eradicate varices. We repeat EVL within 7 to 10 days due to our unreported experience with early rebleeding if the procedure was done later. However, there is limited published experience to support the timing interval. A study from Japan with a total of 63 patients suggested that follow-up sessions every two months was similar, if not numerically better, than every two week follow-up sessions in achieving eradication and control of rebleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of rebleeding occurs in the interval between the initial endoscopic therapeutic session and the time when variceal obliteration is achieved. Part of the benefit seen with EVL compared with ES may be related to the more rapid achievement of variceal obliteration. The average time to obliteration is approximately 3.7 sessions with EVL and 4.9 sessions with EST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/21-26,33\">",
"     21-26,33",
"    </a>",
"    ]. Rebleeding after elective EVL appears to be considerably lower than after emergent EVL (0.5 versus 7.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EVL can be performed in patients who have undergone prior ES, although it may be more difficult if there is extensive esophageal mucosal damage. The mucosa in this situation will not aspirate well into the EVL device, possibly making it difficult to place the bands. Despite this concern, patients who continue to bleed following ES can generally be rescued with EVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the second session, bands can be applied as needed to any persistent varices. There is no need to be concerned about placing them close to an ulcer from a band that has fallen off. This is in contrast to the situation with ES in which injection near an ulcer can increase complications.",
"   </p>",
"   <p>",
"    The patient should have repeat endoscopy every",
"    <strong>",
"     two weeks",
"    </strong>",
"    after the initial two sessions with band applications as needed until there are no varices left to treat. After apparent eradication is achieved, we suggest a repeat examination in one month, followed by an examination every three months for six to nine months. If the patient is still free of varices or only needs an occasional band or two, the interval can be increased to 6 to 12 months, depending upon the rate and degree of variceal return. If the patient has small varices and it is difficult to aspirate the esophageal mucosa into the lumen of the ligating device due to submucosal scarring from prior treatment, a small amount of sclerosant (1 mL of 5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40082?source=see_link\">",
"     ethanolamine oleate",
"    </a>",
"    ) should be injected into the remaining varices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     American Association for the Study of Liver Diseases Guideline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Study of Liver Diseases (AASLD) has issued guidelines for management of variceal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who bled from varices and were treated with EVL or those who underwent EVL for primary prophylaxis, EVL should be repeated every 1 to 2 weeks until obliteration with the first surveillance EGD performed 1 to 3 months after obliteration and then every 6 to 12 months to check for variceal recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have demonstrated that rebleeding after initial treatment followed by repeat treatment aimed at variceal eradication is less likely after EVL compared with ES (27 versus 45 percent cumulative rebleeding rate in eight randomized trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/21-26,28,37\">",
"     21-26,28,37",
"    </a>",
"    ]. A meta-analysis concluded that four patients would need to be treated with ligation instead of sclerotherapy to avert one rebleeding episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have compared mortality in patients treated with EVL or ES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/20-23,25,26,38\">",
"     20-23,25,26,38",
"    </a>",
"    ]. A meta-analysis that included five of these trials suggested that mortality after EVL was less than after ES (24 versus 31 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors estimated that 10 patients would need to be treated with EVL instead of ES to prevent one death. One possible reason for the improved survival after EVL compared to ES may be the lower rate of complications associated with EVL.",
"   </p>",
"   <p>",
"    The efficacy of EVL or ES in preventing rebleeding compared with medical therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining EVL and ES has been proposed to speed variceal eradication and reduce the likelihood of rebleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/39\">",
"     39",
"    </a>",
"    ]. Furthermore, the addition of sclerotherapy may reduce the incidence of recurrent varices, which may be higher with EVL than ES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/40\">",
"     40",
"    </a>",
"    ]. Combination therapy has been evaluated in patients with esophageal and gastric fundal varices with variable success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/39,41-63\">",
"     39,41-63",
"    </a>",
"    ]. Routine initial combination therapy is not indicated for esophageal varices. However, it is probably the best endoscopic method for treating gastric varices in the United States, because other means of controlling bleeding endoscopically (such as with glue injection) are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several variations in the types of sclerosants and the protocol for administering ES in combination with EVL have been described. As an example, one technique involves injection of 1 mL of 5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40082?source=see_link\">",
"     ethanolamine oleate",
"    </a>",
"    into each visible varix above EVL sites during the initial session. Subsequent sessions are performed at the same time intervals as for EVL alone, but both procedures are done as indicated by the findings at each endoscopy. Another study involving a small number of patients suggested that better results might be obtained by placing a band near the GE junction followed by injection of sclerosant in the varix proximally and then ligating again just above the injection site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Esophageal varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating combination therapy for esophageal varices have produced heterogeneous results, depending in part upon the population that is studied (ie, active bleeding versus prior bleeding) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/41-59,64\">",
"     41-59,64",
"    </a>",
"    ]. A randomized trial of 47 patients with active variceal bleeding found that ES combined with EVL conferred no benefit over EVL alone in terms of control of bleeding (75 versus 100 percent with EVL alone), rebleeding rate (36 versus 25 percent), or varix recurrence (23 versus 16 percent); however, combination therapy was associated with a higher complication rate, such as deep ulcers (65 versus 20 percent), and dysphagia (30 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another prospective trial 72 patients with a history of variceal bleeding received EVL until the varices disappeared or only residual small varices remained; the patients were then randomized to sclerotherapy or no further treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/45\">",
"     45",
"    </a>",
"    ]. Sclerotherapy was performed using an even mixture of 50 percent dextrose and 3 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1603?source=see_link\">",
"     sodium tetradecyl",
"    </a>",
"    sulfate injected in 0.5 mL aliquots (4 to 8 mL) into random sites in the distal 3 cm of the esophagus when varices were not seen or into residual small varices. If varices were still visible after a session, then a second session was performed three weeks later. Endoscopy was performed every three months to assess for recurrence of varices, which were treated with repeat band ligation. After a mean follow-up of two years, recurrent esophageal varices and variceal bleeding were significantly less common in patients treated with combined therapy (14 versus 43 percent and 8 versus 31 percent, respectively). One patient treated with band ligation alone developed an esophageal stricture.",
"   </p>",
"   <p>",
"    Similar conclusions were reached in another report involving 86 patients who were randomly assigned to EVL alone or EVL followed by ES to eradicate any small residual varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/49\">",
"     49",
"    </a>",
"    ]. The rebleeding rate for the combination group was nearly 50 percent less at one and two years (14 versus 26, and 24 versus 45 percent, respectively). A Japanese study with 217 patients showed no benefit for EVL with ethanol injection compared to either alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial from Egypt comparing EST alone, EVL alone, EVL plus EST, and EVL plus argon plasma coagulation with 50 patients in each group found that the two combination groups fared better with more rapid variceal eradication and no increase in complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considering the data from multiple studies, the following conclusions can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rebleeding rates after EVL plus ES are similar to EVL alone (range among studies of 19 to 36 versus 20 to 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44,50-57\">",
"       44,50-57",
"      </a>",
"      ], although EVL complemented with ES (as described above) may result in less rebleeding.",
"     </li>",
"     <li>",
"      Most studies have found that more sessions were required to achieve eradication with combination therapy than EVL or ES alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44,53,54,58\">",
"       44,53,54,58",
"      </a>",
"      ], although discordant data have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/55-57\">",
"       55-57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complications with combination therapy were greater than with EVL or ES alone in most reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44,53,54,56,57,59\">",
"       44,53,54,56,57,59",
"      </a>",
"      ]. In two series mortality was higher in patients receiving combination therapy (36 versus 16 percent and 25 versus 20 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44,56\">",
"       44,56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the preponderance of data suggest that there is",
"    <strong>",
"     no",
"    </strong>",
"    advantage to combining EVL and ES for management of variceal bleeding at each and every session, a conclusion also reached in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/64\">",
"     64",
"    </a>",
"    ]. However, adding ES toward the end of a series of EVL sessions to complete eradication of small varices may be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. We perform EVL followed by ES on an \"as needed\" basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other combination therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data suggested that cautery with the argon plasma coagulation system (APC) or a microwave cautery system may improve the treatment of esophageal varices when combined with band ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/60,61,66\">",
"     60,61,66",
"    </a>",
"    ]. One of the largest controlled trials (published in preliminary form) involved 114 patients who were randomly assigned to variceal ligation alone or in combination with APC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/60\">",
"     60",
"    </a>",
"    ]. No statistically significant differences were found between the ligation therapy and combination therapy groups in variceal eradication rates, hemostatic effects of active bleeding, rebleeding rates during active treatment, or recurrence rates. However, patients receiving combination therapy required significantly fewer sessions to achieve variceal eradications (4.5 versus 2.1) and experienced significantly less chest pain during and after the procedure. A controlled trial from Italy suggested that APC following EVL may reduce the incidence of recurrent variceal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/67\">",
"     67",
"    </a>",
"    ]. A Japanese group found that APC could be used to eradicate small residual varices after a course of variceal ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/61\">",
"     61",
"    </a>",
"    ]. A group from Brazil showed that microwave cautery could be added after several ligation sessions to complete the eradication process for small varices that could not be aspirated well by the ligation device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/66\">",
"     66",
"    </a>",
"    ]. None of these techniques has been sufficiently studied to be recommended for routine use.",
"   </p>",
"   <p>",
"    Combining EVL with medical therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful hemostasis and obliteration of gastric varices has been reported with intravariceal injections of sclerosant, absolute alcohol, thrombin, and cyanoacrylate, which is not available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. There is less experience with EVL in this setting, although it has been reported. An approach to treatment of gastric varices is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Gastric varices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined data from a number of studies suggest that complications with EVL are substantially less than with ES, presumably because of the shallower tissue injury (cumulative complication rate of 11 versus 25 percent) (",
"    <a class=\"graphic graphic_table graphicRef61335 \" href=\"mobipreview.htm?42/45/43739\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/20-23,25,26,28,33,37,38\">",
"     20-23,25,26,28,33,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever and mediastinitis do not occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Esophageal strictures are rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/21,28,76,77\">",
"       21,28,76,77",
"      </a>",
"      ]. In two series, strictures developed in 1 and 0 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/21,77\">",
"       21,77",
"      </a>",
"      ]. A series that included 221 ES sessions and 110 EVL sessions found a stricture rate of 26 and 2 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postprocedure pain is uncommon. However, some patients complain of pain immediately after the bands are applied; this may be associated with dysphagia and odynophagia, suggesting that esophageal spasm may be responsible. These symptoms often respond to an oral 50:50 mixture of lidocaine-antacid mixture (Mylanta or Maalox). Patients should be advised to start with liquids after a ligation session and slowly advance their diet beginning with soft foods.",
"     </li>",
"     <li>",
"      Esophageal dysfunction after EVL is less than after ES as determined by motility studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient bacteremia has been documented after EVL, but this is not significant enough to warrant any special precautions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/80-82\">",
"       80-82",
"      </a>",
"      ]. The incidence of transient bacteremia appears to be much lower with EVL than with ES (3.3 versus 17 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/80\">",
"       80",
"      </a>",
"      ]. Antibiotic prophylaxis should be given when doing EVL in the setting of acute variceal hemorrhage or in patients with ascites. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=see_link\">",
"       \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"       \"Treatment of active variceal hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary infections are uncommon and appear to occur with equal frequency with both EVL and ES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/28,83\">",
"       28,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Esophageal ulcers develop at each ligation site as the banded tissue necroses and sloughs off. These ulcers are limited to the mucosa unlike sclerotherapy-related ulcers, which are often deeper and are thus prone to causing mediastinal inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophageal wall scarring. Significant bleeding from postligation ulcers is rare. If these ulcers do bleed, however, standard endoscopic methods for controlling ulcer bleeding are usually effective.",
"     </li>",
"     <li>",
"      Two cases have now been reported in which total esophageal obstruction has occurred after EVL. The latest case was monitored, and the obstruction resolved spontaneously in about seven days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overtube complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the complications related to EVL have been due to placement of the overtube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/10,11,85,86\">",
"     10,11,85,86",
"    </a>",
"    ]. The overtube can traumatize the mucosa in the esophagus at the overtube's distal end, which can rarely lead to perforation. The mechanism of upper esophageal perforation is not completely understood. It is probably due to one or more factors including shear forces from passing the tube, stretching forces from the cross-sectional size of the tube, and pinching (tearing) due to trapping mucosa in the space between the overtube and the endoscope.",
"   </p>",
"   <p>",
"    As discussed above, an overtube is not always necessary when using multiple band ligating devices. Furthermore, since its initial introduction, the overtube has been shortened by 5 cm and its tip tapered to reduce trauma and make introduction easier. The benefit of these modifications was confirmed in a study that compared trauma with the new and old overtubes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/86\">",
"     86",
"    </a>",
"    ]. Although proximal esophageal mucosal injury occurred in approximately 80 percent of patients with either the new or the old overtube, the injuries were all mild with the new overtube, while 20 percent were severe with the old overtube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Esophageal ulcerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerations occur in the esophageal mucosa after all successful ligations. However, ulcers following EVL are less severe than with ES. This was illustrated in a study that found EVL ulcers were shallower than those associated with ES ulcers (0.6 versus 1.8 mm) and healed more quickly (14 versus 21 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/74\">",
"     74",
"    </a>",
"    ]. In another report, 60 percent of EVL ulcers healed at the end of two weeks and 100 percent healed by three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/87\">",
"     87",
"    </a>",
"    ]. Ulcers caused by EVL are usually approximately 1 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/74,87\">",
"     74,87",
"    </a>",
"    ]. They typically develop within 3 to 10 days after EVL, when the necrotic tissue within the band sloughs off. No empiric therapy with acid-suppressing drugs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    has been shown to reliably minimize the effects or presence of these ulcers. Previous variceal bleeding, esophagitis, high platelet ratio index (APRI) score, and low prothrombin index are independent risk factors for bleeding from post EVL ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Portal hypertensive gastropathy and gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concern with both EVL and ES has been the potential to worsen portal hypertensive gastropathy (PHG), which could result in bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/89\">",
"     89",
"    </a>",
"    ]. The exacerbation of PHG may be related to increased gastric blood flow or to increased mucosal congestion following eradication of esophageal varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of PHG may be more common with EVL than ES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/40\">",
"     40",
"    </a>",
"    ]. However, PHG related to EVL may have fewer long-term sequelae. In most reports, a return to baseline occurred more rapidly in patients who developed PHG as a result of EVL compared to ES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/89,92,93\">",
"     89,92,93",
"    </a>",
"    ]. One study suggested that bleeding from PHG was more likely in patients who had PHG prior to EVL compared with those in whom it developed after EVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study found no significant change in portal pressure gradients in 22 patients who were studied before and after EVL eradication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/95\">",
"     95",
"    </a>",
"    ]. After eradication, 12 patients experienced a reduction in portal pressure while 10 had an elevation. Three patients developed fundal varices while gastropathy worsened in nine patients. The initial portal pressure gradient in these patients was not different from those who did not develop new fundal varices or gastropathy. Furthermore, there was no worsening of portal pressure gradients in these patients. The authors concluded that band ligation does not alter the hepatic venous pressure gradient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Unusual complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of unusual complications of EVL have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/96-106\">",
"     96-106",
"    </a>",
"    ]. Examples include local esophageal wall necrosis and perforation, esophageal perforation after EVL and balloon tamponade, excessive bleeding from esophageal or gastric varices, mesenteric vein thrombosis, inadvertent banding of laryngeal mucosa, pyogenic meningitis, esophageal stenosis, altered esophageal motility, paraplegia, and decreased oxygen delivery (suspected to be due to decreased cardiac output from a decreased preload).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study investigating the relative costs of EVL versus ES found them to be comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/107\">",
"     107",
"    </a>",
"    ]. However, the data included a number of observations that have not been consistently observed in other studies such as equal rebleeding rates, achievement of obliteration, hospital length of stay, blood transfusion requirement, shunt requirements and survival. In a report from India the total cost of ES was shown to be significantly greater than the cost for EVL treatment of bleeding varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35689/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A definitive cost-effectiveness analysis has not been performed. Nevertheless, the superior safety of EVL compared with ES and its comparable or superior efficacy suggests that it is cost-effective. The cost-effectiveness of multiple ligating devices has not been well studied. Although they are more expensive, they are easier to use and possibly safer (since an overtube is not required).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/40/8834?source=see_link\">",
"       \"Patient information: Esophageal varices (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic variceal ligation (EVL) works by capturing all or part of a varix within a band, resulting in occlusion from thrombosis. The tissue then necroses and sloughs off in a few days to weeks, leaving a superficial mucosal ulceration, which rapidly heals. EVL avoids the use of sclerosant and thus eliminates the deep damage to the esophageal wall that occurs after endoscopic sclerotherapy (ES).",
"     </li>",
"     <li>",
"      EVL controls bleeding in approximately 80 to 100 percent of patients and has equal or slightly better efficacy than ES in achieving hemostasis. However, use of EVL in patients with severe bleeding may be limited by of poor visibility. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acutely bleeding varices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EVL requires multiple sessions to eradicate varices. A guideline issued by the American Association for the Study of Liver diseases suggests that in patients who bled from varices and were treated with EVL or those who underwent EVL for primary prophylaxis, EVL should be repeated every 1 to 2 weeks until obliteration with the first surveillance EGD performed 1 to 3 months after obliteration and then every 6 to 12 months to check for variceal recurrence. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Follow-up band ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined data from a number of studies suggest that complications with EVL are substantially less than with ES, presumably because of the shallower tissue injury (cumulative complication rate of 11 versus 25 percent). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/1\">",
"      Van Stiegmann G, Cambre T, Sun JH. A new endoscopic elastic band ligating device. Gastrointest Endosc 1986; 32:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/2\">",
"      Stiegmann GV, Sun JH, Hammond WS. Results of experimental endoscopic esophageal varix ligation. Am Surg 1988; 54:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/3\">",
"      Van Stiegmann G, Goff JS. Endoscopic esophageal varix ligation: preliminary clinical experience. Gastrointest Endosc 1988; 34:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/4\">",
"      Stiegmann GV, Goff JS, Sun JH, et al. Endoscopic variceal ligation: an alternative to sclerotherapy. Gastrointest Endosc 1989; 35:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/5\">",
"      Seno H, Konishi Y, Wada M, et al. Improvement of collateral vessels in the vicinity of gastric cardia after endoscopic variceal ligation therapy for esophageal varices. Clin Gastroenterol Hepatol 2004; 2:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/6\">",
"      Wiechowska-Kozowska A, Biaek A, Raszeja-Wyszomirska J, et al. Ligation of oesophageal varices may increase formation of \"deep\" gastric collaterals. Hepatogastroenterology 2010; 57:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/7\">",
"      Avgerinos A, Armonis A, Stefanidis G, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 2004; 39:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/8\">",
"      Vieira da Rocha EC, D'Amico EA, Caldwell SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009; 7:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/9\">",
"      Stiegmann GV, Goff JS, Sun JH, et al. Technique and early clinical results of endoscopic variceal ligation (EVL). Surg Endosc 1989; 3:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/10\">",
"      Berkelhammer C, Madhav G, Lyon S, Roberts J. \"Pinch\" injury during overtube placement in upper endoscopy. Gastrointest Endosc 1993; 39:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/11\">",
"      Jones WF, Alhalel R, Bourke MJ, et al. Efficacy and safety of over the scope vs bougie assisted overtube introduction in upper endoscopy: A prospective, controlled, single blind trial (abstract). Gastrointest Endosc 1995; 41:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/12\">",
"      Saeed ZA. The Saeed Six-Shooter: a prospective study of a new endoscopic multiple rubber-band ligator for the treatment of varices. Endoscopy 1996; 28:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/13\">",
"      Ramirez FC, Colon VJ, Landan D, et al. The effects of the number of rubber bands placed at each endoscopic session upon variceal outcomes: a prospective, randomized study. Am J Gastroenterol 2007; 102:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/14\">",
"      Shibuya S, Takase Y, Chikamori F, et al. An improved endoscopic variceal ligation for esophageal and solitary gastric varices--three-O-band-shooter. Wiad Lek 1997; 50 Suppl 1 Pt 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/15\">",
"      Sackmann M, Gerbes AL. Application of a multiple-band ligator in active variceal bleeding. Endoscopy 1996; 28:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/16\">",
"      Jensen DM, Machicado G, Jutabha R, et al. A multishot, speedbander compared to single shot rubber band ligator for endoscopic hemostasis of canine gastric varices (abstract). Gastrointest Endosc 1995; 41:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/17\">",
"      ASGE Technology Committee, Liu J, Petersen BT, et al. Endoscopic banding devices. Gastrointest Endosc 2008; 68:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/18\">",
"      Stiegmann GV, Goff JS, Sun JH, Wilborn S. Endoscopic elastic band ligation for active variceal hemorrhage. Am Surg 1989; 55:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/19\">",
"      Laine L. Management of actively bleeding esophageal varices. Gastrointest Endosc 1997; 46:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/20\">",
"      Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/21\">",
"      Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/22\">",
"      Laine L, el-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993; 119:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/23\">",
"      Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/24\">",
"      Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/25\">",
"      Hou MC, Lin HC, Kuo BI, et al. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology 1995; 21:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/26\">",
"      Gimson AE, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993; 342:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/27\">",
"      Chen CY, Chang TT, Lin CY, et al. Endoscopic variceal ligation versus conservative treatment for patients with hepatocellular carcinoma and bleeding esophageal varices. Gastrointest Endosc 1995; 42:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/28\">",
"      Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/29\">",
"      Lopes CV, Pereira-Lima JC, Pereira-Lima LF, et al. The efficacy of endoscopic ligation for the prevention of variceal rebleeding in cirrhotic patients according to the hepatocellular function. Hepatogastroenterology 2004; 51:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/30\">",
"      Chen WT, Lin CY, Sheen IS, et al. MELD score can predict early mortality in patients with rebleeding after band ligation for variceal bleeding. World J Gastroenterol 2011; 17:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/31\">",
"      de Souza AR, La Mura V, Reverter E, et al. Patients whose first episode of bleeding occurs while taking a &beta;-blocker have high long-term risks of rebleeding and death. Clin Gastroenterol Hepatol 2012; 10:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/32\">",
"      Yoshida H, Mamada Y, Taniai N, et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol 2005; 100:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/33\">",
"      Baroncini D, Milandri GL, Borioni D, et al. A prospective randomized trial of sclerotherapy versus ligation in the elective treatment of bleeding esophageal varices. Endoscopy 1997; 29:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/34\">",
"      Petrasch F, Grothaus J, M&ouml;ssner J, et al. Differences in bleeding behavior after endoscopic band ligation: a retrospective analysis. BMC Gastroenterol 2010; 10:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/35\">",
"      Saeed ZA, Michaletz PA, Winchester CB, et al. Endoscopic variceal ligation in patients who have failed endoscopic sclerotherapy. Gastrointest Endosc 1990; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/36\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/37\">",
"      Lo GH, Lai KH, Chang CF, et al. Endoscopic injection sclerotherapy vs. endoscopic variceal ligation in arresting acute variceal bleeding for patients with advanced hepatocellular carcinoma. J Hepatol 1994; 21:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/38\">",
"      Avgerinos A, Armonis A, Manolakopoulos S, et al. Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study. J Hepatol 1997; 26:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/39\">",
"      Cotton P. Combination therapies may speed healing, reduce rebleeding of esophageal varices. JAMA 1991; 266:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/40\">",
"      de la Pe&ntilde;a J, Rivero M, Sanchez E, et al. Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. Gastrointest Endosc 1999; 49:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/41\">",
"      Djurdjevic D, Janosevic S, Dapcevic B, et al. Combined ligation and sclerotherapy versus ligation alone for eradication of bleeding esophageal varices: a randomized and prospective trial. Endoscopy 1999; 31:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/42\">",
"      Garg PK, Joshi YK, Tandon RK. Comparison of endoscopic variceal sclerotherapy with sequential endoscopic band ligation plus low-dose sclerotherapy for secondary prophylaxis of variceal hemorrhage: a prospective randomized study. Gastrointest Endosc 1999; 50:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/43\">",
"      Hou MC, Chen WC, Lin HC, et al. A new \"sandwich\" method of combined endoscopic variceal ligation and sclerotherapy versus ligation alone in the treatment of esophageal variceal bleeding: a randomized trial. Gastrointest Endosc 2001; 53:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/44\">",
"      Saeed ZA, Stiegmann GV, Ramirez FC, et al. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. Hepatology 1997; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/45\">",
"      Lo GH, Lai KH, Cheng JS, et al. The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: a prospective, randomized trial. Hepatology 1998; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/46\">",
"      Al Traif I, Fachartz FS, Al Jumah A, et al. Randomized trial of ligation versus combined ligation and sclerotherapy for bleeding esophageal varices. Gastrointest Endosc 1999; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/47\">",
"      Umehara M, Onda M, Tajiri T, et al. Sclerotherapy plus ligation versus ligation for the treatment of esophageal varices: a prospective randomized study. Gastrointest Endosc 1999; 50:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/48\">",
"      Argonz J, Kravetz D, Suarez A, et al. Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial. Gastrointest Endosc 2000; 51:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/49\">",
"      Cheng YS, Pan S, Lien GS, et al. Adjuvant sclerotherapy after ligation for the treatment of esophageal varices: a prospective, randomized long-term study. Gastrointest Endosc 2001; 53:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/50\">",
"      Nishikawa Y, Hosokawa Y, Doi T, et al. Simultaneous combination of endoscopic sclerotherapy and endoscopic ligation for esophageal varices. Gastrointest Endosc 1995; 42:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/51\">",
"      Fujino MA, Nakamura T. Endoscopic evaluation of the therapeutic effect of endoscopic variceal ligation in combination with sclerotherapy for esophageal varices. Gastrointest Endosc 1998; 47:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/52\">",
"      Koutsomanis D. Endoscopic variceal ligation combined with low-volume sclerotherapy: A controlled study. Hepatology 1992; 102:A835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/53\">",
"      Laine L, Stein C, Sharma V. Randomized comparison of ligation versus ligation plus sclerotherapy in patients with bleeding esophageal varices. Gastroenterology 1996; 110:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/54\">",
"      Bhargava DK, Pokharna R. Endoscopic variceal ligation versus endoscopic variceal ligation and endoscopic sclerotherapy: a prospective randomized study. Am J Gastroenterol 1997; 92:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/55\">",
"      Reveille RM, Goff JS, Stiegmann GV, et al. Combination endoscopic variceal ligation (EVL) and low-volume endoscopic sclerotherapy (ES) for bleeding esophageal varices: A faster route to eradication (abstract). Gastrointest Endosc 1991; 37:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/56\">",
"      Jensen DM, Kovacs TO, Jutabha R, et al. Initial results of a randomized, prospective study of combination banding and sclerotherapy vs. sclerotherapy alone for hemostasis of bleeding esophagogastric varices (abstract). Gastrointest Endosc 1995; 41:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/57\">",
"      El Khayat HR, Khamis AA. Comparative evaluation of combined endoscopic variceal ligation (EVL) together with low volume endoscopic sclerotherapy (ES) versus sclerotherapy or band ligation alone for bleeding oesophageal varices (abstract). Gastroenterology 1995; 108:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/58\">",
"      Iso Y, Kawanaka H, Tomikawa M, et al. Repeated injection sclerotherapy is preferable to combined therapy with variceal ligation to avoid recurrence of esophageal varices:--a prospective randomized trial. Hepatogastroenterology 1997; 44:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/59\">",
"      Masumoto H, Toyonaga A, Oho K, et al. Ligation plus low-volume sclerotherapy for high-risk esophageal varices: comparisons with ligation therapy or sclerotherapy alone. J Gastroenterol 1998; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/60\">",
"      Jung IS, Cheon GJ, Ryu CB, et al. Comparison of endoscopic variceal ligation versus combined ligation and endoscopic argon plasma coagulation (APC) for esopahgeal varices (abstract). Gastrointest Endosc 2001; 53:AB119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/61\">",
"      Watanabe Y, Hiraishi H, Mitobe Y, et al. Treatment with argon plasma coagulation for residual esophageal varices after endoscopic variceal band ligation or sclerotherapy (abstract). Gastrointest Endosc 2001; :AB124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/62\">",
"      Okano H, Shiraki K, Inoue H, et al. Long-term follow-up of patients with liver cirrhosis after endoscopic esophageal varices ligation therapy: comparison with ethanol injection therapy. Hepatogastroenterology 2003; 50:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/63\">",
"      Arakaki Y, Murakami K, Takahashi K, et al. Clinical evaluation of combined endoscopic variceal ligation and sclerotherapy of gastric varices in liver cirrhosis. Endoscopy 2003; 35:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/64\">",
"      Karsan HA, Morton SC, Shekelle PG, et al. Combination endoscopic band ligation and sclerotherapy compared with endoscopic band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: a meta-analysis. Dig Dis Sci 2005; 50:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/65\">",
"      Harras F, Sheta el S, Shehata M, et al. Endoscopic band ligation plus argon plasma coagulation versus scleroligation for eradication of esophageal varices. J Gastroenterol Hepatol 2010; 25:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/66\">",
"      Meirelles-Santos JO, Montes CG, Guerrazzi F, et al. Treatment of esophageal varices using band ligation followed by microwave coagulation (abstract).  Gastrointest Endosc 2001; :53AB120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/67\">",
"      Cipolletta L, Bianco MA, Rotondano G, et al. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices: preliminary results of a prospective randomized trial. Gastrointest Endosc 2002; 56:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/68\">",
"      Sarin SK. Long-term follow-up of gastric variceal sclerotherapy: an eleven-year experience. Gastrointest Endosc 1997; 46:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/69\">",
"      Trudeau W, Prindiville T. Endoscopic injection sclerosis in bleeding gastric varices. Gastrointest Endosc 1986; 32:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/70\">",
"      Soehendra N, Nam VC, Grimm H, Kempeneers I. Endoscopic obliteration of large esophagogastric varices with bucrylate. Endoscopy 1986; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/71\">",
"      Williams SG, Peters RA, Westaby D. Thrombin--an effective treatment for gastric variceal haemorrhage. Gut 1994; 35:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/72\">",
"      Przemioslo RT, McNair A, Williams R. Thrombin is effective in arresting bleeding from gastric variceal hemorrhage. Dig Dis Sci 1999; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/73\">",
"      Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001; 33:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/74\">",
"      Young MF, Sanowski RA, Rasche R. Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc 1993; 39:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/75\">",
"      Marks RD, Arnold MD, Baron TH. Gross and microscopic findings in the human esophagus after esophageal variceal band ligation: a postmortem analysis. Am J Gastroenterol 1993; 88:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/76\">",
"      Rai RR, Nijhawan S, Singh G. Post-ligation stricture: a rare complication. Endoscopy 1996; 28:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/77\">",
"      Goff JS, Reveille RM, Stiegmann GV. Three years experience with endoscopic variceal ligation for treatment of bleeding varices. Endoscopy 1992; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/78\">",
"      Schmitz RJ, Sharma P, Badr AS, et al. Incidence and management of esophageal stricture formation, ulcer bleeding, perforation, and massive hematoma formation from sclerotherapy versus band ligation. Am J Gastroenterol 2001; 96:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/79\">",
"      Goff JS, Reveille RM, Van Stiegmann G. Endoscopic sclerotherapy versus endoscopic variceal ligation: esophageal symptoms, complications, and motility. Am J Gastroenterol 1988; 83:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/80\">",
"      Lo GH, Lai KH, Shen MT, Chang CF. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc 1994; 40:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/81\">",
"      da Silveira Rohr MR, Siqueira ES, Brant CQ, et al. Prospective study of bacteremia rate after elastic band ligation and sclerotherapy of esophageal varices in patients with hepatosplenic schistosomiasis. Gastrointest Endosc 1997; 46:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/82\">",
"      Maulaz EB, de Mattos AA, Pereira-Lima J, Dietz J. Bacteremia in cirrhotic patients submitted to endoscopic band ligation of esophageal varices. Arq Gastroenterol 2003; 40:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/83\">",
"      Berner JS, Gaing AA, Sharma R, et al. Sequelae after esophageal variceal ligation and sclerotherapy: a prospective randomized study. Am J Gastroenterol 1994; 89:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/84\">",
"      Nikoloff MA, Riley TR 3rd, Schreibman IR. Complete esophageal obstruction following endoscopic variceal ligation. Gastroenterol Hepatol (N Y) 2011; 7:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/85\">",
"      Holderman WH, Etzkorn KP, Patel SA, et al. Endoscopic findings and overtube-related complications associated with esophageal variceal ligation. J Clin Gastroenterol 1995; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/86\">",
"      Dennert B, Ramirez FC, Sanowski RA. A prospective evaluation of the endoscopic spectrum of overtube-related esophageal mucosal injury. Gastrointest Endosc 1997; 45:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/87\">",
"      Nijhawan S, Rai RR, Nepalia S, et al. Natural history of postligation ulcers. Am J Gastroenterol 1994; 89:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/88\">",
"      Vanbiervliet G, Giudicelli-Bornard S, Piche T, et al. Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: a case-control study. Aliment Pharmacol Ther 2010; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/89\">",
"      Hou MC, Lin HC, Chen CH, et al. Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: an endoscopic observation. Gastrointest Endosc 1995; 42:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/90\">",
"      Pan&eacute;s J, Bordas JM, Piqu&eacute; JM, et al. Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992; 103:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/91\">",
"      Tayama C, Iwao T, Oho K, et al. Effect of large fundal varices on changes in gastric mucosal hemodynamics after endoscopic variceal ligation. Endoscopy 1998; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/92\">",
"      Lo GH, Liang HL, Lai KH, et al. The impact of endoscopic variceal ligation on the pressure of the portal venous system. J Hepatol 1996; 24:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/93\">",
"      Yoshikawa I, Murata I, Nakano S, Otsuki M. Effects of endoscopic variceal ligation on portal hypertensive gastropathy and gastric mucosal blood flow. Am J Gastroenterol 1998; 93:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/94\">",
"      Sarin SK, Shahi HM, Jain M, et al. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000; 95:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/95\">",
"      Pereira-Lima JC, Zanette M, Lopes CV, de Mattos AA. The influence of endoscopic variceal ligation on the portal pressure gradient in cirrhotics. Hepatogastroenterology 2003; 50:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/96\">",
"      Schoonbroodt D, Zipf A, Jung M. Local necrosis and fatal perforation of oesophagus after endoscopic ligation. Lancet 1994; 344:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/97\">",
"      Hou MC, Lin HC, Chang FY, et al. Oesophageal perforation following endoscopic variceal ligation and balloon tamponade. J Gastroenterol Hepatol 1994; 9:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/98\">",
"      Vitte RL, Eugene C, Fingerhut A, et al. Fatal outcome following endoscopic fundal variceal ligation. Gastrointest Endosc 1996; 43:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/99\">",
"      Tachibana I, Yoshikawa I, Sano Y, et al. A case of mesenteric venous thrombosis after endoscopic variceal band ligation. J Gastroenterol 1995; 30:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/100\">",
"      Malpani NK, Somani AK, Vardhan V, Goyal VP. Inadvertent banding of laryngeal mucosa during endoscopic variceal band ligation. Indian J Gastroenterol 1997; 16:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/101\">",
"      Nagamine N, Kaneko Y, Kumakura Y, et al. Occurrence of pyogenic meningitis during the course of endoscopic variceal ligation therapy. Gastrointest Endosc 1999; 49:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/102\">",
"      Saltzman JR, Arora S. Complications of esophageal variceal band ligation. Gastrointest Endosc 1993; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/103\">",
"      Hoepffner N, Foerster E, Menzel J, et al. Severe complications arising from oesophageal varix ligation with the Stiegmann-Goff set. Endoscopy 1995; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/104\">",
"      Hou MC, Yen TC, Lin HC, et al. Sequential changes of esophageal motility after endoscopic injection sclerotherapy or variceal ligation for esophageal variceal bleeding: a scintigraphic study. Am J Gastroenterol 1997; 92:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/105\">",
"      Iida T, Shijo H, Yokoyama M, et al. Effects of endoscopic variceal ligation on oxygen transport and the arterial lactate levels in patients with cirrhosis. Am J Gastroenterol 1998; 93:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/106\">",
"      Debette S, Gauvrit JY, Desseaux G, et al. Paraplegia after ligation of esophageal varices. Neurology 2003; 60:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/107\">",
"      Gralnek IM, Jensen DM, Kovacs TO, et al. The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology 1999; 29:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35689/abstract/108\">",
"      Zargar SA, Javid G, Khan BA, et al. Endoscopic ligation vs. sclerotherapy in adults with extrahepatic portal venous obstruction: a prospective randomized study. Gastrointest Endosc 2005; 61:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1264 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35689=[""].join("\n");
var outline_f34_54_35689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Placement of an overtube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Applying the bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Number of bands to apply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MULTIPLE LIGATING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACUTELY BLEEDING VARICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FOLLOW-UP BAND LIGATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      American Association for the Study of Liver Diseases Guideline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other combination therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gastric varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overtube complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Esophageal ulcerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Portal hypertensive gastropathy and gastric varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Unusual complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1264|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/15/7408\" title=\"picture 1A\">",
"      Fibrin plug eso varix Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/25/7568\" title=\"picture 1B\">",
"      Red wale Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/13/3282\" title=\"picture 2\">",
"      Two varices banded Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1264|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/21/39259\" title=\"table 1\">",
"      Acute bleeding EVL vs ES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 2\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/45/43739\" title=\"table 3\">",
"      Complications EVL vs ES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/40/8834?source=related_link\">",
"      Patient information: Esophageal varices (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_54_35690="Automated hematology instrumentation";
var content_f34_54_35690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Automated hematology instrumentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Tracy I George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/54/35690/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/54/35690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first half of the twentieth century, the complete blood count (CBC), one of the most commonly ordered laboratory tests, was performed using exclusively manual techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cell counts (red cells, white cells, platelets) were performed using appropriately diluted blood samples and a ruled counting chamber (hemocytometer).",
"     </li>",
"     <li>",
"      Hemoglobin concentration was analyzed colorimetrically by the cyanomethemoglobin method.",
"     </li>",
"     <li>",
"      The hematocrit (packed cell volume) was measured by high speed centrifugation of a column of blood, either in a specially designed tube (the Wintrobe tube) (",
"      <a class=\"graphic graphic_picture graphicRef68024 \" href=\"mobipreview.htm?20/49/21265\">",
"       picture 1",
"      </a>",
"      ), or in sealed microcapillary tubes (ie, the \"spun\" hematocrit, often obtained by fingerstick blood collection) (",
"      <a class=\"graphic graphic_picture graphicRef61513 \" href=\"mobipreview.htm?6/37/6737\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The white blood cell differential was obtained by examining and enumerating by class (eg, granulocytes, lymphocytes, monocytes) 100 to 200 individual white blood cells on a suitably stained blood smear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 1932, Wintrobe developed a set of calculated indices that estimated erythrocyte size and hemoglobin content based on the red blood cell count (RBC), hemoglobin concentration (HGB), and hematocrit (HCT). These indices included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean corpuscular volume (MCV) &mdash; the volume (in femtoliters, fL) of the average circulating red blood cell",
"     </li>",
"     <li>",
"      Mean corpuscular hemoglobin (MCH) &mdash; the hemoglobin content (in picograms) of the average circulating red blood cell",
"     </li>",
"     <li>",
"      Mean corpuscular hemoglobin concentration (MCHC) &mdash; the hemoglobin concentration within circulating red blood cells (grams of hemoglobin per 100 mL of packed red blood cells)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three indices were calculated manually, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MCV (fL) = 10 x HCT (percent) &divide; RBC",
"      <span class=\"nowrap\">",
"       (millions/microL)",
"      </span>",
"     </li>",
"     <li>",
"      MCH",
"      <span class=\"nowrap\">",
"       (pg/red",
"      </span>",
"      cell) = HGB",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      x 10 &divide; RBC",
"      <span class=\"nowrap\">",
"       (millions/microL)",
"      </span>",
"     </li>",
"     <li>",
"      MCHC",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      = HGB",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      X 100 &divide; HCT (percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These early methods were laborious, and, for the hemocytometer counts, very imprecise. This topic review will discuss the various methods and apparatus which have been employed in an attempt to automate all of the above procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12469650\">",
"    <span class=\"h1\">",
"     SAMPLE COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samples to be used for a complete blood count should be anticoagulated with a suitable agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or EDTA. The use of EDTA may cause platelet clumping in some patients (ie, pseudothrombocytopenia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is recommended that blood samples be kept at room temperature if analysis is to occur within 8 hours of collection. Samples should be refrigerated if the analysis is to occur up to 24 hours after collection. We do not recommend that samples greater than 36 hours old be used for CBC testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE COULTER IMPEDANCE APERTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1956, Walter and Joseph Coulter patented a device developed in their basement that used an electric impedance aperture to count red cells and white cells. In the impedance method, blood is diluted in a current-conducting solution, such as isotonic saline. The suspension of cells is drawn by a vacuum through a small orifice or aperture positioned between two sensing electrodes connected across a direct current potential. As each cell passes through the aperture, the resistance between the electrodes increases. The non-conductive cell being counted produces a momentary increase in impedance, resulting in an electrical pulse, with the number of pulses indicating the cell count, and the amplitude of the pulse being proportional to the cell's volume. Upper and lower pulse height thresholds could be selected such that only particles within a specific volume range would be counted.",
"   </p>",
"   <p>",
"    Since typical red cell counts are three orders of magnitude greater than white cell counts, and since appropriate settings of the lower pulse height threshold eliminate counting of the smaller platelets (platelet volume is approximately 9 fL, or about one-tenth the volume of mature red cells), a cell count on appropriately diluted whole blood samples served to yield a red cell count. On the other hand, red cell lysing reagents need to be added to the sample before the white blood cells can be counted with accuracy.",
"   </p>",
"   <p>",
"    In the first semiautomated systems, separate red blood cell and white blood cell dilutions were performed manually or by using a separate dilutor. A combination",
"    <span class=\"nowrap\">",
"     lysing/potassium",
"    </span>",
"    ferricyanide solution was added to the white blood cell dilution, allowing enumeration of leukocytes as well as spectrophotometric measurement of hemoglobin (as cyanmethemoglobin) from the same dilution. Red blood cell indices were manually calculated, using the formulae shown above.",
"   </p>",
"   <p>",
"    When the cell count is especially high, two (or more) cells can be so close together while passing through the aperture that they are counted as one cell. To correct for this phenomenon, a \"coincidence\" correction was applied to the raw impedance aperture count. This was accomplished manually, using statistical tables developed for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Multichannel instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1960s, the first multichannel automated hematology instruments appeared. Anticoagulated whole blood samples were aspirated into the apparatus and automatically aliquoted and diluted into RBC and WBC counting chambers (baths) for cell counting and sizing with impedance apertures, and into a spectrophotometric cuvette for hemoglobin determination using the cyanmethemoglobin method. Coincidence correction and calculations of red cell indices were automatically performed.",
"   </p>",
"   <p>",
"    Since these machines measure the red cell count (RBC) directly, as well as the mean corpuscular volume (MCV), the HCT could be electronically calculated by rearranging one of the original Wintrobe formulae shown above:",
"   </p>",
"   <p>",
"    <br/>",
"    &nbsp;HCT (percent) = RBC (in",
"    <span class=\"nowrap\">",
"     millions/microL)",
"    </span>",
"    x MCV (fL) &divide; 10",
"   </p>",
"   <p>",
"    These first multichannel instruments revolutionized the CBC as a laboratory test, enabling high throughput, low cost, and fast turnaround time with the ability to produce immediate (STAT) results. However, the platelet count was not a part of the first automated CBC, since the aperture resolution on the early instruments was not good enough to adequately separate platelets from red cells. Early attempts to automate the platelet count used platelet-rich plasma or whole blood lysing methods, but there were many interferences, particularly when the platelet count was low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The red blood cell volume histogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern cell counting and sizing apertures have sufficient precision to function as \"channelizers.\" As an example, Coulter instruments channel cells within the",
"    <span class=\"nowrap\">",
"     RBC/platelet",
"    </span>",
"    aperture into 256 bins in the size range from zero to 360 fL. RBCs are not only enumerated as those particles with a cell volume within the range of 36 to 360 fL, but they are also classified into appropriate \"channels\" by size (related to the pulse height). For instruments with pulse editing circuitry, aberrant pulses are excluded from these channels. A plot of frequency versus channel size allows the development of a RBC volume histogram, which can be smoothed into a RBC size distribution curve.",
"   </p>",
"   <p>",
"    The red cell size frequency distribution curve typically has a symmetrical or Gaussian shape. The MCV (mean red cell volume) and red cell distribution width (RDW, the coefficient of variation of the RBC volume distribution) are directly calculated from this curve. A number of abnormalities of this curve can be seen in disease settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A left \"shoulder\" extension to the curve, or failure of the curve to reach baseline on the left side (ie, RBCs with smaller volumes) can indicate the presence of a population of very small RBCs (eg, microspherocytes or schistocytes), or might be associated with the presence of unusually large platelets (macrothrombocytes) or platelet clumps.",
"     </li>",
"     <li>",
"      A separate red cell population to the left (ie, microcytic RBCs) can indicate the presence of two populations of red cells, as seen in X-linked sideroblastic anemia (",
"      <a class=\"graphic graphic_figure graphicRef69210 \" href=\"mobipreview.htm?37/51/38717\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Complete blood count'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A right-sided shoulder usually corresponds to a population of extremely large RBCs (macrocytes) or reticulocytes.",
"     </li>",
"     <li>",
"      A trailing erythrocyte population to the extreme right (eg, cells with a MCV &gt;200 fL) can indicate the presence of RBC agglutinins (",
"      <a class=\"graphic graphic_picture graphicRef50522 \" href=\"mobipreview.htm?15/10/15527\">",
"       picture 3",
"      </a>",
"      ), which cause red cells to pass through the aperture in small clumps. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\", section on 'Anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Red cell distribution width",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red cell distribution width (RDW), is an indicator of the degree of variation in RBC size (ie, anisocytosis). In Coulter instruments, the RDW is made equal to the coefficient of variation (CV) of the red cell volume distribution curve, while in some Sysmex instruments, the RDW is equal to the standard deviation of this curve.",
"   </p>",
"   <p>",
"    Initially, Bessman and colleagues proposed a classification of anemia based on a combination of MCV and RDW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/4\">",
"     4",
"    </a>",
"    ]. However, there were many exceptions and overlaps between the different categories. RDW was also proposed as a tool to distinguish iron deficiency (elevated RDW) from thalassemia trait (normal RDW) in samples with low MCV. However, many cases of thalassemia trait were found to have an elevated RDW. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link&amp;anchor=H5#H5\">",
"     \"Mean corpuscular volume\", section on 'Red blood cell distribution width'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Improvements enabling platelet counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1970s, improvement of the cell counting apertures led to more accurate cell sizing and the ability to enumerate platelets in whole blood samples. These techniques helped to eliminate errors in counting the smaller platelet particles. Two technical problems that needed to be overcome were errors due to non-axial passage of RBCs through the aperture and the recounting of RBCs nicking the aperture edge. Both of these problems make a small proportion of red cells look like very small particles, similar in size to platelets. Since each microliter of blood contains millions of RBCs and only tens to hundreds of thousands of platelets, miscounting a small percentage of the RBCs as platelet-size particles led to huge overestimates of the platelet count. Technical advances that corrected these problems included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Erythrocyte/platelet",
"      </span>",
"      counting apertures were produced that are smaller in diameter and longer in length, centralizing the flow of particles.",
"     </li>",
"     <li>",
"      Techniques were developed to ensure that the cell to be counted passes through the center of the aperture, since cells passing near the edge of the orifice are perceived to be larger. With hydrodynamic focusing, sheath fluid (typically isotonic saline) streams around the sample inlet and through the aperture along with the sample, forcing the cells to enter the sensing zone in single file.",
"     </li>",
"     <li>",
"      \"Sweep flow\" of the diluent at the exit of the apertures quickly removes the counted particles so that the RBCs cannot recirculate and nick the counting aperture, and thus erroneously be recounted as a \"smaller\" platelet-size particle.",
"     </li>",
"     <li>",
"      The Von Behrens transducer (present on Cell-Dyn instruments) minimizes recirculation of cells by forcing the counted cell stream through a second opening, and trapping the cells behind a plate.",
"     </li>",
"     <li>",
"      Cells taking a non-axial path through the sensing aperture dwell longer and produce a broader pulse. Similarly, cells that reenter the aperture zone produce a flat, broad pulse. Pulse editing circuitry eliminates these pulses from the platelet count and from RBC sizing calculations (ie, MCV, RBC size histogram, and RDW).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, all pulses in the RBC size range, despite aberrant shape, are enumerated for the RBC count. In addition, the expected symmetrical pulse from a RBC particle assumes a deformable cell with an ellipsoid electronic shadow, producing an electronic pulse 1.3 to 1.5 times that of the actual volume of a spherical RBC. RBCs with other shapes (poikilocytes) or small fragmented RBCs (schistocytes) may result in pulse heights not reflective of their actual volume. However, these pulses may also have an aberrant shape and be edited out of the MCV computation. Thus, the electronic impedance MCV excludes aberrant pulses; in some samples, up to 20 percent of the counted RBCs may be excluded from the MCV calculation.",
"   </p>",
"   <p>",
"    Despite these improvements, impedance apertures have a limited linear range for particle sizing. Failure to accurately enumerate the smallest and largest RBCs can give an overestimation of microcytosis and underestimation of macrocytosis, resulting in an MCHC with a limited range, or a \"clamped\" MCHC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Platelet counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets may be counted in four ways: manual microscopy, impedance, optical scatter, and immunologic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/5\">",
"     5",
"    </a>",
"    ]. Automated platelet counting primarily uses impedance and optical scatter, although immunologic methods are available on some instruments. This section will focus on impedance platelet counting with other platelet counting methods discussed in a subsequent section.",
"   </p>",
"   <p>",
"    On instrumentation that uses impedance-based platelet counting, platelets are enumerated as particles ranging from 2 fL up to 30 fL in volume. Similar to red cells, a frequency curve is generated from a channelized histogram of platelet volumes (eg, raw data curve), and is extrapolated to 70 fL. In contrast to the Gaussian distribution typical of red cells, platelets show a lognormal or skewed distribution. A mean platelet volume (MPV) is calculated from a log transformation of the platelet volume distribution curve (eg, fitted curve), yielding a geometric mean for this parameter. Fitting a lognormal curve to the raw data can help exclude interferences (eg, microcytic red cells, cytoplasmic fragments, debris, electronic noise) and allows the inclusion of giant platelets whose size is greater than 20 fL (",
"    <a class=\"graphic graphic_picture graphicRef72433 \" href=\"mobipreview.htm?17/31/17911\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Abnormal platelet morphology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H2#H2\">",
"     \"Platelet function testing\", section on 'Platelet counting methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inspection of the platelet histogram can aid in determining inaccuracies in the platelet count; these are typically \"flagged\" by the instrument to indicate their presence. A peak or spike at the left end (ie, at volumes &lt;2 fL) suggests the presence of cytoplasmic fragments or sufficient interference by electronic noise, while a failure to return to baseline at the right end (ie, volumes &gt;20 to 30 fL) indicates interference by microcytic RBCs or failure to include giant platelets in the count.",
"   </p>",
"   <p>",
"    When instrument platelet flags occur, it is important to verify the platelet count by estimation from a peripheral blood smear. In an area of the peripheral blood smear where RBCs barely touch, the number of platelets per 100 power field when multiplied by 20 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    gives an estimate of the platelet count, which can then be compared with the machine-derived count. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different instruments employ varying techniques to detect interferences that can result in a spurious platelet count. Some instruments enumerate particles between 2 to 3 fL (on the low end) and 20 to 30 fL (on the high end) as platelets and monitor the percent of total particles near the lower counting threshold (ie, 1 to 2 fL) and the upper counting threshold (ie, 20 to 30 fL). When the number of particles in these regions exceeds certain limits, \"flags\" are generated.",
"   </p>",
"   <p>",
"    The Beckman-Coulter hematology instruments (STKS, MAXM, GEN*S) enumerate platelets as particles between 2 and 20 fL (a counting zone in which erythrocytes are very unlikely to be found), and a smoothed curve is generated from the raw data. The curve is fitted to a lognormal distribution and extended to 70 fL. The integrated area under the curve represents the platelet count. Flags occur on the GEN*S when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A lognormal distributional fit is not obtained",
"     </li>",
"     <li>",
"      The mode of the lognormal distribution curve is not found in the region between 3 to 15 fL",
"     </li>",
"     <li>",
"      The platelet distribution width (PDW, or the standard deviation of the log-transformed data) is greater than 20 fL, or",
"     </li>",
"     <li>",
"      The platelet count is less than 20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;20,000/microL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the above instances, the raw unfitted platelet count between 2 and 20 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    is reported, along with the instrument flag. The",
"    <span class=\"nowrap\">",
"     LH750/780",
"    </span>",
"    Beckman-Coulter hematology instruments enumerate platelets as described above if the data fit a lognormal distribution. If not, the platelet count is derived from the integrated area under the curve between low end and high end valleys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The LH",
"    <span class=\"nowrap\">",
"     750/780",
"    </span>",
"    instruments generate flags on the platelet count based on algorithms as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No flagging at platelet counts &lt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      unless abnormalities are present",
"     </li>",
"     <li>",
"      Low and high end interference criteria used instead of a distributional fit of the lognormal curve",
"     </li>",
"     <li>",
"      Uses a low end valley and a high end valley which can extend less than 2 fL and greater than 20 fL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Beckman-Coulter DxH 800 enumerates platelets as particles with volumes between 2 and 25 fL, and a log-normal curve is developed from the raw data. The raw data curve, fitted curve, and extended platelet histogram (including all platelet and RBC data) are analyzed to determine specific patterns (eg, normal, giant platelets, interference at the low-volume end, etc.) from which platelet parameters (eg, platelet count, MPV, PDW) are derived. Flagging of platelets is generated from analysis of the platelet histogram and is generated by the presence of abnormal platelet morphology (giant platelets, platelet clumps) or interfering substances (eg, debris, microcytic red blood cells, RBC fragments). This data review includes using a new optical NRBC module allowing for more accurate flagging of abnormal findings.",
"   </p>",
"   <p>",
"    The inability to distinguish platelets from other particles such as microcytic red blood cells and electronic noise has been an often cited limitation of impedance methodology. However, automated hematology analyzers such as the Beckman Coulter LH 750 and the Sysmex XE 2100 have shown better correlation of their impedance platelet counts with the reference method compared with optical methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet counting using light scattering and other techniques, which obviates many of the problems enumerated above is discussed in a subsequent section (see",
"    <a class=\"local\" href=\"#H10\">",
"     'The optical platelet count'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mean platelet volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean platelet volume (MPV) is the geometric mean of the transformed lognormal platelet volume data in impedance technology systems. In some optical systems MPV is the mode of the measured platelet volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under normal circumstances, there is an inverse relationship between platelet size and number. Therefore, the total platelet mass, the product of the MPV and platelet count (or \"plateletcrit\") is closely regulated. When platelets decrease in number, bone marrow megakaryocytes are stimulated by thrombopoietin, and their nucleus becomes hyperlobulated, with much higher DNA content (greater ploidy). These stimulated megakaryocytes produce larger platelets. Thus, platelets with a higher MPV are expected to be seen in destructive thrombocytopenia when megakaryocytic stimulation is present. Conversely, platelets with a lower MPV are expected in thrombocytopenic states associated with marrow hypoplasia or aplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=see_link&amp;anchor=H12#H12\">",
"     \"Megakaryocyte biology and the production of platelets\", section on 'Regulation of platelet production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An exception to this relationship occurs with splenic sequestration, in which a low MPV is seen because the spleen sequesters large platelets. Similarly, in hyposplenic states a higher MPV is seen, since there is no spleen to sequester the larger platelets.",
"   </p>",
"   <p>",
"    Although most modern hematology analyzers report the MPV, and the literature indicates that MPV measurement MAY have diagnostic utility (eg, as a marker for increased cardiovascular risk) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/13\">",
"     13",
"    </a>",
"    ], many clinicians do not use this parameter because of difficulties associated with this measurement. Technical problems associated with accurate measurement of MPV include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different technologies for measuring the MPV give different results. Beckman-Coulter systems employ impedance technology and derive the MPV from the fitted lognormal platelet curve. Bayer instruments use laser-based light scatter measurements at two angles; the platelet histogram is derived from measurements of high angle light scatter, and the MPV is calculated as the mode of the measured platelet volumes. Studies comparing results from these instruments have shown MPV differences of up to 40 percent.",
"     </li>",
"     <li>",
"      The reference range for MPV varies with the platelet count, reflecting regulatory homeostasis of the total platelet mass. Thus, a normogram must be used to interpret the MPV, with reference to the platelet count.",
"     </li>",
"     <li>",
"      The calibration of MPV is not standardized between manufacturers or even over time with one manufacturer.",
"     </li>",
"     <li>",
"      The MPV varies with time in EDTA-anticoagulated samples. EDTA-induced platelet shape changes result in a progressive increase in MPV with impedance technology. In general, the MPV increases up to 30 percent within five minutes of exposure, and increases further by 10 to 15 percent over the next two hours. However, some investigators have reported variable increases in MPV with EDTA storage, up to 50 percent. The effect of EDTA on MPV with optical analysis is less well documented, but appears to be unpredictable, decreasing in many patient samples and increasing in others.",
"     </li>",
"     <li>",
"      The MPV is most useful in evaluating thrombocytopenic patients. However, low platelet counts are frequently \"flagged\" by the instrument because of the presence of interfering particles, and thus the MPV may not be accurate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not report the MPV as a routine part of the CBC, because of the EDTA-induced changes over time. Should a clinician order the MPV, we analyze the sample after two hours to allow stabilization of platelet shape changes. Although clinical use of the MPV is problematic due to the above factors we use the current impedance-measured MPV in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high MPV in a thrombocytopenic patient indicates active marrow production of platelets (as in idiopathic thrombocytopenic purpura), whereas a low MPV is indicative of marrow suppression (as in aplastic anemia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/14\">",
"       14",
"      </a>",
"      ]. For example, a MPV &gt;9.5 fL in a patient with a platelet count &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;100,000/microL)",
"      </span>",
"      is likely to be associated with myelodysplasia or idiopathic thrombocytopenic purpura and other platelet consumption processes, and is unlikely to be associated with bone marrow suppression.",
"     </li>",
"     <li>",
"      A sequential increase in MPV over time can indicate megakaryocytic regeneration, such as recovery from a hypoplastic or aplastic state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CELL COUNTING BY LIGHT SCATTERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1970s saw the introduction of cell counting by light scattering technology. In this technique, cells are hydrodynamically focused in a flow cell and illuminated by a narrow beam of laser or tungsten light. The light scattered by each cell is captured by a photodetector and converted to an electrical pulse; the total number of pulses is proportional to the cell count, while pulse amplitude is proportional to cell volume. The number of pulses within a predetermined size range (eg, 30 to 180 fL for red cells and 0 to 20 [or 30] fL for platelets) yields the corresponding RBC and platelet counts. White cells can be counted with light scattering technology after lysis of the RBCs.",
"   </p>",
"   <p>",
"    By analyzing light scatter at multiple angles, better separation of WBC from interferences, such as unlysed RBCs (a problem with neonatal samples, which have difficult-to-lyse RBCs) and nucleated RBCs can be obtained. Some instruments determine both optical and impedance WBC, and compare them to look for interferences.",
"   </p>",
"   <p>",
"    For erythrocyte evaluation with light scattering technology, the erythroid cells first must be isovolumetrically sphered and fixed. Scattered light is measured at low forward angle (0 to 3 degrees) and high forward angle (5 to 15 degrees), yielding pulses proportional to RBC size and refractive index, respectively. The latter is proportional to the hemoglobin content of the cell, allowing hemoglobin content to be directly determined for individual RBCs. This generates a RBC \"cytogram\" that allows calculation of RBC volume and Hb concentration for each individual red blood cell.",
"   </p>",
"   <p>",
"    RBC volume and RBC hemoglobin concentration histograms and smoothed curves can be constructed, and the mean, standard deviation (SD), and coefficients of variation (CV) electronically calculated, yielding the following measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MCV and RDW (as with impedance methods)",
"     </li>",
"     <li>",
"      CHM (mean of directly measured HGB content per red cell) and the CHDW (cellular hemoglobin content distribution width)",
"     </li>",
"     <li>",
"      CHCM (mean of directly measured HGB concentration) and the CHCDW (cellular hemoglobin concentration distribution width).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean value of the directly measured RBC hemoglobin concentration (CHCM) may be decreased and the distribution width of the cellular hemoglobin concentration curve (CHCDW) may be increased in moderate to severe iron deficiency, due to a shift in the percent of hypochromic RBCs. However, these parameters have not proven to be a sensitive indicator of early iron deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link&amp;anchor=H35#H35\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Reticulocyte indices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     The optical platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a manner similar to optical counting of red cells, an optical platelet count and volume can be determined from two dimensional analysis of low and high angle light scatter measurements. These two light scatter measurements are related to platelet volume (size) and refractive index (density) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/15\">",
"     15",
"    </a>",
"    ]. Platelet volume histograms and smoothed curves can be constructed from this plot, and the platelet count, mean platelet volume (MPV) and SD or CV of the volume (ie, platelet distribution width, PDW) derived. Interference by microcytic RBC, RBC fragments, and WBC cytoplasmic fragments is eliminated since these particles have a different refractive index than platelets and are not counted.",
"   </p>",
"   <p>",
"    In the Abbott Cell-Dyn 4000 and Sapphire, platelets are first plotted using scattering angles of 90 degrees versus 7 degrees. The ascending angle of the platelet population is determined and a histogram is formed perpendicular to the axis of this angle. Thresholds are set to isolate the platelets from large and small cells and fragments on either side of the histogram. A second histogram is constructed along the main body of this refined platelet population in order to determine the upper threshold separating platelets from microcytic RBCs.",
"   </p>",
"   <p>",
"    The Sysmex XE 2100 provides both a fluorescent optical platelet count and an impedance count, utilizing a computer algorithm to give the best count based on whether, as an example, interference or an abnormal platelet distribution is detected.",
"   </p>",
"   <p>",
"    There has been much debate in the literature regarding the superiority of impedance platelet counting versus optical platelet counting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/16\">",
"     16",
"    </a>",
"    ]. One article that examined the accuracy of platelet counting using automated hematology analyzers in severe thrombocytopenia found that optical methods were not superior to impedance methods for platelet counting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/17\">",
"     17",
"    </a>",
"    ]. In this study, the Cell-Dyn 4000 and XE-2100 optical methods and the LH750 impedance method all produced similar results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Immunologic counting of platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunologic method of platelet counting by flow cytometry is now the proposed International Reference Method for enumeration of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/18\">",
"     18",
"    </a>",
"    ]. Abbott's Cell-Dyn 4000 and Sapphire utilize an immunologic platelet counting method in which platelets are identified by cluster analysis on a two-dimensional plot of fluorescent monoclonal antibody CD61 reactivity versus high forward angle light scatter. This optional platelet count analysis may be especially useful for very low platelet counts, or when flagged interferences with the platelet count are noted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H6#H6\">",
"     \"Platelet function testing\", section on 'Flow cytometric methods'",
"    </a>",
"    .) The Cell-Dyn 4000 immunologic method was found to be the most accurate of all analyzers in the previously cited study which compared the accuracy of platelet counting among automated hematology analyzers in severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another comparative study, the optical and flow cytometric (immunoplatelet) methods were found to be in good agreement for platelet counts in the range of 25 to 547 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    (25,000 to",
"    <span class=\"nowrap\">",
"     547,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/19\">",
"     19",
"    </a>",
"    ]. However, for platelets counts &lt;25 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    the optical method tended to overestimate the platelet count (",
"    <a class=\"graphic graphic_figure graphicRef80032 \" href=\"mobipreview.htm?18/57/19359\">",
"     figure 2",
"    </a>",
"    ). The lowest absolute platelet count that these methods could reliably distinguish from true zero was 1.730 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    for the optical method and 0.020 and 0.009 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    for the anti-CD41a and the anti-CD61 immunoplatelet methods, respectively.",
"   </p>",
"   <p>",
"    In a follow-up study, the authors compared three different hematology analyzers with the immunoplatelet method and found a coefficient of determination (R2) &gt;0.98 for the overall platelet range. However, examination of each individual platelet range (hematology analyzer versus immunoplatelet method) showed R2 values below 0.98 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/20\">",
"     20",
"    </a>",
"    ]. The XE-2100 (optical mode) and LH-750 showed values R2 &gt;0.9 for all platelet ranges, while for platelet counts less than 50 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    the Advia 120 showed the best correlation with the immunoplatelet method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reticulated platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticulated platelets have increased RNA content and are the youngest circulating platelets, analogous to the relationship between reticulocytes and mature RBC. Measurement of RNA content of platelets with thiazole orange dye can be useful in the diagnostic classification of thrombocytopenia and in monitoring recovering thrombopoiesis (",
"    <a class=\"graphic graphic_figure graphicRef51649 \" href=\"mobipreview.htm?8/22/8558\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/21-29\">",
"     21-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another method to quantify reticulated platelets, expressed as the immature platelet fraction (IPF), has been developed on the Sysmex XE 2100 using its proprietary fluorescent dye containing oxazine and polymethine. This method has demonstrated increased IPF values (ie, an increased population of young platelets) in patients with thrombocytopenia due to increased peripheral platelet destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/30\">",
"     30",
"    </a>",
"    ], consistent with clinical observations in such patients.",
"   </p>",
"   <p>",
"    Comparison of the IPF with reticulated platelets as measured by flow cytometry has shown good correlation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/31\">",
"     31",
"    </a>",
"    ], and studies have argued that the IPF has value in the role of platelet recovery after chemotherapy or hematopoietic cell transplantation, risk index of thrombosis in patients with thrombocytosis, timing for platelet transfusion, evaluation of platelet turnover, myelodysplastic syndrome, disseminated intravascular coagulation, and as a marker of megakaryopoiesis in liver cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/32-39\">",
"     32-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H34#H34\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Increased peripheral destruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALTERNATIVE MEASUREMENTS OF HEMOGLOBIN CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the disposal of the potassium cyanide reagent have led to measurement of hemoglobin by methods other than the conversion of hemoglobin to hemiglobin cyanide (HiCN). These alternatives include the use of sodium lauryl sulphate (SLS), which interacts with hemoglobin to form an SLS-HGB derivative, methemoglobin conversion with imidazole as the heme-ligand, and azide methemoglobin conversion. These methods may show less interference from substances that spuriously elevate HiCN measurement via increase in turbidity, such as high WBC, high triglycerides, or the presence of poorly soluble (at machine temperatures) IgM paraproteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     AUTOMATED COUNTING OF RETICULOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Automated counting of reticulocytes became available at the start of the 1990s, significantly improving the precision of reticulocyte counts as compared with manual counting. A reticulocyte is defined in this methodology as that stage of erythrocyte development following loss of its nucleus in which the cell still contains measurable amounts of RNA. Automation often involves use of a fluorescent dye, such as nucleic acid binding dyes, including thiazole orange, first used in flow cytometry. As well as yielding a reticulocyte count, an immature reticulocyte fraction (IRF) can be measured as the most highly fluorescent reticulocytes (ie, reticulocytes containing the highest amount of RNA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/40-52\">",
"     40-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Sysmex R series instruments use auramine O fluorescent reagent with a precisely controlled temperature and incubation time, and simultaneously count platelets, RBCs, and WBCs, providing an absolute reticulocyte count (ie, the number of reticulocytes per microL of blood), as well as reticulocytes as a percent of all red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/43,44,47\">",
"     43,44,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H38#H38\">",
"     \"Approach to the adult patient with anemia\", section on 'Reticulocyte count'",
"    </a>",
"    .) Fluorescent intensity is divided into low, medium, and high fractions, enabling derivation of the IRF. The machine operator is alerted to interfering substances and potential erroneous results by a number of suspect flags.",
"   </p>",
"   <p>",
"    Automated reticulocyte counts are included on many automated hematology analyzers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Siemens Advia and H series instruments stain reticulocytes with Oxazine 750 and measure light adsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/51\">",
"       51",
"      </a>",
"      ]. Other reticulocyte parameters are reported in sphered reticulocytes (eg, MCVr, CHCMr, HDWr, CHr, CHDWr), similar to those for the sphered mature RBCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/53\">",
"       53",
"      </a>",
"      ]. High, medium, and low fluorescent fractions are also calculated.",
"      <br/>",
"      <br/>",
"      The hemoglobin content of reticulocytes (CHr), measured on the Advia instruments, appears to be a sensitive and specific indicator in detecting iron deficiency, monitoring iron therapy in patients with renal failure on chronic dialysis, and monitoring for the advent of iron deficiency following treatment with erythropoietin in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/54-61\">",
"       54-61",
"      </a>",
"      ]. The reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE 2100 has been reported to correlate with the CHr and may also prove useful in monitoring iron deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/62\">",
"       62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another reticulocyte index, the mean reticulocyte volume, has been proposed to be helpful in diagnosing iron deficiency, monitoring response to treatment of nutritional anemias, an early indicator of erythropoiesis after bone marrow transplantation, and as a tool in the evaluation of erythropoietin abuse in athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/51,63-65\">",
"       51,63-65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Cell-Dyn 4000 and Sapphire use a proprietary fluorescent RNA dye called CD4K540 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/43\">",
"       43",
"      </a>",
"      ]. This dye is 10 times as bright as Auramine O and fluoresces at 530nm (green). A plot of seven degree light scatter versus fluorescence separates platelets from RBC and very highly fluorescent non-viable WBC and nucleated RBC from the reticulocytes. The combined RBC and reticulocytes are gated; a histogram of the mature RBC plus reticulocyte fluorescence is analyzed with a valley-finding algorithm to separate and enumerate the reticulocytes. The IRF is identified arbitrarily by setting a threshold 30 channels above the",
"      <span class=\"nowrap\">",
"       RBC/reticulocyte",
"      </span>",
"      threshold.",
"     </li>",
"     <li>",
"      The Beckman-Coulter STKS, MAXM, GENS,",
"      <span class=\"nowrap\">",
"       LH750/780,",
"      </span>",
"      and DxH 800 instruments stain blood with new",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      , followed by clearing with a hypotonic solution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/41,45,48\">",
"       41,45,48",
"      </a>",
"      ]. Red cells are measured for volume, conductivity, and laser light scatter; the latter signal is proportional to the residual RNA within the red cell. Reticulocyte volume is measured, and those reticulocytes with the most RNA (corresponding to those reticulocytes in the highest light scatter regions) are measured. The DxH 800 captures five laser light scatter measurements for each cell, in contrast to one light scatter measurement for the",
"      <span class=\"nowrap\">",
"       LH750/780.",
"      </span>",
"      The IRF is then the ratio of those reticulocytes with the most RNA over the total number of reticulocytes.",
"      <br/>",
"      <br/>",
"      The immature reticulocyte fraction (IRF) is a measurement of reticulocyte maturation. In some instruments, the medium and high fluorescent regions of reticulocytes are added together to constitute the IRF. The IRF can be the earliest indicator of beginning erythropoiesis and can increase before the actual reticulocyte count increases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/40\">",
"       40",
"      </a>",
"      ]. Thus, an increase in the IRF can indicate early engraftment after bone marrow transplants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/49,50\">",
"       49,50",
"      </a>",
"      ] as well as the therapeutic efficacy of erythropoietin therapy. A combination of the absolute reticulocyte count and IRF is characteristic of different disease states, and may be clinically useful in classifying anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/51\">",
"       51",
"      </a>",
"      ]. Reference intervals for the IRF are dependent on each method used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOMATION OF THE WHITE CELL DIFFERENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cell counts, the classical CBC includes examination of a Wright-Giemsa stained blood film to subclassify the leukocytes (leukocyte or WBC differential) and assess the morphology of the leukocytes, erythrocytes, and platelets. Attempts to automate this process started with image analysis instruments in the 1970s and progressed to flow-through automated differential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/66-75\">",
"     66-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples, the LARC (Corning Medical and Scientific), Hematrak (Geometric Data), and Diff 3 (Perkin-Elmer) apparatus used television cameras fitted to microscopes, which scanned a Wright-Giemsa stained smear. Digital images of cells were analyzed by optical density thresholding, and the cells were classified and counted. These instruments had the same problems inherent in the manual differential. They were slow and could only count 100 to 200 leukocytes, thus yielding the same innate statistical imprecision as a 100 to 200-cell manual differential. In addition, many \"suspect\" cells had to be identified one-by-one by the technologist. Attempts to automate the evaluation of RBC morphology and to estimate the platelet count (ie, low, normal, or high) were unsatisfactory. Because of these limitations, these early instruments were not cost effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     The three part differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating leukocyte subsets in liquid suspension, rather than on a stained smear, began in the 1980s. Flow-through automated differentials were first performed using standard electrical resistance or impedance technology. A weak lysing reagent resulted in lysing of the RBCs and shrinking of the leukocyte membranes about the nucleus, resulting in three peaks of leukocyte subsets in the normal individual:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoid cells and basophils in the smallest size group (35 to 90 fL)",
"     </li>",
"     <li>",
"      Segmented and band neutrophils and eosinophils (\"granulocytes\") in the largest size group (&gt;160 fL)",
"     </li>",
"     <li>",
"      Monocytes and other mononuclear cells, including mononuclear neutrophils and a portion of the eosinophils and band neutrophils, were found in a smaller intermediate size peak between 90 and 160 fL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of abnormal cells obscured the valleys between these three peaks, resulting in error \"flags\" and inaccurate counts. The \"granulocyte\" fraction did not always give a true absolute neutrophil count, particularly if significant numbers of bands, mononuclear neutrophils, or eosinophils were present. In addition, increased numbers of bands and eosinophils, as well as more extreme abnormalities (eg, blasts, reactive lymphocytes, nucleated RBC) all give flagged samples, resulting in a slide review rate &gt;30 percent for a hospital inpatient population. Thus, the three-part differential functioned best in the situation of screening a largely normal population for potential abnormalities.",
"   </p>",
"   <p>",
"    Many of the smaller automated hematology instruments still utilize this technology, including the Sysmex E-5000, Cell-Dyn 1700 and Cell-Dyn 1800.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The five part differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five part differentials were first introduced in the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/67-75\">",
"     67-75",
"    </a>",
"    ]. Different instrument manufacturers all report at a minimum the basic five leukocyte subsets (neutrophils, eosinophils, basophils, lymphocytes, and monocytes) and have flags to detect the presence of abnormal cells (eg, blasts, nucleated RBC, reactive lymphocytes, lymphoma cells, mononuclear granulocytes). Performance in the detection of these abnormalities varies; most instruments are &gt;90 percent sensitive in detecting large numbers of abnormal cells (ie, when the population exceeds 5 percent), but lack sensitivity to low frequency abnormalities (ie, &lt;5 percent). Although these instruments claim to flag increases in band neutrophils, sensitivity and specificity for detection of elevations in this cell type are poor.",
"   </p>",
"   <p>",
"    The current generation of instruments use a combination of technologies for the leukocyte differential, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impedance volume with direct current (DC)",
"     </li>",
"     <li>",
"      Radiofrequency (RF) conductivity (with impedance aperture)",
"     </li>",
"     <li>",
"      Laser light scattering",
"     </li>",
"     <li>",
"      Peroxidase staining",
"     </li>",
"     <li>",
"      Propidium iodide fluorescence (for nucleated RBC and non-viable cells)",
"     </li>",
"     <li>",
"      Cell-specific lysing reagents",
"     </li>",
"     <li>",
"      Polymethine",
"      <span class=\"nowrap\">",
"       RNA/DNA",
"      </span>",
"      histone dye",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both DC and RF methods use impedance technology, in which a cell breaks electrical current generated across an aperture opening, producing a voltage change. When DC current is applied, pulse height is related to overall cell volume. In contrast, when high radiofrequency (RF) current is applied across the counting aperture, the pulse height or voltage change is proportional to nuclear size and density.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Suspect flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instruments performing automated WBC differentials have a variety of \"suspect\" flags used to indicate that abnormal cell populations may be present and that the automated differential may be inaccurate. In general, these \"suspect\" flags can be divided into four types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interfering particles are present at the lower WBC counting threshold, or lowest",
"      <span class=\"nowrap\">",
"       forward/side",
"      </span>",
"      light scatter region for lymphocytes. Typical resulting flags include: (nucleated) nRBC, (platelet) CLUMP, GIANT (platelet).",
"     </li>",
"     <li>",
"      Large mononuclear cells are present at the",
"      <span class=\"nowrap\">",
"       monocyte/neutrophil",
"      </span>",
"      interface or with high values for high angle (90 degree) light scattering. Typical resulting instrument flags: BLAST.",
"     </li>",
"     <li>",
"      Large cells are present in the lymphoid region, or at the interface between lymphoid and monocyte regions. Typical instrument flags include: ATYPICAL LYMPH, BLAST.",
"     </li>",
"     <li>",
"      There is a shifted position in the neutrophil cluster, with a large amount of forward or side light scatter. Typical instrument flags include: IMMATURE NEUTROPHILS, BANDS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     AUTOMATED SAMPLING MODES AND COMPUTER ADVANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in automated hematology instruments in the 1990s were made possible by new, improved, and cheaper computer processing technology and memory. Instruments contained on-board computers to perform curve fitting, multi-dimensional population cluster discrimination, quality control data, and moving averages for quality control. In addition, there is sufficient memory to store and sort samples and to store a finite number of sample scatterplots in \"list\" mode for reanalysis.",
"   </p>",
"   <p>",
"    In the 1980s, analyzers began to include an automated sampling mode. Blood was aspirated from closed tubes, with automated bar code readability, minimizing operator contact with the blood, and allowing positive sample identification. A built-in mixing system ensured sampling of a well-mixed specimen, and instruments usually included a sample aspiration monitor to aid in detecting the presence of clots and determining that the correct sample volume has been aspirated. Sporadic tests, such as reticulocytes or an automated differential, can be selected by random access and performed only when ordered, saving reagent costs. Automated slide makers also are available that can produce and stain blood films as directed by laboratory-programmed algorithms, which consider both the results of specific parameters as well as the presence of instrument flags. The combination of automated hematology analyzers coupled with automated slide makers and stainers have resulted in automated hematology workcells which offer high throughput and increased efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current generation of automated hematology instruments utilize laser light scatter, fluorescence,",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    dyes and monoclonal antibodies to expand the scope of the automated differential. The Cell-Dyn Sapphire uses FITC and PE conjugated monoclonal antibodies to enumerate CD3, CD4 and CD8 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/77\">",
"     77",
"    </a>",
"    ]. The Sysmex XE-2100 utilizes its polymethine dye which binds RNA, DNA and histones and light scatter to enumerate hematopoietic progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/78\">",
"     78",
"    </a>",
"    ], which some authors have suggested be used as a surrogate for CD34 stem cell quantification for peripheral blood stem cell harvesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Sysmex XE-2100 also enumerates immature granulocytes (IGs). The automated IG is being studied as a predictor of sepsis and studies show that, while IG counts are highly specific for infections, they show low sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/81-83\">",
"     81-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enumeration of abnormal cell types, such as blasts, immature granulocytes, and reactive lymphocytes is progressing with laser light scatter, fluorescence and monoclonal antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CAUSES OF SPURIOUS RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although modern hematology instruments are accurate and precise, interfering substances occasionally produce erroneous results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Spurious increase in the MCHC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the MCHC for each sample is one of the best ways to assess for both instrument and sample problems. Although a true increase in the MCHC can be seen when spherocytes are present, a spuriously elevated HGB or spuriously low RBC can result in elevation of the MCHC. Common sample problems leading to these results include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A very high WBC, lipemia, or a precipitating monoclonal protein, all of which produce turbidity in the HGB colorimetric method, will result in a spuriously high HGB.",
"     </li>",
"     <li>",
"      The presence of a cold agglutinin spuriously decreases the RBC count, since RBCs go through the counter in small groups, rather than one-by-one.",
"     </li>",
"     <li>",
"      Artificial hemoglobin-containing solutions increase HGB without an increase in RBC count. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24073?source=see_link\">",
"       \"Oxygen carriers as alternatives to red cell transfusion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Spurious decrease in the MCHC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true decrease in the MCHC can be seen in iron deficiency anemia. However, a high glucose concentration (due to hyperglycemia in the patient or contamination of the blood sample with an intravenous solution containing glucose) causes temporary osmotic imbalance in the diluted RBC in the analyzer chamber, causing them to swell with water for a short period, spuriously increasing the MCV and decreasing the MCHC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Platelet error flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet error flags by automated instruments are important, as they may indicate an erroneous platelet count. Examples include electronic noise, cell cytoplasmic fragments, and microcytic RBCs, all of which can cause a spurious increase in the platelet count. The platelet count can be spuriously decreased when giant platelets are present, since such large platelets may be omitted from the platelet count because of their extreme size. As an example, platelets can be larger than red cells in some patients with the May-Hegglin anomaly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H28#H28\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'May-Hegglin anomaly'",
"    </a>",
"    .) Verification of the platelet count by slide estimate usually is the first step if flags occur, and, if necessary, a manual phase contrast microscopy method is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Leukocyte counting errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferences at the lower",
"    <span class=\"nowrap\">",
"     size/volume",
"    </span>",
"    threshold of WBC counting can be an important clue to the presence of artifacts. These include sample clotting, platelet clumping or giant platelets which can lead to spuriously low platelet counts, high WBC counts, and high percent lymphocytes. Most instruments flag significant particle interference in this region.",
"   </p>",
"   <p>",
"    Most instruments also flag the automated leukocyte differentials when significant interferences are identified. A slide review usually is necessary to validate the instrument results and detect the presence of abnormal cells (eg, atypical lymphocytes, blasts).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Platelet clumping with pseudothrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet clumping can occur, either due to in vitro blood clotting, or in association with an EDTA-dependent platelet agglutinin (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"mobipreview.htm?26/15/26872\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .) Often these platelet clumps are so large that they are beyond the threshold for particle size included in the platelet histogram, leading to spuriously low platelet counts. These platelet clumps are the same size as small WBC, and thus appear as an interference at the lower threshold of an impedance WBC histogram, often spuriously increasing the white cell count. Nucleated RBCs and non-lysing RBCs show a similar interference pattern.",
"   </p>",
"   <p>",
"    If a slide examination confirms the presence of platelet clumps, it is likely that the platelet count is spuriously low, and that the WBC count is spuriously high. If clotting of the blood sample is present, the sample should be redrawn. A correct platelet count often can be obtained for patients with an EDTA-dependent platelet agglutinin by collecting the blood in citrate anticoagulant (and multiplying the results by the dilution effect from the liquid anticoagulant), or by using a heparinized blood sample, in which case there is no need to correct for dilution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SELECTED AUTOMATED HEMATOLOGY INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of commercially available automated hematology instruments, which differ in the methodologies used for determination of the individual elements of the complete blood count. Some of these are listed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Beckman Coulter DxH 800, LH780, and other models",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of Beckman Coulter models are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/70-72,86-92\">",
"     70-72,86-92",
"    </a>",
"    ]. The Beckman Coulter DxH",
"    <span class=\"nowrap\">",
"     800/LH780/LH750",
"    </span>",
"    report the WBC RBC, HGB, HCT (calculated), MCV, MCH (calculated), MCHC (calculated), RDW, platelet count, and MPV. A five part differential includes percent and absolute number of total neutrophils, total lymphoid cells, monocytes, eosinophils, and basophils. When specifically ordered, reticulocytes (percent and absolute number) are analyzed and reported, as well as an immature reticulocyte fraction (IRF). The DxH 800 and",
"    <span class=\"nowrap\">",
"     LH750/LH780",
"    </span>",
"    also enumerate NRBCs, a feature not present on the STKS, MAXM and GEN*S, using the combination of impedance, conductivity and laser light scatter.",
"   </p>",
"   <p>",
"    The Beckman Coulter",
"    <span class=\"nowrap\">",
"     LH750/LH780",
"    </span>",
"    uses electric impedance technology to enumerate WBC, RBC, and platelet counts, and to determine RBC and platelet volume. The",
"    <span class=\"nowrap\">",
"     RBC/platelet",
"    </span>",
"    aperture centers cells by virtue of its architecture (very long and narrow). In addition, sweep flow and pulse editing technology is employed. Hemoglobin is determined by CN-methemoglobin colorimetry. The five-part differential (lymphocytes, neutrophils, monocytes, eosinophils, basophils) is generated by analyzing events in a flow cell with three different technologies: volumetric impedance using direct current (related to cell size or volume), conductivity using high frequency electromagnetic energy (signal related to internal cell complexity), and laser light scatter (related to both cell size and structure). Approximately 8,000 events are classified using these methods. Data are plotted in a three-dimensional matrix (VCS), and clusters are identified as specific cell populations. If the populations are not in expected locations, or a significant number of events are detected outside of the population clusters, flags are generated, indicating that abnormal cells may be present, as well as a need for manual slide review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DxH 800, the newest of the analyzers, enumerates nucleated red blood cells (NRBCs) using a whole blood sample that is diluted and lysed to remove non-nucleated cells and is then directed through the flow cell. Seven parameter measurements are captured characterizing size, shape, and morphology, and these data are analyzed using proprietary algorithms. This analyzer features high-definition digital signal processing and flow cytometric digital analysis using volume, conductivity and multi-angle light scatter, and is notable for a trackless magnetic transport system that contains no exposed moving parts. Reports on the evaluation of NRBCs in neonates using the DxH 800 have shown better correlation with the reference manual technique compared to other analyzers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/90,94\">",
"     90,94",
"    </a>",
"    ]. The LH500 reports the presence of nucleated red blood cells (NRBC) as a flag, but does not specifically enumerate them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Siemens Advia (and H series)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advia",
"    <span class=\"nowrap\">",
"     120/2120",
"    </span>",
"    reports the WBC, RBC, HGB, HCT (calculated), MCV, MCH (calculated), MCHC (calculated), RDW, platelet count, and MPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/95\">",
"     95",
"    </a>",
"    ]. Research parameters include directly measured RBC hemoglobin content (mean=CH, SD=HDW); and directly measured RBC hemoglobin concentration (mean=CHCM, SD=CHDW) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/51,96\">",
"     51,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A six part differential (",
"    <a class=\"graphic graphic_figure graphicRef65298 \" href=\"mobipreview.htm?11/24/11649\">",
"     figure 4",
"    </a>",
"    ) includes percent and absolute number of neutrophils, lymphoid cells, monocytes, eosinophils, basophils, and large unstained cells (LUC, which includes reactive lymphocytes, blasts, and other abnormal cells). When specifically ordered, reticulocyte percent and absolute number are reported, as well as an immature reticulocyte fraction (IRF). Reticulocyte MCV and RDW, as well as directly measured reticulocyte hemoglobin content and concentration parameters, similar to those for mature erythrocytes, are available as research parameters. Instrument flags indicate the presence of potential interferences with individual parameters.",
"   </p>",
"   <p>",
"    The Advia instruments count RBCs by electronic impedance, but measure their volume by two-dimensional laser light scatter, after sphering and fixing the erythrocytes. A RBC cytogram computes the volume and Hb concentration for each individual erythrocyte. From this information, RBC volume and Hb concentration curves can be constructed. Hemoglobin concentration is also determined by colorimetry with a sodium lauryl sulfate-hemoglobin derivative.",
"   </p>",
"   <p>",
"    RBC volume and RBC HGB concentration histograms and smoothed curves as well as the MCV and RDW are reported. In addition, a number of erythrocyte research parameters can be obtained on alternate displays. These include the CHM (mean of directly measured Hb content), the HDW (SD of the Hb content, or RBC hemoglobin distribution width), the CHCM (mean of directly measured Hb concentration) and the CHDW (SD of the Hb concentration, or RBC hemoglobin concentration distribution width). The Advia 120 has been used to quantify schistocytes and has shown a high negative predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. The percentage of hypochromic red cells (%HYPO) and reticulocyte hemoglobin content (CHr) have been shown to be a useful tool in diagnosing iron deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For platelet enumeration and sizing, the platelets are sphered, fixed, and counted by laser light scatter in two dimensions, similar to RBC analysis. This technique allows discrimination between platelets on the one hand and RBCs (microcytic RBCs, RBC fragments, and ghosts) and WBCs on the other, because the latter sets of particles have a different refractive index than platelets. Platelet volume histograms and smoothed curves can be constructed from this plot, and the platelet count, mean platelet volume (MPV) and SD or CV of the volume (PDW) derived.",
"   </p>",
"   <p>",
"    The WBC is determined by duplicate methodologies. The WBCs are fixed and counted in the optical peroxidase channel as well as enumerated in the dual laser light scatter basophil flow cell with stronger lysing reagent. If interference at the lower counting threshold is noted in the peroxidase channel due to unlysed RBCs, the WBC count from the basophil channel is used.",
"   </p>",
"   <p>",
"    A six part WBC differential is performed by cytochemical and laser light scattering technology. After lysing the RBCs, WBCs are fixed and stained for myeloperoxidase using 4-chloro-1-naphthol substrate at 50 to 70&ordm;C. Stained cells are hydrodynamically focused through a flow cell illuminated by tungsten-halogen light, where light scatter as well as light absorption of individual cells is measured with a pair of photodetectors. The data are displayed in a two-dimensional scattergram, plotting cell size (light scatter) versus peroxidase activity. In addition to discriminating between neutrophils, lymphocytes, monocytes, and eosinophils, a sixth population, large unstained cells, is enumerated (",
"    <a class=\"graphic graphic_figure graphicRef65298 \" href=\"mobipreview.htm?11/24/11649\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because myeloperoxidase activity is employed in this method for obtaining the WBC differential, neutrophils in patients with myeloperoxidase deficiency will be enumerated under the population of \"large unstained cells\". (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14280?source=see_link&amp;anchor=H2#H2\">",
"     \"Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency\", section on 'Myeloperoxidase deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basophils are classified in a separate",
"    <span class=\"nowrap\">",
"     \"basophil/lobularity\"",
"    </span>",
"    channel. Using a strong lysing agent, both RBCs and WBCs are lysed, leaving only bare nuclei, except for basophils, which are resistant to this agent. The remaining",
"    <span class=\"nowrap\">",
"     nuclei/cells",
"    </span>",
"    are analyzed with two-angle laser light scatter. Basophils appear the largest, while the smaller bare nuclei can be analyzed as well. The mononuclear round cells scatter the least light, while lobulated cells scatter the most, generating a lobularity index. This information is used to detect the presence of blasts and mononuclear left-shifted neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Abbott Cell-Dyn 4000, Sapphire",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Abbott CD 4000 and Sapphire report the WBC (optical), RBC (impedance), RBC (optical), HGB, HCT (calculated), MCV, MCH (calculated), MCHC (calculated), RDW, platelet count (optical and impedance), MPV, and PDW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/69,102\">",
"     69,102",
"    </a>",
"    ]. The machine also calculates a plateletcrit, the percent of the sample's volume (ie, cells plus plasma) occupied by platelets. The five part differential includes percent and absolute number of neutrophils, lymphoid cells, monocytes, eosinophils, and basophils. Nucleated red blood cells are enumerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/103\">",
"     103",
"    </a>",
"    ], and a nucleated",
"    <span class=\"nowrap\">",
"     RBC/WBC",
"    </span>",
"    ratio is given. A leukocyte viability fraction is also given. When specifically ordered, reticulocyte percent and absolute number are analyzed and reported, as well as an immature reticulocyte fraction (IRF). In addition, research screens on the instrument enumerate blasts, atypical lymphocytes, and immature granulocytes. Instrument flags indicate the presence of potential interferences for individual parameters.",
"   </p>",
"   <p>",
"    The Cell-Dyn 4000 includes a 10-milliwatt Argon-Ion laser capable of measurements of light scatter at 0, 7, and 90 degrees. In addition, depolarized 90 degree light scatter is measured, as well as fluorescence in the green (530 nm) and red (630 nm) ranges. Electronic impedance apertures use a focused flow system to decrease clog rate and improve accuracy, particularly when cell counts are high. The Cell-Dyn Sapphire, Abbott's latest automated hematology analyzer, includes a blue diode laser and new laser assembly with internal pneumatics and better beam stability.",
"   </p>",
"   <p>",
"    An updated Sapphire was released in 2010 including new software. The Cell-Dyn Ruby hematology analyzer targets mid-sized laboratory with the Cell-Dyn Emerald, targeted for small to midsized labs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RBCs are counted by both impedance and laser light scatter, using hydrodynamically focused and sphered RBCs for both measurements. The impedance measurement is used for RBC count and size parameters. A two-dimensional optical RBC count serves to validate the impedance count. Using multi-angle light scatter and fluorescence, a three-dimensional RBC differential analysis has been generated allowing automated analysis of normal and abnormal red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/105\">",
"     105",
"    </a>",
"    ]. Whether this automated red blood cell analysis will supplement or supplant morphologic review remains to be seen.",
"   </p>",
"   <p>",
"    Hemoglobin is measured colorimetrically using a cyanide-free reagent (methemoglobin method with imidazole as the heme-ligand). Sodium hydroxide and lauramine oxide dissolve all cell particles and lipids and destroy bilirubin, minimizing interferences.",
"   </p>",
"   <p>",
"    Platelets are enumerated by both optical and focused impedance methods. The optical platelet count and volume is determined from two-dimensional analysis of low and high angle light scatter measurements. Platelets are first plotted using 90 degree versus 7 degree scattering. The ascending angle of the platelet population is determined and the histogram is formed perpendicular to the axis of the angle. High and low thresholds are set to isolate the platelets from large and small cells and fragments. A second histogram is constructed along the main body of this refined platelet population to determine the upper threshold separating platelets from microcytic RBCs. Interference by microcytic RBCs or RBC fragments and WBC cytoplasmic fragments is eliminated, since these particles have a different refractive index than platelets. Once the platelet particles are identified, the platelet count, MPV, PDW, and PCT are determined.",
"   </p>",
"   <p>",
"    The impedance platelet count appears as a lognormal distribution and serves to validate the optical count. Flagging of the impedance platelet count occurs when a high percentage of particles are noted near either the lower or upper counting threshold.",
"   </p>",
"   <p>",
"    Optional platelet enumeration by immunologic analysis is available on the Abbott CD 4000 and Sapphire. Platelets are identified by cluster analysis on a two-dimensional plot of fluorescent monoclonal antibody CD61 (directed against glycoprotein IIIa) reactivity versus high forward angle light scatter. The CD61 immunoplatelet method correlates the closest with the flow cytometry reference method for platelets, compared with impedance and optical platelets on the Sapphire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/106\">",
"     106",
"    </a>",
"    ]. Using the CD61 method as a gold standard compared with impedance and optical methods results in platelet undertransfusion and overtransfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WBCs are counted by laser light scatter. Events are considered \"WBC\" using analysis in three dimensions: size (0 degree scatter), complexity (7 degree scatter) and DNA fluorescence. Only events that exceed lower thresholds for these three measurements qualify for being counted. Thresholds are set low enough to capture all true WBCs, but exclude significant noise. Further analysis eliminates nucleated RBCs, RBCs resistant to lysis, platelet clumps, and other interfering materials from the final white blood cell count.",
"   </p>",
"   <p>",
"    For the leukocyte differential, blood is diluted with a leukoprotective diluent that maintains the leukocytes close to their native state and includes propidium iodide (PI) to enumerate nucleated RBCs and assess leukocyte viability. Mature erythrocytes are rendered transparent to laser light and do not produce light scatter under these conditions. The WBC dilution is hydrodynamically focused through the sensing region of a laser beam. Laser light scatter is measured at multiple angles, including (",
"    <a class=\"graphic graphic_figure graphicRef77105 \" href=\"mobipreview.htm?2/63/3056\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      zero degree measurement is related to cell size (axial light loss from incident ray)",
"     </li>",
"     <li>",
"      7 degree measurement is related to internal complexity",
"     </li>",
"     <li>",
"      90 degree measurement is related to lobularity",
"     </li>",
"     <li>",
"      90 degree depolarization measurement is specific for eosinophilic granules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, red fluorescence is measured, which is proportional to the amount of DNA in each cell that has become membrane compromised, such that the PI reagent has access to the cell nucleus. Up to 10,000 events are classified, and the measurements are stored in list mode, allowing the algorithm to work through the data incrementally.",
"   </p>",
"   <p>",
"    The first step involves a two-dimensional plot of 0 degrees versus fluorescence, to separate the cells which pick up the DNA stain, either nucleated RBCs or WBCs that are fragile or leaky. Based on the 0 degree size, these fluorescent cells are separated into nucleated RBC (red) or fragile white cells (white). The nucleated RBC particles are eliminated from further analysis, while the fragile WBCs are identified by subpopulation in further steps.",
"   </p>",
"   <p>",
"    In the next step, mononuclear (blue) and polynuclear cells (orange) are separated by a plot of 7 degree versus 90 degree light scatter.",
"   </p>",
"   <p>",
"    The polynuclear (orange) cells are analyzed with polarized laser light, so that eosinophils (green) can be identified within this fraction by the ability of their granules to depolarize light at 90 degrees.",
"   </p>",
"   <p>",
"    The mononuclear cells (blue) are plotted in two dimensions (7 degree versus 0 degree light scatter) to define the basophil region (white). Once the basophil region is defined, floating thresholds separate the lymphocytes (blue) and monocytes (purple) using a histogram along the 0 degree size axis with the basophils removed. The remaining events below the lymphocytes (gray) are non-WBC (and non-nucleated RBC) events, and if in sufficient number, may indicate significant interference from RBCs resisting the lysing reagent.",
"   </p>",
"   <p>",
"    Finally, a plot of fluorescence versus 0 degree size is reviewed again, with classified leukocytes appropriately colored. Non-viable leukocytes (highly fluorescent) can be identified, and a viability ratio is calculated.",
"   </p>",
"   <p>",
"    The plots of the various populations are analyzed for abnormal populations of cells by proprietary algorithms. Flags are reported if abnormal populations are identified. The neutrophil population is analyzed for the presence of bands and immature granulocytes, the mononuclear population is analyzed for the presence of blasts, variant lymphocytes are identified using data on both viable (non-fluorescent) and non-viable (highly fluorescent) lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Abbott CD 3500, CD3700",
"    </span>",
"    &nbsp;&mdash;&nbsp;These instruments are similar to the CD4000 and Sapphire with the following differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impedance technology is used to determine RBC and platelet counts using the Von Behrens plate device to prevent recirculating cells from being recounted. However, the red blood cells are not \"sphered\" and hydrodynamic focusing is not employed; instead, pulse editing algorithms eliminate aberrant pulses from the volume histograms, and MCV and RDW calculations. Both RBC and platelets are analyzed by impedance technology; optical counts are not determined. Hemoglobin is determined by a methemoglobin method with hydroxylamine as a direct oxidant and a quaternary ammonium salt for stable chromogen formation.",
"     </li>",
"     <li>",
"      For the WBC count and the leukocyte differential, the",
"      <span class=\"nowrap\">",
"       CD3500/3700",
"      </span>",
"      employs a Helium-neon laser. Similar to the CD4000 and Sapphire, these instruments use hydrodynamic focusing and laser light scatter with detection at 1 to 3 degrees, 7 degrees, 90 degrees, and depolarized 90 degrees to determine the leukocyte differential and flag for abnormal cell populations. Nucleated RBC and leukocyte viability are not determined.",
"     </li>",
"     <li>",
"      The CD3500 and CD3700 count WBC by both optical (WOC) and impedance (WIC) methods. The analyzers default to the optical WBC unless the two counts significantly differ. Dual determinations are necessary because fragile WBC (as occur in chronic lymphocytic leukemia or acute lymphoblastic leukemia) or nonviable WBC are excluded from the optical WBC count. The CD4000and Sapphire do not need an impedance WBC (WIC), since the improved low forward angle light scatter measurement (0 degree axial light loss) plus enumeration of nonviable WBC captures all leukocytes in the optical WBC count. An extended RBC lyse mode is present on the",
"      <span class=\"nowrap\">",
"       CD3500/3700",
"      </span>",
"      to minimize interference with lysis-resistant red blood cells that are commonly seen in neonatal blood samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Sysmex XE Series",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sysmex XE 2100 and XE-5000 report the WBC",
"    <span class=\"nowrap\">",
"     (optical/fluorescent),",
"    </span>",
"    RBC (impedance), HGB, HCT (from measurements of RBC pulse heights), MCV, MCH (calculated), MCHC (calculated), RDW-SD, RDW-CV, platelet (impedance), platelet (alternate,",
"    <span class=\"nowrap\">",
"     optical/fluorescent),",
"    </span>",
"    MPV, PDW, P-LCR (the percent of larger platelet) and a plateletcrit (PCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/62,67,73,74,108-111\">",
"     62,67,73,74,108-111",
"    </a>",
"    ]. The Sysmex XT-4000 analyzer provides a CBC, six-part differential including immature granulocytes, and also includes reticulocyte hemoglobin equivalent parameters.",
"   </p>",
"   <p>",
"    The five part differential includes percent and absolute number of neutrophils, lymphoid cells, monocytes, eosinophils, and basophils. Nucleated red blood cells are also enumerated. Hematopoietic progenitor cells are reported as a research parameter. When specifically ordered, reticulocyte percent and absolute number are analyzed and reported, as well as an immature reticulocyte fraction (IRF), which is the sum of the moderately and highly fluorescent reticulocytes (MFR+HFR).",
"   </p>",
"   <p>",
"    XE series instruments use impedance apertures for RBC and platelet counting and sizing, with hydrodynamic focusing and back sweep flow technologies. The RDW is expressed in terms of both SD and CV. The impedance platelet count is fitted to a lognormal distribution; flagging of this count occurs when a high percentage of particles is noted near either the lower or upper counting threshold. In addition, an",
"    <span class=\"nowrap\">",
"     optical/fluorescent",
"    </span>",
"    platelet count is determined when the impedance platelet count is flagged, or when the platelet count is less than 30 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (30,000/microL).",
"    </span>",
"    A computerized switching algorithm will give a best platelet count if both methods are enabled on the analyzer. Hemoglobin is determined colorimetrically using sodium lauryl sulphate.",
"   </p>",
"   <p>",
"    The leukocyte count and differential are performed using a combination of DC and RF measurements, as well as laser light scatter (forward and side) and fluorescence with a polymethine",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    histone dye. XE instruments contain a semiconductor diode laser with a short oscillation wavelength (630 nm), measuring fluorescence in the near red region.",
"   </p>",
"   <p>",
"    Four different lysing reagents are employed. First, RBC are lysed with a strong acid hemolytic reagent, removing even lysis-resistant RBC as well as platelet aggregates. Basophils are resistant to lysis, and can be separated from other WBC in a side versus forward light scattergram. The WBC count is measured as the sum of the basophil and other leukocyte events.",
"   </p>",
"   <p>",
"    The second step involves a lysing reagent that acts on the leukocyte membrane to allow dye passage. The fluorescent polymethine dye stains DNA, RNA, and histones. A plot of side light scatter versus fluorescence separates lymphocytes, monocytes, neutrophils plus basophils, and eosinophils. Total neutrophils are computed by subtracting the number of basophils measured in step one. In the third step, a lysing reagent is used to completely expose and shrink the nuclei of the nucleated erythrocytes. The WBCs, however, retain their cytoplasm, and are semi-permeabilized. The polyamine dye stains the small nucleated RBC nuclei and the larger WBC nuclei as well as the WBC cytoplasmic organelles. A plot of side fluorescence versus forward light scatter separates nucleated RBC from the WBC and the non-nucleated RBC ghosts and membrane fragments. Like predecessor Sysmex instruments, the XE 2100 uses an \"IMI (immature cell information) channel\" to detect small numbers of immature granulocytes, blasts, and hematopoietic progenitor cells. Quantitation of immature granulocytes by the Sysmex XE 2100 has been used by some authors as a predictor of infection comparable to the absolute neutrophil count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/83\">",
"     83",
"    </a>",
"    ]. The granularity index has been reported as a useful indicator of neutrophils with toxic granulation on the XE-5000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cells with a higher content of lipid are lysed with a fourth hemolytic reagent, while immature cells retain their membranes. The sample is analyzed in an impedance aperture with direct (DC) and radiofrequency (RF) current. In normal samples, no intact cells are seen in the IMI area. The information from the IMI channel is used to generate flags for left shift, immature granulocytes, and blasts, and to enumerate hematopoietic progenitor cells. Additional flags for abnormal cell types occur as abnormal cell populations are detected in the plot of side light scatter versus fluorescence in step two.",
"   </p>",
"   <p>",
"    Reticulocytes and the IRF are determined using the same polymethine dye capable of staining reticulocyte RNA in a special diluent. A plot of fluorescence versus forward light scatter separates mature RBC from reticulocytes, and enables enumeration of highly fluorescent reticulocytes. Small size platelet and highly fluorescent WBC do not interfere. When the impedance platelet count shows interference, the platelet count is determined from a log-scaled version of this plot. The fluorescent platelet RNA enables separation of platelet from RBC fragments. Fragmented red blood cells can also be quantitated on the XE-2100; this is performed using the reticulocyte channel in which RBC fragments are gated from the RBC area (small size, low RNA content) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/113\">",
"     113",
"    </a>",
"    ]. RBC extended parameters and reticulocyte parameters on the XE-5000 show potential utility in disorders of iron deficiency, anemia due to chronic renal disease, and thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/114,115\">",
"     114,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Sysmex NE/SE Series",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the XE 2100, RBC and platelet measurements occur by impedance aperture technology with hydrodynamic focusing and back sheath sweep-flow. RDW is expressed as SD and CV. Platelet counting algorithms use fitting to a lognormal curve, with flagging if increased percentages of small or large platelet are seen.",
"   </p>",
"   <p>",
"    In contrast to the XE series, the Sysmex",
"    <span class=\"nowrap\">",
"     NE/SE",
"    </span>",
"    series instruments lack laser light scatter and fluorescence analysis. WBCs are enumerated by impedance counting after RBC lysis. A five-part differential (lymphoid cells, neutrophils, monocytes, eosinophils, basophils) is determined using an impedance aperture and weak lysing reagents with controlled leukocyte cell shrinkage. Lymphocytes, monocytes, and granulocytes are identified in one flow cell, using radiofrequency (RF), which provides information related to nuclear size and cell structure, and DC impedance, in which the signal is proportional to cell volume. A two-dimensional scattergram (DC versus RF) uses floating discriminators to separate lymphocytes, monocytes, and total granulocytes.",
"   </p>",
"   <p>",
"    Differential lysing reagents and dedicated direct current channels are used for counting eosinophils and basophils; these cells are then subtracted from the total granulocytes to give total neutrophils. Abnormal location of cells in the DC versus RF plot generates flags for abnormal specimens that require additional review.",
"   </p>",
"   <p>",
"    The SE series measures WBC immaturity using a separate lysing system and IMI channel, in a manner identical to that used in the XE series instruments. Detergents interact with cell membrane lipids and selectively lyse different leukocytes; cells with a high content of cell membrane lipid are completely lysed, while immature cells, with a lower cell membrane lipid content, are only partially lysed. Blasts and immature neutrophils can be found in discrete areas of a",
"    <span class=\"nowrap\">",
"     RF/DC",
"    </span>",
"    scatterplot.",
"   </p>",
"   <p>",
"    In normal samples, no intact cells are seen in the IMI area. In a comparative study, 184 stem cell mobilization products were analyzed by CD34+ flow cytometry and by the WBC, monocyte, mononuclear cell, and IMI channels on a Sysmex SE series instrument [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/78\">",
"     78",
"    </a>",
"    ]. While there were weak correlations between CD34 positivity and counts in the monocyte (r = 0.21), and mononuclear cell (r = 0.36) channels, there was a strong correlation with the IMI channel (r = 0.68). Further work has suggested that enumeration of hematopoietic cells with the Sysmex XE-2100 can guide flow cytometric CD34 measurements and appropriate timing of leukaphereses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/54/35690/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23613394\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review discusses the various methods and apparatus which have been employed in an attempt to automate hematologic testing for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, including red cell indices, red cell distribution width, and reticulocyte count",
"     </li>",
"     <li>",
"      White blood cell count and differential, including &ldquo;flags&rdquo; for abnormal cells (eg, blasts)",
"     </li>",
"     <li>",
"      Platelet count, including measurement of early (reticulated) platelets",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/1\">",
"      Ward PC. The CBC at the turn of the millennium: an overview. Clin Chem 2000; 46:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/2\">",
"      Kickler TS. Clinical analyzers. Advances in automated cell counting. Anal Chem 1999; 71:363R.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/3\">",
"      Buttarello M, Plebani M. Automated blood cell counts: state of the art. Am J Clin Pathol 2008; 130:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/4\">",
"      Bessman JD, Gilmer PR Jr, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol 1983; 80:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/5\">",
"      Briggs C, Harrison P, Machin SJ. Continuing developments with the automated platelet count. Int J Lab Hematol 2007; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/6\">",
"      Kaplan SS, Johnson K, Wolfe N. Validation of low platelet counts from Coulter LH 750 and Coulter Gen*S analyzers. Lab Hematol 2001; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/7\">",
"      Keeney M, Brown W, Yee IC. Platelet counts and flagging rates from the LH750 hematology analyzer compared with the ICSH/ISLH platelet reference method and the Gen*S hematology analyzer. Lab Hematol 2001; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/8\">",
"      Charie LA, Harrison P, Smith CU, et al. Accuracy in the low platelet count range: a comparison of automated platelet counts on Beckman Coulter high-volume hematology analyzers with the ISLH/ISCH platelet reference method. Lab Hematol 2001; 7:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/9\">",
"      Sandhaus LM, Osei ES, Agrawal NN, et al. Platelet counting by the coulter LH 750, sysmex XE 2100, and advia 120: a comparative analysis using the RBC/platelet ratio reference method. Am J Clin Pathol 2002; 118:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/10\">",
"      Jackson SR, Carter JM. Platelet volume: laboratory measurement and clinical application. Blood Rev 1993; 7:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/11\">",
"      Threatte GA. Usefulness of the mean platelet volume. Clin Lab Med 1993; 13:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/12\">",
"      Corash L. Platelet sizing: techniques, biological significance, and clinical applications. Curr Top Hematol 1983; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/13\">",
"      Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/14\">",
"      Kaito K, Otsubo H, Usui N, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005; 128:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/15\">",
"      Chapman DH, Hardin J, Miers M, et al. Reduction of the platelet review rate using the two-dimensional platelet method. Am J Clin Pathol 2001; 115:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/16\">",
"      Kim SY, Kim JE, Kim HK, et al. Accuracy of platelet counting by automated hematologic analyzers in acute leukemia and disseminated intravascular coagulation: potential effects of platelet activation. Am J Clin Pathol 2010; 134:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/17\">",
"      Segal HC, Briggs C, Kunka S, et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 2005; 128:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/18\">",
"      Harrison P, Ault KA, Chapman S, et al. An interlaboratory study of a candidate reference method for platelet counting. Am J Clin Pathol 2001; 115:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/19\">",
"      Kunz D, Kunz WS, Scott CS, Gressner AM. Automated CD61 immunoplatelet analysis of thrombocytopenic samples. Br J Haematol 2001; 112:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/20\">",
"      Hong KH, Kim MJ, Lee KW, et al. Platelet count evaluation using three automated haematology analysers compared with the immunoplatelet reference method, and estimation of possible inadequate platelet transfusion. Int J Lab Hematol 2009; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/21\">",
"      Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001; 115:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/22\">",
"      Chaoui D, Chakroun T, Robert F, et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion 2005; 45:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/23\">",
"      Robinson MS, MacKie IJ, Machin SJ, Harrison P. Two colour analysis of reticulated platelets. Clin Lab Haematol 2000; 22:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/24\">",
"      Abe Y, Wada H, Sakakura M, et al. Usefulness of fully automated measurement of reticulated platelets using whole blood. Clin Appl Thromb Hemost 2005; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/25\">",
"      Stohlawetz P, Stiegler G, Kn&ouml;bl P, et al. The rise of reticulated platelets after intensive chemotherapy for AML reduces the need for platelet transfusions. Ann Hematol 1999; 78:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/26\">",
"      Monteagudo M, Amengual MJ, Mu&ntilde;oz L, et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/27\">",
"      Saxon BR, Mody M, Blanchette VS, Freedman J. Reticulated platelet counts in the assessment of thrombocytopenic disorders. Acta Paediatr Suppl 1998; 424:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/28\">",
"      Robinson MS, Harrison C, Mackie IJ, et al. Reticulated platelets in primary and reactive thrombocytosis. Br J Haematol 1998; 101:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/29\">",
"      Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002; 42:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/30\">",
"      Briggs C, Kunka S, Hart D, et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004; 126:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/31\">",
"      Koike Y, Miyazaki K, Higashihara M, et al. Clinical significance of detection of immature platelets: comparison between percentage of reticulated platelets as detected by flow cytometry and immature platelet fraction as detected by automated measurement. Eur J Haematol 2010; 84:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/32\">",
"      Macchi I, Chamlian V, Sadoun A, et al. Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of bone marrow recovery after aplastic chemotherapy. Eur J Haematol 2002; 69:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/33\">",
"      Zucker ML, Murphy CA, Rachel JM, et al. Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation. Lab Hematol 2006; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/34\">",
"      Briggs C, Hart D, Kunka S, et al. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 2006; 16:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/35\">",
"      Takami A, Shibayama M, Orito M, et al. Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/36\">",
"      Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/37\">",
"      Panasiuk A, Prokopowicz D, Zak J, Panasiuk B. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration. Hepatogastroenterology 2004; 51:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/38\">",
"      Saigo K, Takenokuchi M, Imai J, et al. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. Lab Hematol 2009; 15:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/39\">",
"      Hong KH, Kim HK, Kim JE, et al. Prognostic value of immature platelet fraction and plasma thrombopoietin in disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2009; 20:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/40\">",
"      Choi JW, Pai SH. Reticulocyte subpopulations and reticulocyte maturity index (RMI) rise as body iron status falls. Am J Hematol 2001; 67:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/41\">",
"      Yu PH, So CC, Wong KF, et al. Automated reticulocyte counting--an evaluation of GEN-S, Cell-Dyn 3500 and Cell-Dyn 4000. Clin Lab Haematol 1999; 21:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/42\">",
"      Rowan RM, Cavill I, Corberand JX. The reticulocyte count: progress towards the resurrection of a useful clinical test. Clin Lab Haematol 1996; 18 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/43\">",
"      d'Onofrio G, Kim YR, Schulze S, et al. Evaluation of the Abbott Cell Dyn 4000 automated fluorescent reticulocyte measurements: comparison with manual, FACScan and Sysmex R1000 methods. Clin Lab Haematol 1997; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/44\">",
"      Chang CC, Kass L. Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol 1997; 108:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/45\">",
"      Davies JI, Smyth MS, Martin JH. Automated reticulocyte counting: evaluation of the Coulter STKS Haematology Analyser reticulocyte counting function. Clin Lab Haematol 1997; 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/46\">",
"      Davis BH, Bigelow NC. Automated reticulocyte analysis. Clinical practice and associated new parameters. Hematol Oncol Clin North Am 1994; 8:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/47\">",
"      Peng L, Yang H, Jiang H, et al. Automated reticulocyte counting using the Sysmex RAM-1. Clin Lab Haematol 2001; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/48\">",
"      Siekmeier R, Bierlich A, Jaross W. Determination of reticulocytes: three methods compared. Clin Chem Lab Med 2000; 38:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/49\">",
"      George P, Wyre RM, Bruty SJ, et al. Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma. J Hematother Stem Cell Res 2000; 9:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/50\">",
"      Grotto HZ, Vigoritto AC, Noronha JF, Lima GA. Immature reticulocyte fraction as a criterion for marrow engraftment. Evaluation of a semi-automated reticulocyte counting method. Clin Lab Haematol 1999; 21:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/51\">",
"      d'Onofrio G, Chirillo R, Zini G, et al. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood 1995; 85:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/52\">",
"      Buttarello M, Bulian P, Farina G, et al. Five fully automated methods for performing immature reticulocyte fraction: comparison in diagnosis of bone marrow aplasia. Am J Clin Pathol 2002; 117:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/53\">",
"      Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/54\">",
"      Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002; 99:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/55\">",
"      Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content. Clin Exp Nephrol 2003; 7:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/56\">",
"      Tsuchiya K, Okano H, Teramura M, et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol 2003; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/57\">",
"      Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003; 49:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/58\">",
"      Thomas L, Franck S, Messinger M, et al. Reticulocyte hemoglobin measurement--comparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005; 43:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/59\">",
"      Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/60\">",
"      Locatelli F, Aljama P, B&aacute;r&aacute;ny P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/61\">",
"      KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/62\">",
"      Buttarello M, Temporin V, Ceravolo R, et al. The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol 2004; 121:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/63\">",
"      Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/64\">",
"      Temporin V, Lachin M, Bulian P, et al. Usefulness of reticulocyte indices in the early detection of functional iron deficiency and in the response to therapy with vitamin B12. Automated Blood Cytol 1998; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/65\">",
"      Parisotto R, Wu M, Ashenden MJ, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001; 86:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/66\">",
"      Krause JR. The automated white blood cell differential. A current perspective. Hematol Oncol Clin North Am 1994; 8:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/67\">",
"      Ruzicka K, Veitl M, Thalhammer-Scherrer R, Schwarzinger I. The new hematology analyzer Sysmex XE-2100: performance evaluation of a novel white blood cell differential technology. Arch Pathol Lab Med 2001; 125:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/68\">",
"      Davis BH, Bigelow NC. Performance evaluation of a hematology blood counter with five-part leukocyte differential capability. Am Clin Lab 1999; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/69\">",
"      Grimaldi E, Scopacasa F. Evaluation of the Abbott CELL-DYN 4000 hematology analyzer. Am J Clin Pathol 2000; 113:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/70\">",
"      Picard F, Gicquel C, Marnet L, et al. Preliminary evaluation of the new hematology analyzer COULTER GEN-S in a university hospital. Clin Chem Lab Med 1999; 37:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/71\">",
"      Kessler C, Sheridan B, Charles C, et al. Performance of the Coulter GEN*S system's white cell differential on an abnormal specimen data set. Lab Hematol 1997; 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/72\">",
"      Cornbleet PJ, Myrick D, Levy R. Evaluation of the Coulter STKS five-part differential. Am J Clin Pathol 1993; 99:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/73\">",
"      Bartels PC, Schoorl M, Willekens FL. Evaluation of Sysmex SF-3000 performance concerning interpretive morphology flagging of the leucocyte differential count. Clin Lab Haematol 1997; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/74\">",
"      Thalhammer-Scherrer R, Kn&ouml;bl P, Korninger L, Schwarzinger I. Automated five-part white blood cell differential counts. Efficiency of software-generated white blood cell suspect flags of the hematology analyzers Sysmex SE-9000, Sysmex NE-8000, and Coulter STKS. Arch Pathol Lab Med 1997; 121:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/75\">",
"      Vives-Corrons JL, Besson I, Jou JM, Gutierrez G. Evaluation of the Abbott Cell-DYN 3500 hematology analyzer in university hospital. Am J Clin Pathol 1996; 105:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/76\">",
"      La Porta AD, Bowden AS, Barr S. Workflow improvement and impact of the new Beckman Coulter LH 1500 high throughput automated hematology workcell. Lab Hematol 2004; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/77\">",
"      Molero T, Roemer B, Perera Alvarez Mdel M, et al. Analysis and enumeration of T cells, B cells and NK cells using the monoclonal antibody fluorescence capability of a routine haematology analyser (Cell-Dyn CD4000). Clin Lab Haematol 2005; 27:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/78\">",
"      Park KU, Kim SH, Suh C, et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/79\">",
"      Letestu R, Marzac C, Audat F, et al. Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring. Leuk Lymphoma 2007; 48:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/80\">",
"      Stolzel F, Oelschlagel U, Holig K, et al. Increased accuracy of HPC quantification using the XE-HPC master technology. Sysmex J Int 2003; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/81\">",
"      Nigro KG, O'Riordan M, Molloy EJ, et al. Performance of an automated immature granulocyte count as a predictor of neonatal sepsis. Am J Clin Pathol 2005; 123:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/82\">",
"      Briggs C, Kunka S, Fujimoto H, et al. Evaluation of immature granulocyte counts by the XE-IG master: upgraded software for the XE-2100 automated hematology analyzer. Lab Hematol 2003; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/83\">",
"      Ansari-Lari MA, Kickler TS, Borowitz MJ. Immature granulocyte measurement using the Sysmex XE-2100. Relationship to infection and sepsis. Am J Clin Pathol 2003; 120:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/84\">",
"      Zandecki M, Genevieve F, Gerard J, Godon A. Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. Int J Lab Hematol 2007; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/85\">",
"      Zandecki M, Genevieve F, Gerard J, Godon A. Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. Int J Lab Hematol 2007; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/86\">",
"      Aulesa C, Pastor I, Naranjo D, et al. Validation of the Coulter LH 750 in a hospital reference laboratory. Lab Hematol 2003; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/87\">",
"      Igout J, Fretigny M, Vasse M, et al. Evaluation of the coulter LH 750 haematology analyzer compared with flow cytometry as the reference method for WBC, platelet and nucleated RBC count. Clin Lab Haematol 2004; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/88\">",
"      Kaplan SS, Johnson K, Wolfe N, et al. Performance characteristics of the Coulter LH 500 hematology analyzer. Lab Hematol 2004; 10:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/89\">",
"      Tan BT, Nava AJ, George TI. Evaluation of the Beckman Coulter UniCel DxH 800, Beckman Coulter LH 780, and Abbott Diagnostics Cell-Dyn Sapphire hematology analyzers on adult specimens in a tertiary care hospital. Am J Clin Pathol 2011; 135:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/90\">",
"      Tan BT, Nava AJ, George TI. Evaluation of the Beckman Coulter UniCel DxH 800 and Abbott Diagnostics Cell-Dyn Sapphire hematology analyzers on pediatric and neonatal specimens in a tertiary care hospital. Am J Clin Pathol 2011; 135:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/91\">",
"      Jean A, Boutet C, Lenormand B, et al. The new haematology analyzer DxH 800: an evaluation of the analytical performances and leucocyte flags, comparison with the LH 755. Int J Lab Hematol 2011; 33:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/92\">",
"      Hedley BD, Keeney M, Chin-Yee I, Brown W. Initial performance evaluation of the UniCel&reg; DxH 800 Coulter&reg; cellular analysis system. Int J Lab Hematol 2011; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/93\">",
"      Yee IC, Keeney M, Johnson K, et al. White blood cell flagging rates of the Coulter LH 750 analyzer compared with the Coulter Gen*S hematology analyzer. Lab Hematol 2001; 7:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/94\">",
"      Kwon MJ, Nam MH, Kim SH, et al. Evaluation of the nucleated red blood cell count in neonates using the Beckman Coulter UniCel DxH 800 analyzer. Int J Lab Hematol 2011; 33:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/95\">",
"      Harris N, Jou JM, Devoto G, et al. Performance evaluation of the ADVIA 2120 hematology analyzer: an international multicenter clinical trial. Lab Hematol 2005; 11:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/96\">",
"      Giacomini A, Legovini P, Gessoni G, et al. Platelet count and parameters determined by the Bayer ADVIA 120 in reference subjects and patients. Clin Lab Haematol 2001; 23:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/97\">",
"      Lesesve JF, Salignac S, Alla F, et al. Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. Am J Clin Pathol 2004; 121:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/98\">",
"      Lesesve JF, Salignac S, Lecompte T, Bordigoni P. Automated measurement of schistocytes after bone marrow transplantation. Bone Marrow Transplant 2004; 34:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/99\">",
"      Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/100\">",
"      Maconi M, Cavalca L, Danise P, et al. Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: comparison of two methods. Scand J Clin Lab Invest 2009; 69:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/101\">",
"      Buttarello M, Pajola R, Novello E, et al. Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol 2010; 133:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/102\">",
"      M&uuml;ller R, Mellors I, Johannessen B, et al. European multi-center evaluation of the Abbott Cell-Dyn sapphire hematology analyzer. Lab Hematol 2006; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/103\">",
"      De Keijzer MH, van der Meer W. Automated counting of nucleated red blood cells in blood samples of newborns. Clin Lab Haem 2002; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/104\">",
"      Lehto T, Hedberg P. Performance evaluation of Abbott CELL-DYN Ruby for routine use. Int J Lab Hematol 2008; 30:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/105\">",
"      Kim YR, van't Oever R, Landayan M, Bearden J. Automated red blood cell differential analysis on a multi-angle light scatter/fluorescence hematology analyzer. Cytometry B Clin Cytom 2003; 56:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/106\">",
"      Grimaldi E, Del Vecchio L, Scopacasa F, et al. Evaluation of the platelet counting by Abbott CELL-DYN SAPPHIRE haematology analyser compared with flow cytometry. Int J Lab Hematol 2009; 31:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/107\">",
"      Cid J, Nascimento JD, Vicent A, et al. Evaluation of low platelet counts by optical, impedance, and CD61-immunoplatelet methods: estimation of possible inappropriate platelet transfusion. Transfusion 2010; 50:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/108\">",
"      Briggs C, Harrison P, Grant D, et al. New quantitative parameters on a recently introduced automated blood cell counter--the XE 2100. Clin Lab Haematol 2000; 22:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/109\">",
"      Nakul-Aquaronne D, Sudaka-Sammarcelli I, Ferrero-Vacher C, et al. Evaluation of the Sysmex Xe-2100 hematology analyzer in hospital use. J Clin Lab Anal 2003; 17:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/110\">",
"      Wang FS, Itose Y, Tsuji T, et al. Development and clinical application of nucleated red blood cell counting and staging on the automated haematology analyser XE-2100. Clin Lab Haematol 2003; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/111\">",
"      Briggs CJ, Linssen J, Longair I, Machin SJ. Improved flagging rates on the Sysmex XE-5000 compared with the XE-2100 reduce the number of manual film reviews and increase laboratory productivity. Am J Clin Pathol 2011; 136:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/112\">",
"      Zimmermann M, Cremer M, Hoffmann C, et al. Granularity Index of the SYSMEX XE-5000 hematology analyzer as a replacement for manual microscopy of toxic granulation neutrophils in patients with inflammatory diseases. Clin Chem Lab Med 2011; 49:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/113\">",
"      Banno S, Ito Y, Tanaka C, et al. Quantification of red blood cell fragmentation by the automated hematology analyzer XE-2100 in patients with living donor liver transplantation. Clin Lab Haematol 2005; 27:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/114\">",
"      Urrechaga E, Borque L, Escanero JF. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin Chem Lab Med 2009; 47:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/115\">",
"      Urrechaga E, Borque L, Escanero JF. Analysis of reticulocyte parameters on the Sysmex XE 5000 and LH 750 analyzers in the diagnosis of inefficient erythropoiesis. Int J Lab Hematol 2011; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/54/35690/abstract/116\">",
"      Oelschlaegel U, Bornhaeuser M, Thiede C, et al. HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34(+) measurements and timing of leukaphereses. Cytotherapy 2003; 5:414.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4430 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35690=[""].join("\n");
var outline_f34_54_35690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23613394\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12469650\">",
"      SAMPLE COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE COULTER IMPEDANCE APERTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Multichannel instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The red blood cell volume histogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Red cell distribution width",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Improvements enabling platelet counting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Platelet counting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mean platelet volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CELL COUNTING BY LIGHT SCATTERING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      The optical platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Immunologic counting of platelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reticulated platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALTERNATIVE MEASUREMENTS OF HEMOGLOBIN CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      AUTOMATED COUNTING OF RETICULOCYTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOMATION OF THE WHITE CELL DIFFERENTIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      The three part differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The five part differential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Suspect flags",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AUTOMATED SAMPLING MODES AND COMPUTER ADVANCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CAUSES OF SPURIOUS RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Spurious increase in the MCHC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Spurious decrease in the MCHC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Platelet error flags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Leukocyte counting errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Platelet clumping with pseudothrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SELECTED AUTOMATED HEMATOLOGY INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Beckman Coulter DxH 800, LH780, and other models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Siemens Advia (and H series)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Abbott Cell-Dyn 4000, Sapphire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Abbott CD 3500, CD3700",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Sysmex XE Series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Sysmex NE/SE Series",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23613394\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4430|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/51/38717\" title=\"figure 1\">",
"      RBC size sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/57/19359\" title=\"figure 2\">",
"      Automated platelet counting low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/22/8558\" title=\"figure 3\">",
"      Predicting platelet recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/24/11649\" title=\"figure 4\">",
"      WBC differential Advia2120",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/63/3056\" title=\"figure 5\">",
"      WBC differential CD4000",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4430|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/49/21265\" title=\"picture 1\">",
"      Manual hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/37/6737\" title=\"picture 2\">",
"      Microhematocrit determination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/10/15527\" title=\"picture 3\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/31/17911\" title=\"picture 4\">",
"      Giant platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/15/26872\" title=\"picture 5\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14280?source=related_link\">",
"      Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_54_35691="Summary of tests for blunt aortic injury";
var content_f34_54_35691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of tests for blunt aortic injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Diagnostic tests for aortic rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain radiograph",
"       </td>",
"       <td>",
"        <p>",
"         Upright preferable; sensitivity of supine unclear",
"        </p>",
"        <p>",
"         Normal PA radiograph has high negative predictive value; good test for patients with low to moderate suspicion",
"        </p>",
"        <p>",
"         If high clinical suspicion, or abnormal radiograph, further testing required",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest CT scan",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Test of choice",
"         </strong>",
"        </p>",
"        <p>",
"         Highly sensitive and specific",
"        </p>",
"        <p>",
"         Requires IV contrast",
"        </p>",
"        <p>",
"         Can usually proceed directly to OR with a positive CT",
"        </p>",
"        <p>",
"         Equivocal study necessitates angiography",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiography",
"       </td>",
"       <td>",
"        <p>",
"         Highly sensitive and specific",
"        </p>",
"        <p>",
"         Mainly used for equivocal CT scans",
"        </p>",
"        <p>",
"         Rarely adds value in the setting of a diagnostic CT and delays potentially life-saving operative intervention",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transesphosageal echocardiography",
"       </td>",
"       <td>",
"        <p>",
"         Highly accurate",
"        </p>",
"        <p>",
"         Can be performed at bedside, in OR, or in patients who cannot tolerate contrast",
"        </p>",
"        <p>",
"         Limited in proximal ruptures, but overall an excellent test when CT is unavailable or contraindicated",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35691=[""].join("\n");
var outline_f34_54_35691=null;
var title_f34_54_35692="Risk factors and proposed screening recs for gastric cancer";
var content_f34_54_35692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors and proposed screening recommendations for gastric cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk for developing gastric cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Helicobacter pylori (HP) infection",
"       </td>",
"       <td rowspan=\"2\">",
"        Odds ratio (OR): 2.3",
"       </td>",
"       <td>",
"        High risk area - mass screening possible benefit",
"       </td>",
"       <td rowspan=\"2\">",
"        Huang 1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk area - mass screening not cost-effective",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        1. HP without atrophic gastritis",
"       </td>",
"       <td>",
"        1. Hazard ratio 7.13 (compared with no HP)",
"       </td>",
"       <td>",
"        See above",
"       </td>",
"       <td rowspan=\"3\">",
"        Ohata 2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. HP with atrophic gastritis",
"       </td>",
"       <td>",
"        2. Hazard ratio 14.5",
"       </td>",
"       <td>",
"        HP eradication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Atrophic gastritis and extensive intestinal metaplasia",
"       </td>",
"       <td>",
"        3. Hazard ratio 61.9",
"       </td>",
"       <td>",
"        HP eradication",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pernicious anemia",
"       </td>",
"       <td>",
"        Standardized incidence ratio: 5",
"       </td>",
"       <td>",
"        Screening by upper endoscopy (UE) recommended",
"       </td>",
"       <td>",
"        Kokkola 1998",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Partial gastrectomy",
"       </td>",
"       <td>",
"        15-24 years, RR = 9.4",
"       </td>",
"       <td rowspan=\"2\">",
"        Screening by UE recommended",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Lundegardh 1988",
"        </p>",
"        <p>",
"         Tersmette 1991",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-46 years, RR = 55.6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sporadic adenomas",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"       <td>",
"        Surveillance post polypectomy for established dysplasia",
"       </td>",
"       <td>",
"        Ming 1965",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Familial adenomatous polyposis",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"       <td>",
"        Screening by UE recommended",
"       </td>",
"       <td>",
"        Alexander 1989",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hereditary nonpolyposis colorectal cancer",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"       <td>",
"        Screening by UE recommended",
"       </td>",
"       <td>",
"        Aarnio 1997",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Positive family history of gastric cancer",
"       </td>",
"       <td>",
"        OR: 2.5-5.1",
"       </td>",
"       <td>",
"        HP eradication +/- UE screening",
"       </td>",
"       <td>",
"        <p>",
"         Yatsuya 2004",
"        </p>",
"        <p>",
"         Chen 2004",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Annie O O Chan, MD, and Benjamin C Y Wong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35692=[""].join("\n");
var outline_f34_54_35692=null;
var title_f34_54_35693="Perioperative VTE prevention";
var content_f34_54_35693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hospital Quality Alliance/Centers for Medicare &amp; Medicaid Services (CMS) Surgical Care Improvement quality measures for perioperative VTE prevention*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Surgery type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended prophylaxis options",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Intracranial neurosurgery",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Intermittent pneumatic compression devices (IPC) with or without graduated compression stockings (GCS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low-dose unfractionated heparin (LDUH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low molecular weight heparin (LMWH)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LDUH or LMWH",
"        <sup>",
"         &loz;",
"        </sup>",
"        combined with IPC or GCS",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        General surgery",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low-dose unfractionated heparin (LDUH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low molecular weight heparin (LMWH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Factor Xa Inhibitor (fondaparinux)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        General surgery with contraindications to pharmacological prophylaxis",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Graduated compression stockings (GCS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Intermittent pneumatic compression devices (IPC)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Gynecologic surgery",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low-dose unfractionated heparin (LDUH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low molecular weight heparin (LMWH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Factor Xa Inhibitor (fondaparinux)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Intermittent pneumatic compression devices (IPC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Urologic surgery",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low-dose unfractionated heparin (LDUH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low molecular weight heparin (LMWH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Factor Xa Inhibitor (fondaparinux)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Intermittent pneumatic compression devices (IPC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Graduated compression stockings (GCS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Elective total hip replacement",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Any of the following started within 24 hours of surgery:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Low molecular weight heparin (LMWH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Factor Xa Inhibitor (fondaparinux)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Warfarin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Excluded populations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients less than 18 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients who have a length of stay &gt;120 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Burn patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients with procedures performed entirely by laparoscope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients enrolled in clinical trials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients who are on warfarin prior to admission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients whose ICD-9-CM principal procedure occurred prior to the date of admission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients whose total surgery time is less than or equal to 60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients who stayed less than or equal to 3 calendar days postoperatively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &bull; Patients with contraindications to both mechanical and pharmacological prophylaxis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Taken from: Specifications Manual for National Hospital Inpatient Quality Measures. Available at: www.qualitynet.org.",
"     <br>",
"      &Delta; Patients who receive neuraxial anesthesia or have a documented contraindication to pharmacological prophylaxis may pass the performance measure if either appropriate pharmacological or mechanical prophylaxis is ordered.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Current guidelines recommend postoperative low molecular weight heparin for intracranial neurosurgery.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35693=[""].join("\n");
var outline_f34_54_35693=null;
var title_f34_54_35694="Papulonecrotic tuberculid on penis";
var content_f34_54_35694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papulonecrotic tuberculid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 245px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A purulent ulcer is present on the penis in this patient with papulonecrotic tuberculid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. M Ramam, New Delhi.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35694=[""].join("\n");
var outline_f34_54_35694=null;
var title_f34_54_35695="HSG with air bubble artifact";
var content_f34_54_35695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing a filling defect in the left cornual area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It proved to be a superimposed gas bubble from the bowel over the uterine shadow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_54_35695=[""].join("\n");
var outline_f34_54_35695=null;
